The development of recombinant vaccines against Jembrana disease by Ditcham, William
The Development of Recombinant Vaccines against 
Jembrana Disease 
 
 
 
 
 
 
 
 
William Ditcham 
HND, M.I.Biol. 
 
 
 
A thesis submitted to Murdoch University for the degree of  
Doctor of Philosophy. 
 
 
March 2007Abstract.  
Jembrana disease virus (JDV) is a lentivirus causing an acute infection with a 17% 
case fatality rate in Bali cattle in Indonesia. Control of the disease is currently 
achieved by identification of infected areas and restriction of cattle movement. A 
detergent-inactivated whole virus tissue-derived vaccine is sometimes employed in 
affected areas.  
This thesis reports initial attempts to produce genetically engineered vaccines to 
replace the inactivated tissue-derived vaccine, which as it is made from 
homogenised spleen of infected animals, is expensive to produce and could contain 
adventitious agents present in the donor animals.  
4 potential DNA vaccine constructs were created containing the JDV genes coding 
for the Tat, capsid (CA), transmembrane (TM) and surface unit (SU) proteins in a 
commercially available vaccine plasmid. These were assessed for functionality in a 
range of in vitro and in vivo assays. All proteins were expressed in vitro and 
administration of 2 of the constructs by a commercial ‘gene gun’ into the epidermis 
of mice resulted in antibody production to the appropriate protein. Due to the 
difficulties of licensing such a DNA vaccine in Indonesia, these vaccines were not 
progressed further. 
A mathematical model was developed to describe the progression of the acute phase 
of Jembrana disease following experimental infection with JDV. The model divided 
the disease into 6 phases based on the rates of viral replication and clearance 
calculated from data on sequential plasma viral RNA load detected by quantitative 
reverse-transcription polymerase chain reaction. This allowed statistical comparison 
of each phase of the disease and comparison of the severity of the disease process in 
groups of animals. The use of the model overcame the difficulty of comparing the 
disease in different animals as a consequence of the animal-to-animal variation in 
the disease process.  
The mathematical model was used to identify differences in the pathogenicity of 2 
strains of JDV. One strain, JDVTAB caused a more rapid onset of disease in non-vaccinated controls, a significantly higher virus load at the onset of the febrile period 
and a higher peak viraemia than in animals infected with JDVPUL. This provided the 
first evidence of variation in pathogenicity of JDV strains. 
The measurement of virus load also demonstrated that some JDV infected animals 
developed a clinical disease that was not typical of that which had been reported 
previously. When infected with less than 1,000 infectious virus particles, up to 20% 
of infected animals failed to develop a febrile response. Infection of these animals 
was confirmed, however, by the detection of a high titre of circulating virus particles 
in plasma. These atypical infections had not been reported previously. 
Application of the mathematical model describing the progression of the disease in 
individual animals was used to examine the effect of vaccination with the inactivated 
tissue-derived vaccine on the progression of the disease. Several effects were noted 
in vaccinated animals that were subsequently infected with JDV: a reduction in the 
duration of the febrile response, a reduction in the severity of the febrile response in 
the early phases of the acute disease, and a reduction in virus load in the early and 
later phases of the disease process.  
The effect of vaccination with recombinant Tat, matrix (MA) and CA protein 
vaccines expressed in a bacterial expression system on subsequent JDV infection 
was also examined. A vaccine incorporating recombinant Tat and CA vaccine 
emulsified with Freund’s incomplete adjuvant decreased the febrile response 
particularly in the later stages of the acute disease process, decreased the severity of 
the leucopenia in the later phases of the acute disease, and decreased the virus load 
in some but not all phases of the acute disease process. Vaccines administered with 
Freund’s incomplete adjuvant were more efficacious than vaccines administered 
with QuilA, the latter actually exacerbating the disease process in vaccinated 
animals. Declaration. 
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Chapter 1 
Introduction. 
The initial outbreak of Jembrana disease (JD) in 1964 on the island of Bali had a 
devastating effect on the Bali cattle (Bos javanicus) population, with estimates of 
mortalities varying from 25,000 to 70,000 out of a total cattle population of about 
300,000 (Pranoto, 1967). The source of the virus was never determined. The disease 
is now endemic in Bali and has since been reported in the other islands of Sumatra, 
Java and Kalimantan in the Indonesian archipelago (Wilcox, 1997). As the disease 
appears specific for Bali cattle (Soeharsono et al., 1995a), and as significant 
numbers of these cattle occur only within Indonesia where they are used as draft 
animals for rice production and for beef production, the disease has not been 
reported in any other country. 
The aetiological agent of JD was identified as a lentivirus (Kertayadnya et al., 1993), 
closely related to bovine immunodeficiency virus (BIV), and designated Jembrana 
disease virus. Control strategies are based on containment of animals in affected 
areas and restriction of the movement of cattle from these areas to disease-free areas. 
The disease remains not only a major problem for cattle farmers but the restriction of 
the movement of cattle has had a significant effect on the economics of the 
Indonesian cattle industry. 
Improved control procedures for the disease are needed. An inactivated whole virus 
vaccine prepared from homogenised spleen tissue from infected animals, inactivated 
with detergent and emulsified in a mineral oil adjuvant, has been reported for JD 
(Hartaningsih et al., 2001). This vaccine had a sufficient level of efficacy, and it is 
currently used to vaccinate animals in areas surrounding an outbreak to decrease the 
likelihood of spread of disease. However, the possible presence of adventitious 
agents in the tissue-derived vaccine, the inability to distinguish serologically 
between vaccinated and infected carrier animals, the high cost of production and the 
difficulty of producing large quantities of the vaccine has led to the search for an 
alternative. This thesis reports an investigation of the suitability of selected   13 
genetically engineered vaccines to replace the inactivated vaccine currently used in 
Indonesia. 
As background to the thesis, a review of the literature relating to JD and possible 
vaccination strategies for lentivirus infections was undertaken and is reported in 
Chapter 2. The review includes the history of JD and how JDV compares in 
morphology, genome arrangement and pathogenic effects with the other members of 
the lentivirus family. The remainder of the review covers the history of both DNA 
and recombinant protein vaccination and how these technologies have been utilised 
to produce vaccines against the lentiviruses.  
Chapter 3 describes preliminary attempts to develop a nucleic acid or ‘DNA’ 
vaccine against JD. There were many potential advantages to such a DNA vaccine 
which seemed applicable to the control of JD in Indonesia: the vaccines are stable, 
the response attained can be long lived from a single injection, the production of 
large amounts of vaccine is simple and low cost, and nucleotide sequences can be 
incorporated into the design to tailor the immune response attained (Whalen, 1996a). 
Several simple constructs were tested in vitro and in vivo in laboratory animals. 
Assessment of the efficacy of vaccination against JD in cattle has previously relied 
on clinical indicators such as the effect on the duration and severity of the febrile 
period and case fatality rates (Hartaningsih et al., 2001), but these indicators did not 
reveal the underlying dynamics of viral growth and clearance during infection. Real-
time quantitative PCR methods were employed to assay the virus load during 
infection and to use this additional parameter to assess the response of cattle to 
infection by 2 strains of JDV. From the real-time PCR and other clinical data 
obtained from these experiments, a mathematical model of the acute infection was 
developed and this is reported in Chapter 4. The mathematical model was used to 
examine the pathogenesis infection using 2 different virus strains and the results are 
also reported in Chapter 4. The model was also used to re-examine the effect of 
vaccination with the inactivated tissue-derived whole virus vaccine on infection, and 
these results are reported in Chapter 5. The same model was then used to examine   14 
the effect of vaccination with recombinant JDV Tat and CA protein vaccines on 
subsequent infection with JDV and these results are reported in Chapter 6. 
A general discussion of the research reported in this thesis in the context of the need 
to produce a JD vaccine in Indonesia is presented in Chapter 7.   15 
 
Chapter 2  
Review of the literature.  
In this chapter, a general review of the literature relevant to this research project is 
presented. The chapter is divided into 4 sections. The first of these includes a review 
of the history of JD and the subsequent identification of the causative agent as a 
lentivirus, JDV. The second section describes the features of the lentiviruses that 
differentiate them from other viruses and the relationship of JDV to other 
lentiviruses. The third section reviews the literature relating to different vaccination 
strategies. The fourth section examines the literature relating to vaccination of 
animal, non-human primate and human hosts against the diseases caused by the 
lentiviruses and the relevance of the current situation to the possibility of vaccinating 
Bali cattle against JDV infection.  
By convention, when the name of a gene or open reading frame (ORF) is mentioned 
it is in italics and lower case, e.g. tat. The product of a gene or ORF is not italicised 
and the first letter is in upper case, e.g. Tat, or the name is abbreviated to 2 
uppercase letters, e.g. capsid, CA, or nucleocapsid, NC. 
History of Jembrana disease. 
The first cases of an emerging infectious disease of banteng or Bali cattle (Bos 
javanicus) were reported in December 1964, on the island of Bali in the Indonesian 
archipelago. Within 12 months, the disease had spread across the whole island and 
had killed an estimated 25,000 to 70,000 of the total population of about 300,000 
Bali cattle (Pranoto, 1967). Infected cattle suffered a febrile period of 2-10 days, 
with symptoms of diarrhoea, anorexia, nasal discharge, erosions on the oral mucosa 
and enlarged superficial lymph nodes. At necropsy, symptoms included 
splenomegaly, and haemorrhages in the myocardium, serous and mucous 
membranes (Dharma et al., 1991).   16 
 
Figure 2.1 Necropsy of Bos javanicus infected with JDV, showing enlarged spleen. 
(Photo W. Ditcham) 
The disease was named Jembrana disease after the Jembrana region of West Bali 
where it was first reported. Further outbreaks in Bali occurred in the Tabanan region 
in 1971 and in Karangasem in 1981. The disease was also detected in other 
provinces in other islands: Lampung (Sumatra) in 1976, East Java province in 1978, 
West Sumatra in 1992, South Kalimantan in 1992 and Bengkulu (Sumatra) in 1995.  
Figure 2.2 A map of Indonesia, with areas where Jembrana disease is endemic within the 
cattle population shown in red.  
The initial outbreak in 1964 was mistakenly diagnosed as rinderpest and a mass 
vaccination against this disease was undertaken (Adiwinata, 1968). A ban on export 
of cattle from Bali was also introduced, except for cattle taken to Jakarta for 
slaughter, and coincidentally there were no outbreaks for several years. In the 1976   17 
outbreak, investigations led to the hypothesis that the causative agent was rickettsial 
on the basis of the apparent detection within monocytes from infected cattle of 
intracytoplasmic particles similar in size to rickettsia (Budiarso and Hardjosworo, 
1976). The clinical signs, pathology and haematology of JD were also similar to 
those seen in bovine ehrlichiosis and particularly Ondiri disease seen in East Africa 
(Ressang, 1985). However, only occasional monocytes from animals experimentally 
infected with the JD agent showed the rickettsial-like particles and anti-rickettsial 
drugs had no effect on the progress of the disease (Ramachandran, 1996). 
Transmission studies revealed that the agent was present at a high titre in the plasma 
of animals during fever (Soeharsono et al., 1990). An infectious dose that infected 
50% of inoculated animals (ID50) was determined by titration of the infectious agent 
in naïve animals, where cattle were inoculated with serial dilutions of blood from an 
infected animal (Kertayadnya et al., 1993). It was determined that there were up to 
10
8 ID50/ml in the plasma of animals during the second day of the febrile response. 
There was a strong inverse correlation between inoculum concentration and an 
incubation period that ranged from 5-12 days, but no correlation between viral dose 
and severity of subsequent fever (Soeharsono et al., 1990). Other transmission 
studies proved that the agent of JD caused severe disease in only Bali cattle, but it 
could also at least transiently infect Ongole (Bos indicus), Bos taurus (Friesian 
breed) and buffalo (Bubalis bubalus) as well as Ongole x Bos javanicus cattle 
(Rambon and Madura breeds) and sheep. In those species other than Bali cattle, a 
transient subclinical disease was seen, marginally more severe in Friesian and 
Ongole cattle than in the other species (Soeharsono et al., 1990). The agent persisted 
in the blood and spleen of these animals for up to 9 months. Bali cattle that had 
survived the disease were resistant to further challenge for at least 2 years after the 
initial disease, and retained the agent in plasma for this period at least, and possibly 
for life (Soeharsono et al., 1990). 
Haematological studies revealed that experimentally infected animals developed 
leucopenia, principally due to a lymphopenia but with a moderate neutropenia at the 
onset of fever, which persisted throughout the febrile period. During this period, 
cattle also showed elevated blood urea levels, decreased total protein levels and   18 
thrombocytopaenia (Soesanto et al., 1990). Histologically, 3 phases of the disease 
were apparent in tissues. The initial phase in the first week of infection consisted of 
a general lymphoreticular reaction in the lymphoid organs, followed by an intense 
non-follicular proliferation of reticular and lymphoblastic cells, with infiltration of 
lymphoblastoid cells into the visceral organs including lungs, liver, kidneys and 
heart but not the brain. This phase lasted from 8-21 days post-infection (PI) and was 
followed by a third phase, commencing 5 weeks after infection when plasma cell 
formation occurred in the lymph nodes and spleen. These observations indicated that 
the acute phase of the illness was predominantly characterised by a T-cell response 
with a transient humoral immunosuppression (Dharma et al., 1991). 
The discovery that the agent could be filtered through a 100 nm average pore 
diameter (APD) filter but was retained by a 50 nm APD filter indicated that it was a 
virus (Wilcox et al., 1992). It was subsequently identified as a retrovirus on the basis 
of electron microscopic studies demonstrating the presence of a spherical enveloped 
virus of about 100 nm diameter with an eccentric core, by detection of reverse 
transcriptase activity in purified virus preparations, and because antiserum reactive 
with the 26 kDa CA protein of BIV cross-reacted in Western blots (WB) with the 26 
kDa protein of JDV, and vice-versa (Kertayadnya et al., 1993). Examination of the 
nucleotide sequence of a conserved region of the pol gene of JDV allowed 
classification of the virus as a lentivirus, most closely related to BIV (Chadwick et 
al., 1995a).  
Knowledge of the nucleotide sequence of JDV allowed in situ hybridisation studies, 
with riboprobes to detect viral RNA in tissues at different time points after 
inoculation with virus (Chadwick et al., 1998). These studies showed that 2 days PI, 
before disease was apparent, the majority of infected cells were seen in the 
parafollicular areas of the spleen, with very few in the lymph nodes, bone marrow, 
lungs, kidneys or myocardium. 2 days after the onset of the febrile period, virus 
started to appear in the lymph nodes and in the cellular infiltrate in other organs. 
After 4 days of fever, JDV-infected cells were disseminated widely in all tissues, 
with the follicular architecture of the spleen destroyed by proliferating cells. The 
specific cell type infected was not identified but the prevalence of infected cells in   19 
the lymphoproliferative infiltrate in lymphoid tissues suggested that cells of a 
lymphoid origin or of the monocyte/macrophage lineage were infected (Chadwick et 
al., 1998).  
Bali cattle are of considerable importance to the economy of Indonesia and in 1995 
the species accounted for 26.8% of all cattle in Indonesia (Wiryosuhanto, 1996). 
They are utilised as pioneer animals in new settlements, as draft animals and for beef 
production. Although they grow slowly when fed a poor quality diet, with low fat 
deposition in the muscle mass, they have the capacity to fatten rapidly when 
concentrate is included in the diet. The cattle reach maturity at around 4-5 years of 
age, and there is a marked size difference and coat colour difference between the 
sexes. The animals display better heat tolerance than other cattle types, and better 
ability to survive drought conditions, which is offset by comparatively high calf 
mortality. The cattle are resistant to internal and external parasites, except liver 
flukes, but are very susceptible to malignant catarrhal fever and JD. The cattle are 
timid, and can revert to the wild state at any stage of life, an indication of their 
relatively recent domestication (Wiryosuhanto, 1996). 
JD has spread in the 40 years since the first outbreak in Bali to several other islands 
of the Indonesian archipelago, probably through the illegal movement of cattle from 
Bali. In 2006, it is present in Bali, Java, Sumatra and Kalimantan; it is not known to 
occur in islands east of the Wallace Line, including Sulawesi and the Moluku group 
of islands where there are large numbers of Bali cattle (Wilcox, 1997). The 
movement of cattle from endemic areas has been banned in an attempt to prevent the 
spread of JD to currently JD-free areas. Locally, when an outbreak is suspected, 
control measures include preventing the free mingling of animals by stopping free 
grazing, spraying of barns with insecticide to kill insect vectors, and the rapid 
disposal of the carcasses of dead animals (Soeharsono, 1996). The use of 
insecticides is a residual belief by some in Indonesia that the disease has a rickettsial 
aetiology. In 1993, vaccination was started utilising a locally produced vaccine made 
from the spleen of infected animals emulsified in a mineral oil adjuvant. This 
vaccine decreases the duration and severity of disease in experimentally infected   20 
animals, but did not induce a sterilising immunity, at least when animals were 
challenged with 100 ID50 of JDV (Hartaningsih et al., 2001).  
Anecdotal reports suggest that the severity of the disease has been decreasing in the 
areas where it is endemic (Hartaningsih, personal communication), suggesting 
evolution of the host/pathogen relationship towards a more stable state, probably by 
selection for resistant animals in the population of the endemic areas (Coffin, 2004). 
New outbreaks in naïve populations still cause high case fatality rates among 
infected animals.  
The Retroviridae. 
The Retroviridae is a large and diverse family of viruses and contains many 
important human and mammalian pathogens, causing mainly but not exclusively, 
immunosuppressive and transformational diseases. They are, typically, enveloped 
positive-sense single-stranded RNA (ssRNA) viruses ranging from 60-120 nm in 
diameter, with each virion containing 2 identical copies of the genome, which are 
capped and polyadenylated in the manner of messenger RNA (mRNA). The viral 
genome is not processed directly as mRNA, however, but a virus encoded reverse 
transcriptase (RT) produces a double-stranded DNA (dsDNA) intermediate in the 
cytoplasm of an infected cell that is transported to the nucleus and incorporated into 
the host cell genome (Pringle, 1999). Incorporation into many sites of the genome is 
possible with a wide range of preferences, mediated by the central core of the virally 
encoded integrase (IN) (Shibagaki and Chow, 1997). The unique feature of the 
retroviruses is the subsequent expression of viral proteins from this integrated 
provirus (Flavell, 1995). Most retroviruses only replicate in actively dividing cells, 
with the exception of the lentiviruses which require terminally differentiated cells 
for replication. 
Before the advent of nucleic acid sequencing, the classification of this group was 
based on electron microscopic studies revealing the morphology, subcellular 
location and the nature of the budding process as the virus is released from the cell 
(Pringle, 1999). Type-A viruses are non-infectious, replication-deficient and passed 
on to the daughter cells as provirus during mitosis. They are only found   21 
intracisternally, surrounded by a membrane, forming what is termed an intracisternal 
A particle (IAP). Type-B virions are assembled by budding of pre-assembled 
immature particles, resembling IAP, through the plasma membrane to produce virus 
particles possessing an eccentric core, whilst Type-C particles are not seen in the 
cytoplasm, but are assembled at the plasma membrane during budding. Type-D 
viruses form in a similar manner to Type-B, but possess a characteristic cylindrical 
or cone-shaped core (Pringle, 1999). Differences in genome nucleotide sequences 
revealed by molecular techniques have superseded this original taxonomy, although 
it is still used to identify the mode of budding and viral assembly. Contemporary 
taxonomic techniques currently divide the Retroviridae into 7 genera (Pringle, 
1999): Alpharetrovirus, Betaretrovirus, Gammaretrovirus, Deltaretrovirus, 
Epsilonretrovirus, Lentivirus and Spumavirus. In addition, there are endogenous 
retroviruses that have not yet been classified into genera. 
The genus Alpharetrovirus, which contains the former avian type C retroviruses, 
includes the avian leucosis and avian reticuloendotheliosis viruses associated with 
transformation of cells and neoplasia (Pringle, 1999). The earliest evidence for the 
ability of a transmissible agent to cause neoplasia was obtained in a series of 
experiments in chickens early in the 20
th century, and the alpharetrovirus responsible 
was ultimately named Rous sarcoma virus (Rous, 1979; Rous, 1983).  
The genus Betaretrovirus contains the former mammalian type B and type D 
retroviruses. The type D retroviruses are morphologically similar to the type B but 
differ genetically and most members, including the prototype Mason-Pfizer monkey 
virus, cause an acquired immunodeficiency in primates (Pringle, 1999). The only 
non-primate virus in this group, Jaagsietke retrovirus, infects sheep and causes a 
pulmonary adenomatosis. This virus is closely related to an endogenous retrovirus in 
sheep and represents one of the few instances where both an exogenous and 
endogenous form of a retrovirus exists (Bannert and Kurth, 2004).  
The genus Gammaretrovirus, consisting of the former mammalian type C 
retroviruses, includes the murine leukaemia virus-related viruses and the feline 
leukaemia virus group (Pringle, 1999).   22 
The genus Deltaretrovirus contains the human and simian T-lymphotropic viruses 
together with bovine leukaemia virus, based on their genomic organisation. These 
viruses transform lymphocytes readily in an integration-site independent manner, 
causing T and B cell leukaemias (Pringle, 1999).  
The genus Epsilonretrovirus comprises a group of fish retroviruses (Pringle, 1999). 
The genus Spumaretrovirus, the foamy virus group (Delelis et al., 2004), originally 
consisted of a small number of isolates present in cell cultures derived from 
mammalian tissues, but recently they have been isolated directly from a variety of 
mammalian sources including non-human primates and these may have been 
transmitted to humans (Jones-Engel et al., 2005). They are not known to be 
associated with any disease syndrome.  
Endogenous retroviruses, or transmissible retrovirus-like agents, are not yet 
subclassified within the family Retroviridae. These retroelements comprise about 
5% of the human genome and the genome of many other animal species. Most are 
replication deficient, having acquired many deletions since their integration into the 
germ-line genomes of their hosts. “Younger” endogenous retroviruses have fewer 
deletions and one human endogenous retrovirus (HERV-K113), estimated to have 
integrated less than 200,000 years ago, contain ORFs for all retroviral genes and are 
theoretically capable of producing viable virus (Bannert and Kurth, 2004). The 
endogenous retroviruses are currently the subject of much research effort, as there 
are suspicions they may be implicated in the pathogenesis of many human and 
animal diseases. Oncogenesis, schizophrenia and multiple sclerosis are possible 
deleterious results of ancient endogenisation of retroviruses; conversely, the 
presence of an endogenous retrovirus can protect against infection with its 
exogenous counterpart (Bannert and Kurth, 2004). 
The lentiviruses. 
This group of retroviruses are a morphologically and genetically distinct genus 
infecting a wide range of mammalian host species. The name ‘lentivirus’ was coined 
because the disease caused by the first member of the group to be identified was a 
very slowly progressive chronic viral pneumonia in sheep, first seen in Montana in   23 
1923 (Dawson, 1980). The genus includes equine infectious anaemia virus (EIAV), 
ovine maedi-visna virus (MVV) and caprine arthritis-encephalitis virus (CAEV), 
feline immunodeficiency virus (FIV), 2 bovine lentiviruses (BIV and JDV) and the 
primate lentiviruses. The primate viruses include several simian immunodeficiency 
viruses (SIV) and the 2 human immunodeficiency viruses (HIV-1 and HIV-2) (Joag, 
1996). 
Organisation of the lentivirus genome.  
All of the known lentiviruses possess a characteristic genome organisation, 
increasing in complexity from the most simple, EIAV, to the most complex, HIV-1. 
In each virion, there are 2 identical strands of ssRNA joined by a 5’ hydrogen bond 
(Coffin, 1992a). These strands each consist of the 3 obligatory gag, pol and env ORF 
characteristic of all retroviruses, flanked at each end by long terminal repeats (LTR) 
containing enhancer and promoter regions as well as 3’ RNA processing sequences. 
The ORF gag, pol and env each encode polyproteins that are post-translationally 
cleaved to give the structural and functional proteins of the virus. The ORF gag 
encodes a precursor polyprotein that is cleaved to give the 3 major non-glycosylated 
structural proteins MA, CA and nucleocapsid (NC), as well as p6 in HIV-1. The 
ORF pol encodes the viral protease (VP), polymerase (POL), IN and reverse 
transcriptase (RT). The ORF env encodes the surface glycoproteins SU and TM. In 
addition to these 3 main ORFs encoding the major proteins, which are expressed 
from singly spliced mRNA’s, multiple splicing of transcripts can give rise to a range 
of accessory genes, not all present in all virus species, including tat, rev, vif, vpr, vpu 
and tmx (Figure 2.3), each coding for proteins of the same names, with various 
functions described in the section outlining the viral replication cycle. The regions of 
env coding for SU and TM are proposed to also encode the Rev response element 
(RRE). The ends of the RNA strand consist of U3, R and U5 regions together 
making up the LTR which exists functionally only in the proviral genome. This 
contains the TATA box, essential for eukaryotic promoter recognition, the primer 
binding site used for initiation of negative-strand synthesis and transcription 
termination motifs, other enhancer sequences, the NF-k binding site and the trans-  24 
activation response site (TAR), the binding site for the trans-activating protein Tat 
(Chadwick et al., 1995b).  
 
Figure 2.3 Schematic representation of the proviral genomic organisation of the lentiviruses: 
HIV-1, HIV-2 (Coffin, 1992b), SIV (Hayden et al., 1998), BIV (Gonda et al., 1994), JDV 
(Chadwick et al., 1995b), FIV(Zou et al., 1997), the small ruminant lentiviruses (CAEV and 
MMV) (Pyper et al., 1986; Harmache et al., 1995) and EIAV (Noiman et al., 1991). The ORF 
are depicted in 3 rows that are not indicative of the reading frame arrangement. 
Morphology of the lentiviruses. 
Figure 2.4 shows the typical morphology of a spherical encapsulated lentivirus 
particle, approximately 100 nm diameter. The envelope is derived from the lipid 
bilayer membrane of the host cell as the virus buds during the final maturation 
process. The surface projections consist of the env-encoded glycoproteins SU and   25 
TM, formed into ‘spikes’ visible by electron microscopy. The viral membrane 
contains an eccentrically located bar-shaped nucleocapsid, distinct from the central 
spherical capsid seen in C-type retroviruses (Desrosier, 2001), surrounding the viral 
RNA and virion enzymes. 
 
Figure 2.4 Schematic diagram of the structure of HIV, typical of other lentiviruses. The 
viruses are approximately 100 nm diameter and contains the inner core or capsid (CA) which 
may be bar or cone-shaped, within which is the 2 segments of the virus RNA genome and 
various virus-coded enzymes required for replication (IN, PR and RT). The capsid is 
surrounded by the matrix (MA) and an envelope derived from the membrane of the host cell 
as the virus matures by budding. Projecting from the envelope are 2 virus-encoded 
glycoproteins, SU and TM. Diagram reproduced from www.fsm.ac.fj (accessed 31/08/05).  
Pathogenesis of lentivirus infections. 
While there is an obvious similarity in the genome organisation of the 8 main 
genera, the pathology of the diseases caused by them varies markedly. The diseases 
they induce range from transient acute infections, chronic lymphoproliferative 
diseases associated with immunosuppression, chronic lymphoproliferative disease 
without immunosuppression but leading to organ failure, and an acute episodic 
disease with immunologically-mediated anaemia (Joag, 1996). The complex 
replication cycle of lentiviruses in target cells is in part responsible for the differing 
pathogenesis seen.   26 
The primate lentiviruses HIV and SIV. 
The type species of the genus Lentivirus, human immunodeficiency virus type 1 
(HIV-1), infects CD4
+ lymphocytes leading to an immunosuppression and 
subsequent secondary infections. This virus has been the subject of an intense 
research effort since its discovery and identification as the causative agent of human 
acquired immunodeficiency syndrome (AIDS) (Barre-Sinoussi et al., 1983; Gallo 
and Wong-Staal, 1985). HIV-1 originated from a cross-species transmission from 
chimpanzees Pan troglodytes troglodytes of simian immunodeficiency virus (SIVcpz) 
to humans on at least 3 or 4 separate occasions (Gao et al., 1999); AIDS is therefore, 
“a human infectious disease of zoonotic origin” (Apetrei et al., 2004; Marx et al., 
2004; Keele et al., 2006). Contaminated oral polio vaccines prepared in primate 
primary cell cultures were proposed as a possible route of infection of the virus to 
humans but this has since been refuted (Worobey et al., 2004) and contact with 
blood during slaughter of chimpanzees for food is thought to be the most likely 
source of the original transmission (Marx et al., 2004).  
Another distinct retrovirus causing AIDS in humans, HIV-2, arose as a consequence 
of cross-species transmission from sooty mangabeys (Cercocybus atys) to humans of 
SIVsm (Marx et al., 1991). These cross-species transmissions seem to occur 
relatively frequently between simian species as well as from simians to humans 
(Sharp et al., 2000) and analysis of the mutation rates of HIV-1 places the 
transmission of SIVcpz to humans at approximately the middle of the 20
th century 
(Sharp et al., 2000). The human and simian retroviruses form the largest related 
group of retroviruses, and an indication of their variety and relatedness to each other 
and the non-primate lentiviruses is shown in Figure 2.5.   27 
 
Figure 2.5 Phylogenetic relationship among representative primate and non-primate lentiviruses 
based on the sequence of gag genes. For HIV-1, 3 genetic groups (M, N and O) are shown. Strains 
of SIV have a subscript denoting the species from which they were isolated: chimpanzee (cpz), 
macaque (mm), African green monkey (agm), l’Hoest monkeys (lhoest), suntailed monkeys (sun), 
sykes monkeys (syk),and mandrills (mnd). Adapted from Lesnik (2002). 
Transmission of HIV is caused mainly by transmission of cell-associated virus in 
semen during heterosexual sex, resulting in infection of dendritic cells in the mucous 
membrane, with alternative routes possible and including homosexual sex, blood 
borne transmission either through contaminated needles or contaminated blood 
products, and maternal transmission either during parturition or in breast milk (Pillay 
et al., 2000). The pathogenicity of the various human and simian retroviruses 
appears to be related to the length of time since the original infection of the host. In 
their natural hosts, SIVcpz and SIVsm are transmitted by both sexual means and via 
breast milk, and in these natural hosts they have adapted and produce asymptomatic 
infections (Emau et al., 1991; Rey-Cuille et al., 1998; Hirsch et al., 1999). Cross-
species transmission results in a range of outcomes, one of which is a conversion 
from an asymptomatic infection to a highly pathogenic infection that progresses to 
an AIDS-like state (Apetrei et al., 2004).  
FIV. 
The immunodeficiency resulting when humans are infected with HIV-1 or HIV-2, 
and when primates are infected with heterologous SIV isolates, is also seen when 
domestic cats are infected with heterologous members of the FIV group. 9 species of   28 
Felidae including lions (Panthera leo) and puma (Felis concolor) and one member 
of the Hyaenidae, the spotted hyena, harbour FIV-like lentiviruses, mostly without 
any associated pathology, suggesting a commensalism analogous to that seen in 
primates infected with SIV. Cross-species transmission of these adapted viruses can 
result in disease that is similar to that seen after FIV infection of domestic cats 
(Troyer et al., 2005). The disease seen in domestic cats is very similar to that seen 
after human infection with HIV and therefore FIV infection of cats been used 
extensively as a non-primate animal model for the study of HIV infection in humans, 
especially for the study of vaccine strategies (Hosie et al., 1995; Hosie et al., 2000). 
FIV is spread horizontally by biting, and also vertically in utero, and to kittens while 
suckling, although sexual transmission has been demonstrated (Jordan et al., 1998). 
The diseases induced by HIV-1 and HIV-2, the SIVs and FIV have many 
similarities. Initial infection and dissemination of the virus throughout the body is 
followed by an acute flu-like disease, sometimes with a range of other symptoms 
such as oral candidiasis, anorexia and neurological features, associated with high 
levels of virus replication (Vanhems et al., 1999). These high levels of virus 
replication then decrease to much lower levels (but are not eliminated entirely) 
initially by non-specific and later by specific host immune responses (D'Souza and 
Mathieson, 1996). The ability of the immune system to reduce virus load varies from 
individual to individual, and the level of the “set-point” (the steady state viral load 
attained after the initial clinical disease) is strongly correlated with the rate of 
progression to immune collapse and the onset of AIDS (Blattner et al., 2004). The 
incubation period prior to development of acute disease, as well as the duration of 
acute disease, is also prognostic of the rate of progression to disease, with longer 
incubation periods and a longer duration of the acute disease significantly correlated 
with delayed progression (Vanhems et al., 2000).    29 
 
Figure 2.6 Infection time course of a typical HIV-1 infection, the best characterised lentivirus 
infection. Soon after primary infection an acute disease process occurs that is associated with 
flu-like symptoms, a transient high plasma virus load and a decrease in CD4
+ cells. This is 
followed by a long symptom-free period, with a progressive slow decrease in CD4
+ cells and 
eventual further increase in virus load leading to the onset of immunosuppression and 
opportunistic secondary infections (AIDS). Adapted from Weiss (1993). 
 
The time course of a typical HIV-1 infection in humans is illustrated in Figure 2.6. 
After the initial acute disease process, a symptom-free period follows that can range 
in duration from a few weeks in SIVsmmPBJ14 infections of non-human primates to 
many years in HIV infection of humans. The lack of progression to AIDS in 
monkeys naturally infected with homologous SIV strains may be simply due to the 
clinically latent period exceeding the lifespan of the animal, as AIDS has recently 
been seen in a naturally infected sooty mangabey kept in captivity for 18 years (Ling 
et al., 2004). The initial acute phase of the disease is characterised by a transient 
depletion of circulating immune cells and very high plasma virus loads, with up to 
10
9 virus particles/ml of plasma. Even in the asymptomatic period, the virus is not 
latent but is continually produced from newly infected cells. The virus load during   30 
HIV-1 infections may slowly increase by about 0.1 log10/year until symptoms of 
AIDS appear (Sabin et al., 2000). 
The increase in levels of virus replication during the later phase of infection is 
characterised by the development of AIDS, the onset of multiple opportunistic 
infections due to destruction of the CD4
+  T-cell population. Other effects include 
central nervous system effects such as dementia due to aberrant signalling from 
infected macrophages, and the wasting associated particularly with HIV-2 infections 
in Africa. Switching of receptor utilisation from CCR5 to CXCR4 late in the course 
of the infection hastens the onset of AIDS as these strains are more virulent (Weiss, 
2000). 
EIAV. 
In contrast to the progressive immunodeficiencies caused by the lymphotropic 
retroviruses, the macrophage-tropic members of the family cause diseases with a 
different pathogenesis. EIAV, the only equine lentivirus, was the first non-plant 
virus to be discovered (Vallee, 1904) and was only characterised about 30 years ago 
(Charman et al., 1976). It causes a contagious disease in horses and mules and is 
capable of infecting donkeys without causing clinical disease. Initial infection is 
associated with an acute disease, characterised by anorexia and depression and a 
very high fever, which can be fatal (Dawson, 1988). In animals that survive this 
acute disease, this is followed by a persistent episodic anaemia, as erythrocytes 
become coated in viral components, leading to haemolysis and phagocytosis 
(Cheevers and McGuire, 1985; Sentsui and Kono, 1987). Central nervous system 
involvement is only occasionally seen (Oaks et al., 2004). The periodic clinical 
relapses, of a couple of days duration, are initially seen every 1-2 weeks but the 
intervals between relapses progressively lengthen until complete remission is 
attained. During the relapses, body temperature is elevated, there is anaemia and 
oedema of the abdomen, and an increase in the viral load in plasma, which has to 
reach a ‘pathogenic threshold’ to cause disease (Leroux et al., 2004).  Remission is a 
result of the establishment of immune control, involving both arms of the immune 
system, which reduces the rate of viral replication below the pathogenic threshold.   31 
However,  virus persists within macrophages in tissue sites (Harrold et al., 2000) and 
recrudescence of  disease can be induced by administration of immunosuppressive 
drugs throughout the animals life (Leroux et al., 2004). Transmission is by 3 
methods: by biting flies that are able to mechanically transmit the infection; by 
vertical transmission to foals from infected dams; by prolonged contact with infected 
animals, either clinically affected or asymptomatic carriers, even in fly-free 
conditions (Dawson, 1988). 
The small ruminant lentiviruses, MVV and CAEV. 
MVV causes 2 conditions in sheep, a slowly progressive chronic pneumonia and a 
neurological disease. The respiratory form of the disease (maedi) is caused by the 
same virus associated with the paralytic form of the disease referred to as ‘visna’ 
(Cutlip et al., 1988). MVV is an exogenous retrovirus that can infect both sheep and 
goats (Shah et al., 2004) and is closely related to CAEV causing caprine arthritis and 
encephalitis in goats, and the 2 viruses are sometimes grouped together and referred 
to as small ruminant lentiviruses (SRLV) (Leroux et al., 1997). The 2 clinical forms 
of the disease, maedi and visna, occur in sheep over 3 years of age, and mastitis and 
arthritis are also seen occasionally (Dawson, 1987). Transmission is via nasal 
secretions when sheep are penned together for long periods, as is the case in 
Icelandic winter, and transmission from infected dam to lamb during suckling is also 
common (De Boer et al., 1979; Preziuso et al., 2004). In goats infected with CAEV, 
the arthritis occasionally seen in MVV-infected sheep is the dominant clinical 
manifestation in mature goats, with pneumonia and mastitis also manifest in many 
infected animals. The lesions are slowly progressive and can persist for several 
years. Transmission is through kids drinking milk from infected females, and spread 
from sheep to goats and vice versa of a subtype of the SRLV has also been 
demonstrated recently (Shah et al., 2004). The lesions are associated with viral 
infection of monocytes and macrophages. 
The bovine lentiviruses, BIV and JDV. 
BIV was originally isolated in the early 1970’s in the USA from a cow with 
persistent lymphocytosis, emaciation and weakness (Van der Maaten et al., 1972).   32 
Little research effort was expended on this virus until the emergence of HIV/AIDS 
in the human population, and the resultant upsurge in interest in all lentiviruses, 
when the nature of the virus was revealed by molecular genetics and antigenic 
studies (Gonda et al., 1987). Serological studies have indicated this virus or an 
antigenically related virus is widespread in the cattle population in many countries 
and while it has been reported in association with secondary disease due to 
immunosuppression, lesions of the legs and feet and CNS involvement presenting as 
‘dullness and stupor’(Snider et al., 1997), its association with these disease 
syndromes is unclear. The virus is strongly cell-associated, and has been identified 
in milk, suggesting a lactogenic pathway of transmission (Nash et al., 1995), as well 
as infection in utero (Moody et al., 2002) 
JDV was classified as a lentivirus on the basis of its close genetic relationship to 
BIV even though the nature of the disease associated with JDV is very different to 
that detected in association with BIV (Chadwick et al., 1995a). Although the nature 
of the disease process, an acute disease process after a short incubation period with 
no recurrence of disease in those animals that survive the acute disease, is very 
different to that associated with most other lentivirus infections, there are similarities 
between the JDV-associated disease and the acute transient disease process observed 
soon after infection by some other lentiviruses. 
Based on the finding of Bali cattle in Indonesia sero-positive to JDV in areas where 
JD is not present, an endemic infection of Bos javanicus with BIV or another 
antigenically-related non-pathogenic bovine lentivirus has been postulated 
(Hartaningsih, personal communication). 
Replication of the lentiviruses. 
A schematic illustration of the various steps involved in the replication of 
lentiviruses is shown in Figure 2.7. The cell surface receptors used by lentiviruses 
include molecules such as heparan sulphate (Nisole and Saib, 2004), and in the case 
of macrophage tropic (M-tropic) HIV-1, the macrophage mannose receptor via 
mannosylated resides on SU (Nguyen and Hildreth, 2003). In HIV-1 infections, the 
surface glycoprotein complex of SU (gp120) and TM (gp41) of which there are   33 
about 100/virion, mediates entry of the virus into the cell via their specific 
interaction with cell receptors and co-receptors. SU initiates viral entry by 
specifically binding to cell surface receptors (CD4 in the case of HIV) and co-
receptors CXCR4 (used by T-tropic HIV isolates) and CCR5 (used by M-tropic HIV 
isolates). Other strains of HIV have been found to utilise CCR3, CCR2b, 
Bonzo/STRL33 and BOB/GPR15 as co-receptors (Frankel and Young, 1998). SIV 
isolates utilise the same array of receptors and co-receptors as HIV (Muller-Trutwin 
et al., 2000; Owen et al., 2000) and it has been postulated that similarities in the 
amino acid profile of the C2-V3-C3 region of the SU protein to that of the 
chemokines whose receptors these viruses utilise indicates their ancestral acquisition 
of host chemokine genes (Shimizu and Gojobori, 2000). The identity of the receptor 
for the SRLV’s, which are capable of infecting macrophages and dendritic cells in 
vivo, is not known. Icelandic and UK strains of MVV can infect a wide range of 
cells in vitro, while North American isolates are restricted to ruminant cell lines 
(Hotzel and Cheevers, 2002b) as is CAEV (Hotzel and Cheevers, 2001; Hotzel and 
Cheevers, 2002a).  
EIAV has been shown recently to utilise a single molecule, related to the tumour 
necrosis factor receptor, to enter permissive host cells of the monocyte-macrophage 
lineage, without a requirement for co-receptors (Zhang et al., 2005). 
FIV, despite its tropism for CD4
+ T-cells early in infection, does not use CD4 as a 
receptor, although it does use CXCR4 as a co-receptor. Instead, the receptor has 
been identified as CD134, which is up-regulated in activated CD4
+ T-cells cells (de 
Parseval et al., 2004; Shimojima et al., 2004).    34 
 
Figure 2.7 Steps in the replication of a typical lentivirus. Reproduced from www.molmo.be 
(accessed 28/07/06). Initial attachment via the viral envelope glycoprotein SU to cell surface 
receptors is followed by fusion of the viral envelope with the plasma membrane of the cell, 
involving TM, then uncoating of the virus particle, reverse transcription of the viral ssRNA 
genome to a dsDNA intermediate or provirus, integration of this provirus into one or more sites 
in the cellular genome, transcription and translational events involving the proviral DNA to 
produce virus proteins, followed by assembly involving budding from the plasma membrane 
and final maturation of the virus particle after release. 
The receptor for BIV is not known but there are reports this virus is pantropic, 
infecting T-cells and B-cells as well as cells of monocyte-macrophage lineage 
(Whetstone et al., 1997; Heaton et al., 1998). This is in contrast to the tropism for 
monocyte/macrophage cell populations exhibited by the other ungulate lentiviruses.   35 
The target cell and receptor for JDV are also not known, although a reported 
decrease in the ratio of bovine CD4
+/CD8
+ cells in the lymph nodes of Bali cattle 
infected with JDV (Dharma et al., 1994) suggests that the virus exhibits tropism for 
at least T-cells, again in contrast to the other ungulate lentiviruses. The close 
relationship of BIV and JDV may be reflected in a similar pantropic array of target 
cell types for JDV. 
After the initial interaction of SU with its specific receptor and co-receptors, 
conformational changes bring TM into contact with the cell surface, initiating fusion 
of the viral envelope with that of the target cell. Fusion is thought to be initiated by 
an N-terminal hydrophobic peptide, with a transmembrane core region also 
important for fusion as well as anchoring the Env complex into the viral particle 
(Frankel & Young, 1998). The main feature of the TM molecule is a highly 
conserved region, bounded by 2 cysteine residues, that is highly immunogenic and 
termed the Principal Immunodominant Domain (PID). The TM monomer of JDV is 
slightly bigger than that of HIV-1, consisting of 359 amino acids with a molecular 
weight of 41.1 kDa (Chadwick et al., 1995b). 
Following fusion of the viral particle with the host cell membrane, and as depicted in 
Figure 2.8, the viral core enters the cytoplasm and is disassembled or “uncoated” to 
create sub-viral particles termed reverse transcription complexes (RTC) and pre-
integration complexes (PIC). PICs contain the viral enzymes present in the viral 
particle, the accessory proteins Nef and Vif, and the host protein cyclophorin A 
(Nisole and Saib, 2004). Reverse transcription of the viral genome occurs during this 
phase, as the complex moves towards the nucleus. A tRNA
Lys packaged into the 
virion acts as a primer for transcription initiation, binding to the site in the U3 region 
of the genome (Le Grice, 2003). Transcription proceeds to the 5’ end of the genome, 
producing what is known as the strong-stop DNA (Huthoff and Berkhout, 2001). 
Continued synthesis of the negative-sense ssDNA utilises this strong-stop DNA as a 
primer for reverse transcription of the second strand of viral RNA from the 3’end. 
Degradation of the viral RNA occurs as the ssDNA is produced, except for the 
polypurine tract at the 5’ end of the U3 region(Roda et al., 2003), which acts as a 
primer for synthesis of the positive-sense DNA strand also by the reverse   36 
transcriptase. The error-prone nature of the RT (about 3.4 x 10
-5 errors/bp/cycle) 
(Mansky and Temin, 1995) is responsible for the high mutation rate characteristic of 
the lentivirus family.  
 
Figure 2.8 Steps involved in the replication of HIV until integration of the dsDNA intermediate 
provirus into the cellular genome. Further description of the events involved in provided in the 
text. Reproduced from Bukrinsky (2004).  
The movement of the RTC through the viscous cytoplasm appears to be via 
interaction with the cytoskeleton of the cell, although the mechanics of the process 
are still unclear (Bukrinskaya et al., 1998). Phosphorylation of MA by virion-
associated mitogen-activated protein kinase (MAPK) has been proposed as a 
possible targeting mechanism (Tang et al., 1999). The ability of the lentiviral PIC to 
enter the intact nucleus, rather than waiting for nuclear membrane breakdown as in 
the case of other retroviruses, confers the characteristic ability of lentiviruses to 
infect terminally differentiated non-dividing cells (Weinberg et al., 1991).    37 
The entry of the PIC into the nucleus is probably reliant on the host cell nuclear 
import proteins. The viral proteins MA, IN and Vpr are proposed to interact with the 
host nuclear transport machinery. MA is found in close proximity to the PIC as well 
as in the extra-capsid layer, and in HIV-1 it carries 2 nuclear localisation signals 
(Dingwall and Laskey, 1991). The IN is karyophilic and interacts with importins 
presenting a possible route for the PIC to enter the nucleus via the nuclear pores 
(Bukrinsky, 2004). The role of Vpr in the entry of the PIC of HIV-1 into the nucleus 
is unclear; it is not strictly required, as viruses lacking Vpr can still replicate but with 
reduced efficiency in macrophages (Heinzinger et al., 1994). 
Integration of viral dsDNA into the host chromosome ensures the survival of the 
virus, as it can then be transmitted from cell to cell as a provirus in the normal 
course of cell division. Integration requires the viral IN: initially, 2 3’ nucleotides 
are removed from the linear viral DNA, leaving overhanging ends, which are then 
covalently joined to the 5’ ends of the target DNA. The integration is completed as 
unpaired nucleotides are removed form the viral 5’ ends, and these are joined to the 
target 3’ ends (Frankel and Young, 1998). Integration can be at many sites within the 
genome (Shibagaki and Chow, 1997) but in HIV infection, mapping of over 500 
integration sites has revealed a preference for genes actively transcribed by RNA Pol 
II (Schroder et al., 2002), thus ensuring transcription of viral genes. The process of 
integration is complex, requiring interaction of the viral integrase and DNA with 
numerous host proteins and culminating in the permanent integration of the viral 
genome into that of the host, where it resides ready for eukaryotic expression of viral 
genes (Nisole and Saib, 2004). 
Within 30 min of infection of T-cells with HIV, changes in the expression levels of 
an array of host genes are seen, with about 8% being upregulated and 9% being 
downregulated. Integration into the upregulated genes is favoured (Schroder et al., 
2002). The changes in expression levels occur before integration can have taken 
place, and several routes of activation, such as signalling post-CD4 binding events 
(Davis et al., 1997) or Nef-related activation of signalling pathways (Simmons et al., 
2001) are postulated. The result is to engender an environment conducive to viral 
replication.    38 
Initial transcription is controlled by constitutive host factors, including activation of 
the NF-κβ family of transcription factors involved in the response of the cell to 
infection, which interact with the LTR region of the proviral genome (Cullen, 1991). 
Early events in transcription produce multiply spliced mRNAs, encoding the 
regulatory proteins Tat and Rev, Nef and S2 (Saltarelli et al., 1996). Of these, Tat is 
responsible for greatly enhancing the synthesis of viral RNA through interaction 
with the transactivation response (TAR) element in the LTR region, increasing the 
processivity of the transcribing polymerases (Frankel and Young, 1998). Further 
regulation is provided by Rev. The default pathway is for the production of multiply 
spliced transcripts, and to overcome this, Rev binds to the RRE enabling the 
transport to the cytoplasm of unspliced mRNA transcripts coding for the viral 
structural proteins and glycoproteins, thus committing the virus to the final 
cytopathic stage of the replication cycle (Cullen, 1991). The RRE in HIV-1 is in env 
and of 2 putative RRE in JDV, one is postulated to consist of bases 6399-6590, lying 
across the junction between su and tm in env, while the other lies entirely within tm, 
spanning bases 7015-7423 (Lesnik et al., 2002). Nef is capable of downregulating 
CD4, and may thus aid release of the Env polyprotein from the endoplasmic 
reticulum, where newly synthesised molecules held by interaction with CD4 
(Frankel and Young, 1998) allow incorporation of SU and TM into the cell 
membrane and aid in budding by removing CD4 from the cell surface (Weiss, 2000). 
This may also decrease subsequent entry of further viruses into a previously infected 
cell. 
The translation of the lentiviral structural genes within the cytoplasm is 
accompanied by translation of a range of accessory genes that are more numerous in 
the complex primate lentiviruses and they aid in assembly and to confer infectivity 
and pathogenicity to the assembled particle. In the primate lentiviruses, these genes 
include vif, vpr, vpu in HIV-1, vpx in HIV-2 (Weiss, 2000) and in BIV they are vpw 
and vpy. JDV possesses vif only, which is likely to aid packaging of NC during 
assembly. 
Assembly of the new virus is directed by the Gag protein and its interaction with a 
network of cellular proteins (von Schwedler et al., 2003). Gag is produced as a   39 
polyprotein and cleaved by viral PR. The cleavage products are MA which is present 
between the viral membrane and the capsid in the assembled virion, CA that forms 
the core containing the RNA and NC which coats the RNA (Tritel and Resh, 2000). 
The p6 protein in HIV is responsible for controlling the size of the assembled 
particle (Garnier et al., 1998; Garnier et al., 1999) and for incorporation of Vpr 
during assembly of HIV-1 (Frankel and Young, 1998). Vpr is involved in cell-cycle 
arrest (Weiss, 2000). The assembly of the virus is an ordered process, with 
membrane-bound Gag, mediated by an N-terminal motif, progressively undergoing 
multimerisation under the plasma membrane, which contains SU and TM at this 
stage. Some host proteins are thought to be excluded, and viral proteins are 
requisitioned, as the new viral particle buds from the membrane (Tritel and Resh, 
2000). As stated above, the retroviruses were originally classified according to the 
type of budding utilised, and JDV utilises type C budding (Kertayadnya et al., 
1993). In T-lymphocytes, the production of virus usually results in cell death, 
whereas in macrophages viral production can continue at a lower level for long 
periods (Weiss, 2000). 
Natural and immune resistance to lentiviral infections. 
The analysis of the protective immune response to infection provides an approach to 
rational vaccine design but the paucity of examples of natural immunity to HIV 
infection largely precludes this approach to identification of the biological correlates 
of protection. Though rare, examples of resistance to infection occur in some people 
(exposed-uninfected) who were exposed to the virus, often repeatedly, notably sex-
workers, sexual partners of infected individuals, babies born to infected mothers, 
intravenous drug users, and haemophiliacs. Of interest in the search for immune 
correlates are people who are infected but in whom disease does not develop or its 
progression is slow, termed long-term non-progressors (Marmor et al., 2006). 
Natural resistance can be genetic, resulting from mutations in the viral receptor 
genes, differences in the MHC and HLA allotypes between infected and uninfected 
individuals (Trachtenberg et al., 2003) or differences in the regulation of cytokine 
production. Co-infection with the hepatitis C virus-related GB virus-C was linked to   40 
long-term non-progression of HIV-1 infections in intravenous drug users [reviewed 
by (Marmor et al., 2006)]. Adaptive immunity-mediated resistance to infection in 
this group is rare although CTL responses may be important in the resistance to HIV 
infection of sex-workers in Kenya (Rowland-Jones et al., 1998) and in health care 
workers that do not develop infection after exposure to body fluids from infected 
individuals (Pinto et al., 1995). However, HIV-1 specific CTL were not deemed 
responsible for resistance to infection in one study of apparently resistant 
homosexual men (Koning et al., 2004). 
High levels of mutation are responsible for lack of natural 
immunity. 
The lack of examples of natural immunity highlights the problem of designing 
vaccines to engender immunity to lentiviruses, due in part to the extreme variability 
of the lentiviral genome. Lentiviruses lack an RT proofreading mechanism and so 
have a very high rate of spontaneous introduction of errors into their genome. 
Multiple insertions of viral genomes into a single cell also gives rise to heterozygous 
virus (Jung et al., 2002). Insertions, duplications, deletions and recombinations of 
genetic material all contribute to heterogeneity of the population. During HIV-1 
infection, the high mutation rate ranging from 0.2-2 mutations per genome per cycle 
and the very high replication rate results in the generation of ~10
4-10
8 mutant virus 
particles/day in chronically infected individuals (Peyerl et al., 2004). This, combined 
with good tolerance of changes arising from the continual mutations, means that 
while any new infection probably arises from a fairly homogenous viral inoculum, 
the intrahost population quickly becomes a swarm of quasispecies (Saag et al., 1988; 
Goodenow et al., 1989). Under selection pressure from the immune system, the 
stochastic nature of the process of mutation gives rise, over periods of time 
calculated to be up to several years (Liu et al., 2006a), to new variants with 
mutations in epitopes previously recognised by both arms of the immune system, 
allowing escape from immune surveillance. These ‘escape mutants’ outgrow the 
original population under immune control. Escape from the CTL response is due to 
mutations in viral epitopes recognised by T-cell receptors in the context of MHC   41 
class 1 presentation (Phillips et al., 1991), or in the initial infection by exhaustion of 
clonotypes specific for viral epitopes (Pantaleo et al., 1997b). The selection pressure 
exerted by the immune system on the intra-host viral population means that 
immunocompetent individuals tend to have a heterogeneous viral burden. In 
progressors, the constant attack on the immune defences leads eventually to immune 
collapse and as a result of the absence of continued selection pressure the viral 
population then tends to become more homogenous (Lukashov, 2001). The 
production of mutants by selection pressure can, however, be at a cost to the fitness 
of the virus and the mutations do not necessarily become fixed in the general viral 
population if the pressure is removed (Barouch and Letvin, 2004). 
The early cell-mediated immune response to lentiviral infections. 
The initial burst of viral replication in HIV-1 infection of humans is controlled by an 
oligoclonal expansion of virus-specific CD8
+ T-cells with a restricted pattern of 
variable β-chain T-cell receptor usage (Pantaleo et al., 1997a). The T-cell receptor 
repertoire of the HIV-specific CTL decreases rapidly due to clonal exhaustion, 
contributing to an inability of the immune system to control the replication and 
spread of the virus (Pantaleo et al., 1997b). The specificity of any T-cell response is 
closely correlated to the rates of disease progression and CD8
+ populations 
possessing restricted repertoires of TCR are more rapidly depleted in infected 
individuals than in those possessing wider repertoires, leading to more rapid 
progression of disease (Pantaleo et al., 1997b). The frequency of HIV-specific 
memory T-cells is also closely correlated to progression of disease (Musey et al., 
1997). Virus control in horses infected with EIAV is similarly dependent on the 
induction of specific CTL following infection (McGuire et al., 2004) and depletion 
of CD8
+ lymphocytes was shown to interfere with the ability of macaques to clear 
primary infections with SHIV, a chimeric SIV-HIV (Matano et al., 1998), and lead 
to a rise in plasma viral load (Jin et al., 1999). In contrast, control of replication 
during primary MVV infection of sheep is not dependent on CD8
+ lymphocytes 
(Eriksson et al., 1999).    42 
Control of viral replication is dependent on the quality of the CTL response, with the 
recognition that the response to viral core proteins is associated with slower disease 
progression in HIV-infected individuals (Klein et al., 1995). Constraints on the 
ability of different MHC class 1 alleles to bind viral epitopes, and mutation of viral 
CTL recognition epitopes giving rise to escape mutants, provides another method for 
virus to evade immune control (Phillips et al., 1991; Borrow et al., 1997). Soluble 
factors are secreted by CD8
+ T-cells, including an antiviral factor that acts at the 
level of viral transcription and associated with non-progression during HIV infection 
(Copeland et al., 1995); a range of cytokines are also secreted that are natural 
ligands for CCR5, and interfere with viral entry (Zagury et al., 1998). A role for 
CD4
+ cells in abortive HIV infections has been proposed, following recognition of 
viral epitopes presented by MHC class II alleles and subsequent secretion of 
cytokines and cell proliferation (Clerici et al., 1994).  
Humoral responses to lentivirus infections.  
Neutralising antibodies are also important in controlling virus replication. In HIV-1 
infection the neutralising antibody response is largely directed to epitopes on the 
highly variable V3 loop of the gp120. This variability allows escape mutants to 
evade humoral immune control and replicate for a period until the humoral immune 
system responds by producing further neutralising antibody (Albert et al., 1990). 
Cynomolgus monkeys infected with SIVsm
 showed a strong correlation between the 
presence of a broad repertoire of neutralising antibodies and non-progression to an 
AIDS-like condition. In HIV-1 infection this is not universal amongst non-
progressors, and it is possible that neutralising antibody is merely one method of 
control of an established HIV infection, or that the broad array of neutralising 
antibodies is simply a result of long-term infection whilst remaining 
immunocompetent (Cao et al., 1995; Pantaleo et al., 1995; Montefiori et al., 1996). 
A pre-existing humoral immunity could be effective at preventing the establishment 
of an infection after natural challenge with virus; passive immunisation studies in 
chimpanzees and macaques have shown solid protection in immunised animals when 
subsequently challenged with HIV and SHIV, respectively (Pincus et al., 1996;   43 
Mascola et al., 1999). However, passive administration of antibodies 
prophylactically is only effective if administered within a 6 h period prior to 
exposure (Nishimura et al., 2003). 
Subversion of the immune system by lentivirus proteins. 
In the more complex lentiviruses, several viral proteins are able to manipulate the 
immune system of the host. Apart from the effects on viral transcription seen in 
infected cells, soluble Tat is secreted into the milieu surrounding infected cells and it 
has the capacity to enter uninfected cells directly through the cell membrane in a 
non-receptor-mediated manner (Frankel and Pabo, 1988). Upregulation of CXCR4 
on uninfected T-lymphocytes and macrophages, and CCR5 receptors in 
macrophages is mediated in a dose-dependent manner by soluble Tat (Huang et al., 
1998), postulated to enhance the susceptibility to infection with cell-free virus. 
However, Tat has also been shown to sensitise uninfected cells to apoptosis, whilst 
protecting infected cells from apoptosis (McCloskey et al., 1997). Extracellular Tat 
has profound effects on B-cell differentiation, depending on the receptor used, and 
this leads to the follicular hyperplasia seen in the asymptomatic period of the 
infection (Lefevre et al., 1999). Effects on the regulation of cytokines TNF-β, IL-2 
and IL-4 have been reported in transgenic mice (Garza et al., 1996). Maturation of 
monocyte-derived dendritic cells is induced by biologically active HIV-1 Tat and the 
associated up-regulation of MHC and IL-12, TNF-α and β-chemokines drive Th-1 
responses, presumably providing more target cells for the infecting virus (Fanales-
Belasio et al., 2002). In HIV infections, Nef has been shown to down-regulate CD4 
and MHC Class 1 receptors on the surface of infected cells (Stoddart et al., 2003) 
affecting cytokine activity in Th-1 cells (Collette et al., 1997) and predisposing T-
cells to undergo apoptosis (Zauli et al., 1999). Vpu is also associated with CD4 
degradation in the Golgi apparatus, allowing Env to be transported to the viral 
surface (Willey et al., 1992). In the bovine lentiviruses, the Vpw and Vpy proteins of 
BIV are postulated to have similar functions to Vpu and Vpr in HIV-1 (Gonda et al., 
1990), and the Tmx protein of JDV and BIV may possibly be a Nef-equivalent based 
on its location in the genome (Gonda, 1992).    44 
Vaccination strategies for the control of lentivirus infections. 
The World Health Organisation (WHO) has identified vaccination, or more 
specifically immunisation, as the most cost effective method of increasing health in 
the global population. 9 major human diseases have now been controlled by global 
vaccination programmes. Many vaccines have been introduced in the 2 centuries 
since Jenner’s experiments with variolation as a means of control of smallpox, 
including rabies (1885), plague (1897), diphtheria (1923), pertussis (1926), 
tuberculosis and tetanus (1927), yellow fever (1935), polio (1955, 1962), measles 
(1964), mumps (1967), rubella (1970) and hepatitis B (1981).  
However; new diseases arise constantly and have included Ebola virus, Lassa fever, 
Nipah virus and many others. In 1983, HIV was identified as the causative agent of 
AIDS. The subsequent global pandemic of AIDS has led, as of 2006, to an estimated 
65 million cases worldwide and 25 million deaths (Merson, 2006). 18,000 new 
infections are estimated to occur every day. A vaccine is urgently required. 
The approach to vaccination has in the past been largely empirical, with the exact 
mode of action of effective vaccines and the reasons for the failure of others, often 
unclear. In the veterinary field, this approach has led to vaccines for a wide variety 
of companion and production animal diseases (Carter and Carmichael, 2003). 
However, the 'molecular revolution' in genomics, proteomics and bioinformatics and 
the advances in the knowledge of the precise functioning of the immune system, 
have enabled the concept of rational vaccine design, where the administered antigen 
can be tailored to induce the appropriate immune response to a pathogen by 
targeting the correct pathway for antigen display depending on the route of 
administration. There is, additionally, now a wide choice of adjuvants to induce a 
favourable cytokine milieu for the type of response desired (Singh and O'Hagan, 
1999).  
Many approaches have been tried in attempts to produce effective vaccines against 
lentivirus infections. The research effort invested in the past 25 years to develop a 
vaccine to halt the world-wide increase in HIV infection and the subsequent   45 
pandemic of AIDS has been unprecedented, and yet no safe and effective vaccine 
has been produced.  
Effective vaccines for HIV and probably for all lentivirus infections need to 
stimulate both the humoral and cell-mediated arms of the immune system (Letvin et 
al., 2002; McMichael and Hanke, 2003; Moore and Burton, 2004). Broadly 
neutralising repertoires of antibody combined with robust CTL responses to viral 
epitopes are required for effective control of viral replication, if not sterilising 
immunity, and numerous strategies attempting to elicit these responses have been 
employed.  
Attenuated virus vaccines. 
While some very effective attenuated whole virus vaccines have been developed 
against a range of animal pathogens, problems exist with the use of these vaccines. 
Attenuation can be achieved by the repeated passage of a pathogen in culture but 
although attenuated vaccines may be effective, there is a danger of reversion to 
virulent forms or the failure of the attenuation process to completely remove 
virulence. There are also problems associated with the occurrence of antigenic 
variant organisms that are not controlled by a single vaccine. Additionally, the use of 
inactivated pathogens as vaccines potentially poses a risk of incomplete inactivation, 
as seen with polio vaccines in the 1950s (Brown, 1993; Furesz, 2006), and presents 
difficulties of finding methods of vaccine production and inactivation that do not 
reduce antigenicity and efficacy (Katz and Webster, 1989; Sawyer et al., 1994).  
Attenuation of lentiviruses for use as vaccines has been attempted with some 
success. Cats vaccinated with FIV attenuated by 381 passages in cell culture were 
completely resistant to systemic challenge with a heterologous pathogenic strain of 
FIV and showed greatly decreased clinical signs when challenged with the same 
strain intravaginally (Pistello et al., 2003). A targeted approach to attenuation, where 
individual genes are modified or removed from a vaccine strain of virus, has proved 
effective in several trials. Creation of deletions in the nef gene of a pathogenic strain 
of SIV attenuated the virus such that it could only replicate to a low level in rhesus 
monkeys, in which the virus normally replicated well. Monkeys infected with this   46 
nef deletion mutant were resistant to challenge by a pathogenic strain of SIV but 
reversion of the attenuated vaccine strain to a pathogenic strain eventually occurred, 
with development of AIDS-like symptoms in the inoculated rhesus monkeys (Stahl-
Hennig et al., 1996). The restoration of virulence of the originally attenuated strain 
was shown to be by recombination between the vaccine strain and the virulent 
challenge strain, which occurred after a long period (Gundlach et al., 1998; 
Khatissian et al., 2001). In horses, complete protection against both a rigorous, 
artificially high challenge dose and a low challenge dose repeated several times 
designed to mimic natural transmission, was attained in horses vaccinated with an 
EIAV strain modified by deletion of the S2 accessory gene; this mutant strain 
replicated to low levels but caused no disease and the continuous low level exposure 
to virus resulted in an immune response that enabled the horses to maintain an 
apparent sterile immunity post-challenge with a virulent strain (Li et al., 2003). 
Efficacy of the vaccine was dependent, however, on the degree of attenuation of the 
virus, and the level of maturation of the immune response (Craigo et al., 2005), 
which is a drawn-out process (Hammond et al., 1997). 
As with other lentivirus diseases, the most effective vaccine against CAEV has 
proved to be modified attenuated virus, a tat deletion mutant. Although challenge 
with pathogenic CAEV did not cause severe disease, sterilising immunity was not 
achieved (Harmache et al., 1998). Partial protection against MVV in sheep has also 
been achieved by intratracheal vaccination with an attenuated molecular clone 
(Petursson et al., 2005). 
A different approach to attenuation is to utilise recombinant viruses, where entire 
genes of a pathogenic strain are replaced with that from a non-pathogenic strain. 
When this was tried with the pathogenic SIVmac239, different levels of attenuation 
were attained by replacing the SU region of the genome with that from a non-
pathogenic strain (SIVmac1a11) or conversely by inserting the SIVmac239 SU gene into 
the non-pathogenic SIVmac1a11. The levels of attenuation were determined by the 
initial period of viraemia following inoculation of the viruses into macaques, which 
ranged from 4-6 weeks for the non-pathogenic strain, to 6-8 weeks for the mostly 
SIVmac1a11 strain to 27 weeks for the strain consisting of mostly SIVmac239. The initial   47 
length of viraemia correlated well with the protection achieved and only those 
monkeys vaccinated with the least attenuated strain resisted infection on challenge 
(Lohman et al., 1994).  
The existence of closely related viruses infecting members of the same family, for 
instance the many species of cats infected with FIV, presents the possibility of 
utilising infectious but non-pathogenic virus from a closely related host species as a 
vaccine. Cats infected with puma or lion strains of FIV develop a persistent low 
level, cell-associated viraemia, and when challenged with FIV develop a lower viral 
load (VandeWoude et al., 2002; VandeWoude et al., 2003). A conceptually similar 
approach has been taken with vaccination of horses with EIAV attenuated by 
passage in donkey leucocytes, which induced specific CTL responses and good 
protection against heterologous and homologous challenge (Zhang et al., 2006). This 
suggests that perhaps BIV could induce a protective immunity against the closely 
related JDV.  
An approach to the problem of attenuating virus to a safe level while still retaining 
its ability to engender an effective immune response has been addressed by co-
expression of interleukins in a nef-deficient strain used to infect macaques before 
challenge with SIVmac239. All vaccinated animals were protected against productive 
infection in this way, although pathogenic virus could be detected (Gundlach et al., 
1998). Attenuation of a SIV strain that already had a stop codon mutation in nef, 
SIVmac239nefstop, by replacing the promoter/enhancer region with the immediate early 
promoter region of human cytomegalovirus produced a virus that only replicated to a 
very low level when inoculated into macaques; on challenge with a pathogenic strain 
of SIV viraemia was decreased 1,000-fold (Blancou et al., 2004).  
Inactivated viral vaccines. 
Early studies with inactivated whole FIV showed good protection against low 
challenge doses (Yamamoto et al., 1991). However, initial experiments showed no 
correlation between anti-Env neutralising antibodies and protection in cats 
vaccinated with inactivated FIV, in fact an enhancement of infection occurred 
(Hosie et al., 1992). Further studies, though, involving vaccination of kittens with   48 
paraformaldehyde-inactivated cultures of FIV with a deletion of the endocytosis 
motif from the env gene gave strong antibody responses and a decrease in the peak 
viral load post-challenge (Hosie et al., 2005).  
Inactivation of an infectious molecular clone of SIV provided a protective immune 
response when used as a vaccine but interestingly, individual proteins cloned and 
expressed from the same source did not (Mills et al., 1992). 
The commercially available FIV vaccine (Fel-O-Vax®; Fort Dodge) has shown up 
to 84% protection against intramuscular challenge with heterologous virus in 
vaccinated kittens (Uhl et al., 2002). The importance of a realistic challenge has 
been shown by demonstrating protection in vaccinated animals housed with infected 
cats, as opposed to the failure of protection in animals challenged by more “robust” 
parenteral routes (Matteucci et al., 2000). An apparent enhancement of infection in 
some cats vaccinated with Fel-O-Vax® has been noted where higher levels of virus 
in the acute phase have led to wider dissemination of virus (Dunham, 2006). 
The use of formaldehyde-inactivated SIVmac as a vaccine gave short-term protection 
in macaques against both homologous and heterologous challenge with a low dose 
of cell-free virus; the resistance induced was transient and approximately half of the 
animals succumbed when rechallenged 3 months after the final vaccination 
(Putkonen et al., 1992). The level of protection attained with this vaccine was 
reduced when the monkeys were challenged with PBMC from an infected macaque 
(Heeney et al., 1992). The protection attained with inactivated SIV seems dependent 
on the source of the challenge strain of the virus, as monkeys vaccinated with human 
T-cell culture-derived SIVmac251 were resistant to challenge with homologous virus 
grown in human T-cell culture, but not to virus grown in cells from rhesus monkeys 
(Le Grand et al., 1992).  
Inactivated EIAV coupled to iron oxide beads was used as a particulate vaccine 
designed to activate the phagocytic pathway to obtain a strong CTL response; 
delayed progression to disease post-challenge was seen, although a reliable CTL 
response was not obtained (Hammond et al., 1999).    49 
An inactivated viral vaccine has been tried for control of JD in Indonesia; the spleen 
from an infected animal was emulsified in a mineral oil adjuvant, the virus was 
inactivated by detergent treatment. This vaccine has shown efficacy in reducing 
clinical signs in experimentally infected animals (Hartaningsih et al., 2001) and 
anecdotally has been reported to contain the spread of disease in natural outbreaks 
(Hartaningsih, personal communication). 
Subunit vaccines. 
The first recombinant protein was expressed in a bacterial system in 1979 (Goeddel 
et al., 1979), utilising the discovery that bacteria harbour self-replicating plasmids. 
The discovery of restriction enzymes and ligases allowed plasmids to be cut at 
specific sites and foreign genes to be inserted. These ‘recombinant’ plasmids could 
then be taken up into their host bacterium, normally Escherichia coli, in a process 
termed ‘transformation’, with subsequent expression of the protein encoded by the 
foreign gene. The advent of this technology promised inexpensive methods of 
producing pure proteins in bioreactors.  
Recombinant protein vaccines have several advantages over the use of whole 
pathogens as vaccines. The principal benefit is the removal of the possibility of 
inadvertently infecting the vaccinate with adventitious organism that may be present 
in inactivated or attenuated vaccines, or of reversion to virulence of attenuated virus 
vaccines. It can overcome problems in culturing sufficient whole virus for use as 
vaccine.  
HIV-1 has been described as a molecular entity consisting of ‘15 proteins and an 
RNA’ (Frankel and Young, 1998). The majority of these proteins, or their functional 
analogues, are expressed by the non-primate lentiviruses, and have been the subject 
of research into their suitability as subunit vaccines for the control of animal 
lentivirus diseases, mirroring the effort of the research community in the hunt for an 
effective vaccine against HIV.   50 
Env glycoprotein vaccines. 
The structural envelope glycoproteins SU and TM together mediate viral entry into 
the target cell (described above) and so have attracted interest as potential vaccine 
targets, with the aim of blocking receptor recognition and so preventing the initial 
entry of the virus into the cell.  
Vaccination trials with recombinant envelope proteins expressed in bacterial and 
baculovirus systems have given partial protection against homologous challenge 
with FIV in cats (Leutenegger et al., 1998) and EIAV in horses (Issel et al., 1992). 
However, heterologous challenge with EIAV of horses in the same trial showed a 
degree of potentiation of disease. Goats vaccinated with recombinant CAEV 
glycoproteins raised high titres of anti-glycoprotein antibodies, but were not 
protected against challenge with homologous virus (Cheevers et al., 1994). There is 
no information available regarding the immune response to the bovine lentivirus Env 
glycoproteins but there is considerable variation in the sequence of BIV env (Suarez 
and Whetstone, 1995) due to duplication and insertion of a 33-54 nucleotide 
fragment by template switching during the synthesis of the DNA minus strand (Li 
and Carpenter, 2001). However, this variation has not been observed in JDV, which 
displays little sequence variation over time (Desport, 2007). 
Clearance of virus after the initial acute phase of lentivirus infection is thought to be 
associated with an effective CTL response. Difficulty in raising effective CTL 
responses to recombinant glycoproteins has led to research designed to dissect the 
specificity of CMI responses during natural infections. Elucidation of the viral 
epitopes required to induce an effective response has led to the technique of peptide-
based vaccination of animals. Horses vaccinated with Env peptides shown to be 
CTL epitopes in vitro demonstrated a measure of protection against challenge 
(McGuire et al., 2004). Analysis of  the T-helper responses to Env peptides in 
macaques infected with SIV is being used to develop peptide vaccines to induce 
anti-SIV CD4
+ T-helper (Th) cell activity (Sarkar et al., 2002). 
Increasingly, the necessity for specific CTL-mediated immunity to lentiviruses has 
led to the use of chimeric viruses or virus-like particles where genes for the vaccine   51 
antigen are incorporated into non-pathogenic or replication-deficient virus, cultured 
exogenously as distinct from DNA vaccination with viral genomes, to allow realistic 
presentation of correctly post-transitionally modified viral proteins to the immune 
system. This approach has shown varying levels of success: vaccination of macaques 
with recombinant Ankara vaccinia virus expressing genes from SIV primed the 
animals to produce a rapid neutralising antibody response following infection 
(Ourmanov et al., 2000). Addition of a baculovirus-expressed Env boost to this 
approach was also effective (Hu et al., 1992), on the other hand, vaccination of cats 
with Venezuelan equine encephalitis virus engineered to express FIV Env failed to 
confer any protection to subsequent challenge despite high levels of antibody to FIV 
(Burkhard et al., 2002). 
Gag protein vaccines.  
The Gag polyprotein is cleaved by viral protease to produce the structural proteins 
CA, MA and NC. These structural proteins show good conservation throughout the 
lentiviruses, and so are of interest as potential vaccines to induce broad immunity to 
a wide range of heterologous isolates. Of these proteins, CA is highly immunogenic, 
inducing an early and strong antibody response when administered as a vaccine and 
in animals infected with a lentivirus, including the bovine lentiviruses (Whetstone et 
al., 1990; Burkala et al., 1998). Both cell-mediated and antibody responses to CA 
may be important for control of natural lentivirus infection, as horses infected with 
EIAV possess Th cells responsive to an array of peptides containing both CTL and 
Th epitopes derived from EIAV CA, with multiple epitopes clustering in the major 
homology region (MHR) which is highly conserved throughout the animal 
lentiviruses (Chong et al., 1991; Lonning et al., 1999).  
MA is important during viral assembly (Frankel and Young, 1998) and MA from 
HIV-1 has been shown to stimulate pro-inflammatory cytokine production, possibly 
creating a favourable milieu for viral replication. The stimulation is receptor-
mediated and presents the opportunity of blocking the interaction with specific 
antibodies raised by vaccination with MA (De Francesco et al., 2002). Horses 
infected with EIAV also possess MA peptide-specific CTL responses (Lonning et   52 
al., 1999), raising the possibility of inducing specific CTL against EIAV by 
vaccination with peptides derived from this protein. 
The Gag proteins have been employed as candidate vaccine antigens for both HIV 
and the animal lentiviruses either as recombinant proteins expressed in bacterial or 
eukaryotic systems (Hanke et al., 1994; Rafnar et al., 1998; Leavell et al., 2005) or 
as artificial peptides (De Francesco et al., 2002; Fraser et al., 2005) either singly, or 
in combination with others (McGuire et al., 2004). Many studies have attempted to 
induce specific CTL responses by incorporation of Gag proteins into chimeric virus-
like particles, mimicking the particulate antigen properties of intact viral capsids 
(Wong and Siliciano, 2005) or utilising the self assembly properties of Gag to 
produce virus-like particles either designed to induce response to Gag itself or to 
other antigens included in the construct (Kang et al., 1999).  
The sub-unit vaccine trials carried out with Gag-derived antigens against lentiviral 
infections have shown varying degrees of success. Preliminary trials with peptide 
antigens failed to induce protective immunity in horses (Fraser et al., 2005) despite 
attempts to circumvent the restriction of antigen presentation by Class 1 equine 
leucocyte alloantigen by administration of multiple peptides to induce an effective 
CTL response (Zhang et al., 1998). Cats vaccinated with HIV derived p24 were 
protected against FIV challenge by CTL-mediated immunity, indicating cross-
reactivity of the response to CA in these animals (Coleman et al., 2005). 
Tat protein vaccines.  
There are several reasons to target Tat as a potential vaccine. Tat is multifunctional, 
it is produced early in the virus replication cycle and it is indispensable for virus 
replication (Arya et al., 1985; Dayton et al., 1986; Frankel and Young, 1998). The 
lentivirus regulatory genes tend to be more conserved than the structural proteins, 
and the resulting antigenic conservation of Tat reduces the lack of cross-reaction 
common with antisera to structural and envelope proteins (Demirhan et al., 1999). 
The protein is highly immunogenic and in HIV-infected humans, Tat antibodies 
have been shown to correlate with delayed progression to AIDS (Re et al., 1995; Re 
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infected cells and can enter uninfected cells directly through the cell membranes 
(Ensoli et al., 1993; Chang et al., 1997) when through upregulation of the viral 
receptors it renders the cell more susceptible to viral infection (Huang et al., 1998; 
Secchiero et al., 1999). An immune response against this protein could therefore 
reasonably be expected to interfere with the viral replication cycle. 
Candidate Tat antigens with potential for use as vaccines have been produced in 
several forms. Tat-derived peptides induced virus inhibitory antibodies in mice 
(Boykins et al., 2000; Goldstein et al., 2000) and have also been used in vaccines 
trials against SIV infection in macaques (Goldstein et al., 2000). Biologically active 
Tat protein has been used alone (Ensoli and Cafaro, 2000) and in combination with 
modified Env (Ensoli et al., 2005) as a vaccine in macaques. The potential toxic 
effects of biologically active Tat can be avoided by its conversion to an inactivated 
toxoid (Pauza et al., 2000). 
Several of the studies utilising Tat as a vaccine, both against HIV and animal 
lentivirus infections, have demonstrated this effectively ameliorated disease or 
prevented infection post-challenge, and established the importance of a Tat-specific 
immune response as one correlate of protection. Cynomolgus monkeys vaccinated 
with bacterially expressed Tat were able to control infection with highly pathogenic 
SHIV89.6P (Cafaro et al., 1999; Maggiorella et al., 2004). Vaccination with Tat 
toxoid attenuated disease in rhesus macaques, as demonstrated by a lower viral load, 
lower p24 levels and preservation of CD4
+ counts in the animals (Pauza et al., 
2000). In humans, the strong correlation between high levels of antibody to Tat and 
slow progression to AIDS has led to vaccination experiments attempting to 
reproduce this state in immunocompromised individuals (Gringeri et al., 1998). The 
type of immunological responses needed for protection are still being elucidated but 
some studies are showing that both arms of the immune system are required for 
protection (Pauza et al., 2000). Despite the correlation of antibody levels with non-
progression of disease in HIV-infected humans (Re et al., 1995), studies in rhesus 
macaques vaccinated with Tat-derived peptides showed that even with the induction 
of a strong Tat antibody response no protection was achieved against challenge 
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Nucleotide vaccines.  
In the early 1990’s there were reports that the intramuscular administration of naked 
plasmid DNA encoding a foreign gene, under the control of a mammalian primer, 
could lead to the expression of the foreign gene product in cells within the muscle 
and that the immune response raised to this endogenously produced protein could be 
protective (Tang et al., 1992; Fynan et al., 1993; Robinson et al., 1993; Ulmer et al., 
1993). Following these initial experiments the field of DNA or, more correctly, 
nucleic acid (NA) vaccination has grown rapidly. The potential advantages of the 
technology over more established methods of vaccine production are enormous. NA 
vaccination presents the possibility of achieving expression of a vaccine protein or 
peptide directly in the cells of a vaccinated animal or person, avoiding the potential 
problems of reversion to virulence when attenuated pathogen vaccines are used, or 
failure of inactivation with inactivated pathogen vaccines. Likewise, the problems of 
purification, correct conformation, solubility and stability associated with sub-unit 
vaccines produced with in vitro expression systems are avoided by the use of this 
technology (Whalen, 1996a). Furthermore, unlike conventional vaccines which tend 
to produce mainly humoral responses, NA vaccines can be tailored to produce a cell-
mediated response, often essential in the control of viral diseases (Whalen et al., 
1995; Babiuk et al., 1999a). 
The simplest approach to NA vaccination is intramuscular injection of a naked 
plasmid DNA shuttle vector, encoding a gene derived from a pathogen. This 
approach has provided variable results; it proved effective in protecting dogs against 
canine distemper virus (Cherpillod et al., 2000) but was less effective in protecting 
cattle against bovine leukaemia virus (Brillowska et al., 1999) and bovine 
respiratory syncytial virus (Schrijver et al., 1997). However, improvements in the 
efficacy of these so-called ‘first generation’ NA vaccines have been achieved in a 
variety of ways. With intramuscular injection of plasmid, the DNA has to be taken 
up by myocytes within the muscle before any expression of the foreign antigen can 
occur. This antigen then has to be presented to the immune system for a response to 
be raised. The problems of poor response to vaccination of large animals with NA   55 
vaccines developed in mouse models (Babiuk et al., 1999b; Gerdts and Mettenleiter, 
2001), due to unexpectedly high dose levels required, have led to the development of 
strategies designed to increase both the efficiency of antigen presentation and the 
strength of the response to that antigen. Targeting of antigen-presenting cells has 
proved effective at enhancing the efficacy of NA vaccination in sheep against 
Corynebacterium pseudotuberculosis (Chaplin et al., 1999) but not against Taenia 
ovis (Drew et al., 2001). Co-administration of cytokine genes has proved effective at 
enhancing protective responses to NA vaccination (Nobiron et al., 2000; Wong et 
al., 2002). Co-administration of genes for heat shock proteins (Chen et al., 2000; 
Hauser and Chen, 2003), co-stimulatory molecules (Somasundaram et al., 1999; Flo 
et al., 2000) and chaperone genes (Lin et al., 2005) have all proved effective at 
enhancing the response to the antigens. The correct choice of adjuvants is as 
important in NA vaccination as in the more developed field of protein and 
inactivated pathogen vaccinology (Singh and O'Hagan, 2002; Sasaki et al., 2003).  
Microparticle bombardment of target cells, commonly termed ‘gene gun 
vaccination’, introduces foreign DNA, bound to a carrier, directly into target cells. 
The system can be used both in vitro or in vivo, and in vivo it has proved effective in 
raising a protective immune response to rabies virus in mice (Lodmell et al., 1998), 
and primates (Braun et al., 1999; Lodmell et al., 2001). These studies all utilised 
gold microparticles as carriers, chosen for their uniform size, inertness and high 
density, to carry DNA into the immune surveillance cells of the skin, such as 
dendritic cells. Other workers have targeted the skin-associated lymphoid cells by 
utilising liposomes, atelocollagen microparticles or simple topical application to the 
skin (Watabe et al., 2001; Raghavachari and Fahl, 2002).  
The route of administration of a NA vaccine effects the type, intensity and duration 
of the immune response obtained (Bohm et al., 1998; Shkreta et al., 2003). In 
addition to intramuscular or intracutaneous methods, routes used have included 
intranasal administration of DNA/liposome complexes to elicit mucosal IgA 
responses (Klavinskis et al., 1999) or as suppositories in cattle (Loehr et al., 2001). 
Administration of NA vaccines directly into lymph nodes has been shown to 
increase the efficacy of induction of immunity by up to 100-fold compared with   56 
intradermal and intramuscular routes of administration (Maloy et al., 2001). 
Intracellular proteins will be presented to the immune system by MHC Class 1 
receptors, and so activate the cell-mediated arm of the immune system (Mascola et 
al., 1999). This may be advantageous in raising a protective response to a viral 
pathogen, where antigens are produced intracellularly during the course of a natural 
infection. However, it may be necessary to produce an effective antibody response to 
clear a viral infection and as such a vaccine would need to also activate the humoral 
arm of the immune system. Tailoring of the induced immune response has been 
attempted by altering the destinations of the proteins expressed from the introduced 
plasmid (Mascola et al., 1999). Inclusion of oligonucleotides to code for tags to 
direct the foreign protein to be membrane bound, retained intracellularly, or to be 
secreted from the cell can change the response raised to that protein (Mascola et al., 
1999). Changes in the cytokine microenvironment in the draining lymph node of a 
DNA vaccine administration site can be induced by the inclusion of CpG motifs, to 
switch the cytokine profile to a Th-1 biased response (Liu et al., 2005). Co-
administration of genes encoding cytokines or other co-stimulatory molecules have 
also proved effective at altering the induced response (Leutenegger et al., 2000; 
Nobiron et al., 2003; Egan et al., 2005). 
NA vaccination has proved effective at inducing protective effects against animal 
lentivirus infections. Proviral infectious clones attenuated by removal of specific 
genes have been developed as vaccines against several lentiviral infections, 
including FIV (Flynn et al., 2000; Lockridge et al., 2000), CAEV (Cheevers et al., 
2003) and SIV (Busch et al., 2003; Liu et al., 2006b). Constructs expressing viral 
proteins have been also employed in vaccine trials against MVV (Gonzalez et al., 
2005) and with less success against EIAV (Cook et al., 2005). Administration of NA 
vaccines encoding viral proteins have proved more successful in protecting against 
SIV when coupled with a boost strategy, either with recombinant vaccinia virus 
expressing the same proteins (Someya et al., 2006) or with attenuated SIV (Amara et 
al., 2005). 
Although the technology of NA vaccination shows promise, especially where cell-
mediated immunity is required to control a pathogen, and although several vaccines   57 
have proved efficacious, there are problems that still need to be overcome before the 
full potential of the technique is realised. Safety considerations present hurdles for 
the acceptance of NA vaccines for general use, especially the possibility of 
integration of the vaccines constructs into the germ line, or transfection of gut flora 
allowing dissemination of resistance and vaccine genes into the environment (Davis 
and Whalen, 1995; Ertl and Xiang, 1996; Donnelly et al., 1997; Gregersen, 2001). 
Approaches utilising minimalistic immunologically-defined gene expression (or 
MIDGE) constructs, containing no bacterial resistance genes, and often consisting of 
a string of synthesised polynucleotides coding for multiple epitopes, or multiple 
copies of single epitopes rather than entire genes, have been examined as a solution 
(Leutenegger et al., 2000; Moreno et al., 2004). 
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Chapter 3 
Preliminary studies on constructs for Jembrana disease 
virus DNA vaccines. 
This chapter describes the production of several potential DNA vaccine constructs. 
The methods for PCR amplification of the vaccine genes, ligation into commercial 
vaccine plasmids, and the results of the subsequent in vitro  and in vivo  testing of the 
constructs for functionality and immunogenicity are described. 
Introduction. 
In 1992, it was discovered that injection of naked plasmid DNA encoding a gene 
under the control of an appropriate viral promoter could raise an immune response 
directed to the protein encoded by the transgene (Tang et al., 1992). This raised the 
possibility of relatively cheap and simple production of nucleic acid vaccine 
constructs, to induce immune responses to vaccine proteins expressed endogenously 
has led to considerable research effort.  
DNA vaccination with naked plasmids is often less effective in a large target animal 
than in the murine model systems used to develop the vaccine. The reasons for this 
are not clear, but such factors as low dosage relative to body mass in larger animals, 
or lower transfection efficiency, indicating a requirement for a more sophisticated 
vaccine delivery system, may play a part (Babiuk et al., 2003). The potential for this 
novel vaccination strategy is so great, however, that despite initial discouraging 
results, much research has continued into engendering protective immune responses 
against several diseases of production animals. DNA-mediated vaccination of 
production animals has shown some promising results using cytokine or CpG 
adjuvancy (Pontarollo et al., 2002; Nobiron et al., 2003). Experimentation with 
different routes of administration, such as intradermal (Schrijver et al., 1998), 
mucosal (Babiuk et al., 2003), or even intramammary (Shkreta et al., 2003), has 
given information on the best method to induce immune responses of different types 
and magnitude in large animals. Other promising trials in cattle have included DNA 
vaccination against bovine herpesvirus-1 (van Drunen Littel-van den Hurk et al., 
1998), and bovine leukaemia virus (Brillowska et al., 1999).   59 
Manipulation of the final destination of an expressed antigen, whether secreted, 
cytoplasmic or membrane bound, also affects the magnitude and type of immune 
response obtained (Lewis et al., 1999; Morel et al., 2004). It is apparent that careful 
design of the vaccine construct, and considered choice of adjuvant, route and site of 
administration can overcome the problem of obtaining a satisfactory response to 
vaccination in large animals. Several DNA vaccines for non-primate lentiviral 
infections have been trialled, with varying levels of success. Intradermal vaccination 
with a tat-deleted CAEV proviral genome proved able to establish a mild infection 
and confer protection against challenge with the homologous pathogenic virus in 
goats (Harmache et al., 1998). Similarly, vaccination of cats with replication-
deficient FIV proviral DNA clones conferred protection against the prototypic 
Petaluma strain of FIV, but not against challenge with a different strain (Hosie et al., 
2000). 2 out of 3 macaques in a small trial were protected against challenge with 
SIVmac251 by vaccination with plasmids containing proviral DNA with deletions in 
both LTR regions (Kent et al., 2001), and deletion of 12 nucleotides from the 
nucleocapsid gene of SIV(Mne) produced a replication-deficient proviral clone that 
when inoculated into macaques protected against challenge with the pathogenic strain 
(Gorelick et al., 2000).  
In the light of the foregoing and, in addition, because of the potential of this 
technology to allow development of a low cost, easy to produce and stable vaccine, 
with no danger of inadvertantly spreading virus or reversion to virulence (as can 
occur with inactivated or modified viral vaccines) a project was initiated to design a 
DNA vaccine against JDV that would be applicable for use in Indonesia. 
Maintenance of an unbroken cold chain is often unreliable, so a stable vaccine not 
requiring refrigeration was desirable. As purification of large amounts of plasmid is a 
relatively simple operation compared with the often complex techniques required for 
protein purification, the simplicity of production of DNA vaccines was also seen as a 
great potential advantage. The possibility of attaining a long lasting protective 
response with only one vaccination, as was seen in macaques after a single DNA-
mediated vaccination against rabies (Lodmell et al., 2001) would also have been of   60 
advantage in Indonesia as animals are often unmarked and hence difficult to find for a 
second vaccination.  
To have the best chance of success in a DNA vaccine trial, it is necessary to ensure 
that constructs are functioning correctly before administration to the target animal 
species (Whalen, 1996b). This chapter describes the production and testing in vitro 
and in vivo of several vaccine constructs designed to raise an immune response to 
JDV proteins. Since little is known about the immunogenic or protective epitopes of 
JDV, each of the vaccine constructs included either whole genes, or a large 
proportion of a gene, from the JDV genome, in an initial attempt to raise and 
characterise an immune response. Intradermal delivery was chosen for the route of 
administration, using a “gene-gun” biolistic device to deliver DNA coated gold 
particles into the skin, for ease of use and reported ability to produce a stronger 
immune response to small amounts of DNA vaccine in large animals than other 
administration methods (Oliveira et al., 2000). Use of the gene-gun to administer 
vaccines has given protection against the early stages of MVV infection in sheep 
(Gonzalez et al., 2005), BHV-1 in cattle (Braun et al., 1999), and partial protection of 
pigs against foot-and-mouth disease virus (Beard et al., 1999).   61 
Materials and methods. 
Production of DNA vaccines. 
2 commercially available plasmids designed for DNA vaccination were used in these 
trials. These were pCDNA3.1 His A (Invitrogen) and pVAX (Invitrogen) (Figure 
3.1). The features of these plasmids include bacterial origins of replication and 
antibiotic resistance genes, to allow propagation and selection in Escherichia coli, a 
eukaryotic promoter to drive expression in mammalian cells, and the bovine growth 
hormone poly-A tail to stabilise the mRNA transcripts. 
 
Figure 3.1 Map of pVAX1, a plasmid designed for eukaryotic DNA vaccination studies. 
4 genes from the JDV genome were amplified by PCR for ligation into vaccine 
constructs. The entire gene encoding the CA protein was amplified from Clone #139, 
containing nucleotides 19 to 2881 of the JDV genome. The genes encoding exon 1 of 
the tat protein, a 5’ truncated SU protein and the entire TM protein were amplified 
from Clone #55, containing DNA from nucleotide 3847 to 7732 of the genome of the 
type strain of JDV, Tabanan87 (JDVTAB) (Chadwick et al., 1995a). PCR primers were 
designed by eye for all PCR reactions required, and are shown in Table 3.1.   62 
Amplification of vaccine genes. 
Table 3.1 Primers used for amplification of SU and TM genes, and sequencing of all constructs. 
Tm denotes calculated melting temperature of the primer. 
Primer Sequence  Tm Gene/protein   
605JCaFOR  5’-CCACAACTTAGAAAGAACTTCC-3’ 62˚C 
1282JCaREV  5’-GAATTCCATCTTCTGTTTACTTG-3’ 62˚C 
cap / capsid protein (CA) 
5007JTatFOR  5’-GATATGCCTGGTCCCTGGG-3’ 62˚C 
5301JTatEx1REV  5’-CGCGCAGTTAGGTGCCCT-3’ 60˚C 
tat / transactivating 
protein (Tat) 
6463JTmKozFOR  5’-GCCACCATGGTCATATTCCTTCTCG-3’ 76˚C 
7545JTmStopREV  5’-GTGTCACATCTCAACTGGG-3’ 58˚C 
tm / transmembrane 
protein (TM) 
5194JSuFOR  5’-GACATGATGGAAGAAGGAAG-3’ 58˚C 
6465JSuREV  5’-GGCTCTCTTTCCCCTAGG-3’ 58˚C 
su / surface unit protein 
(SU) 
pVAX75FOR  5’-CGGGGTCATTAGTTCATAGC-3’ 60˚C  Vector forward primer. 
pVAX960REV  5’-GACACCTACTCAGACAATGC-3’ 60˚C Vector  reverse  primer. 
PCR assays were conducted using a  master mix consisting of the following final 
concentrations was prepared in Ultrapure water. 1:10 dilution of 10X Buffer, 1.5 mM 
MgCl2, 0.15 mM of each dNTP, 1.2 mM of each primer, and 0.5 units of Taq 
polymerase. 24 µl of master mix was added to 1µl of target DNA, and the reaction 
mix was subjected to an initial denaturation step of 96˚C for 5 min followed by 25 
cycles of denaturation at 96˚C for 1 min, annealing at 57˚C for 1 min (CA), 57˚C 
(Tat), 55˚C (TM), and extension at 72˚C for 1 min. A final extension step of 72˚C for 
10 min was included to allow complete extension of all amplicons. Unincorporated 
nucleotides, contaminating enzymes and salts were removed with a QIASpin PCR 
cleanup kit (Qiagen) following the manufacturer’s instructions.  
Preparation of T-tailed vectors. 
For the preparation of T-tailed vectors, pure plasmid was prepared from a culture 
(37˚C, overnight, 200 r.p.m) of the host strain Top10 (Invitrogen) harbouring the 
vector pVAX, in Luria-Bertani (LB) broth supplemented with 50 µg/ml kanamycin. 
The plasmid was purified from the stationary phase culture using an Aurum plasmid 
mini-preparation kit (BioRad) following the manufacturer’s instructions. Purified 
plasmid was linearised with the blunt ending restriction enzyme EcoRV, (New 
England Biolabs) following the manufacturer’s instructions. An overhanging T was 
added to the ends of the linearised plasmid by incubating (70˚C, 15 min) 0.5 µg of the   63 
linearised pVAX in 10 µl of 1X PCR buffer containing final concentrations of 0.5 
mM MgCl2 and 0.2 mM dTTP, and 5 units of Taq polymerase. The unincorporated 
dTTP molecules, contaminating enzymes and salts, were removed with a QIASpin 
PCR cleanup kit (Qiagen) following the manufacturer’s instructions.  
Construction and identification of vaccine constructs. 
The amplified genes were ligated into the T-tailed vector with T4 DNA ligase 
(Promega) following the manufacturer’s instructions. Recircularised plasmids were 
transformed into chemically competent Top10 E. coli by the heat-shock method, and 
successfully transformed bacteria were identified by growth (37˚C, overnight) on 
selective LB Agar plates containing 50 µg/ml kanamycin. 
Directional PCR was used to identify those transformants harbouring the insert in the 
correct orientation. 50 colonies were patched with sterile tips onto selective agar, and 
cultured (37˚C, overnight). Colonies were screened in pooled batches of 5. A small 
amount from each of 5 large colonies in the 10 batches was pooled into 50 µl of 
ultrapure water (Fisher Biotec) and boiled for 5 min. Following centrifugation 
(14,000 g, 1 min), 1 µl of the lysate was added to 24 µl of a PCR master mix, 
incorporating the relevant reverse primer of the gene of interest and the plasmid 
forward primer, pVAX75FOR. Cycling was carried out as above with an annealing 
temperature of 55˚C. Positive batches were then individually screened to identify the 
positive clone. This colony was then recultured and a single colony was inoculated 
into 50 ml of selective LB broth and incubated (37˚C, overnight, 200 r.p.m). This 
culture was used to prepare a glycerol stock (20% glycerol:80% log culture) of the 
bacteria harbouring the DNA vaccine plasmid. 
Confirmation of inserts. 
Plasmids were extracted from 2.5 ml of overnight culture using an Aurum MiniPrep 
kit (BioRad), following the manufacturer’s instructions and the purified plasmids 
were sequenced using BigDye version 3.1 dye terminators (Applied Biosystems) in a 
¼ volume reaction, following the manufacturer’s instructions. Sequence data was 
viewed with Chromas version 2.3 (Technelysium), and sequence comparisons   64 
performed with the GCG programme package, accessed via the Australian National 
Genomic Information Service (http://www.angis.org.au).  
Extraction of plasmids for coating gold beads. 
50 ml of LB broth containing 50 µg/ml kanamycin or ampicillin as appropriate were 
inoculated with a scrape taken with a sterile loop from the surface of the frozen 
glycerol stock of the host strain bearing the desired plasmid. The culture was 
incubated (37˚C, overnight, 200 r.p.m) and plasmid extracted from the stationary 
phase culture using an EndoFree plasmid extraction kit (Sigma) following the 
manufacturer’s instructions. Final elution was in ultrapure water (Fisher Biotec). 
Yield was determined with a fluorometer (Pharmacia) and adjusted to 1µg/µl with 
ultrapure water for use in the gold bead coating procedure. 
Coating of gold beads. 
Gold beads (BioRad, 0.1 µm) were coated with the extracted plasmid according to the 
manufacturer’s instructions, with a microcarrier loading quantity (MLQ) of 
0.5 mg/shot, and DNA loading ratio (DLR) of 2 µg of each plasmid 
administered/0.5 mg of gold. Polyvinylpyrrolidone (PVP) was used at 0.1 mg/ml. 
Dryness of the ethanol used in the procedure was ensured by storing the ethanol over 
a molecular sieve to remove contaminating water molecules. 
To verify the coating procedure, plasmid DNA was eluted from the gold coating 5 
cartridges according to the manufacturer’s instruction, by vortexing and sonicating 
the cartridges in TE8 (100mM Tris, pH 8, 100mM EDTA, pH 8). 1 µl of the resulting 
eluate was used as target nucleic acid in 25 µl PCR reactions, with vector forward 
primer and insert reverse primer, as described above in directional PCR, to confirm 
the presence and orientation of the gene of interest, and, by extension, the integrity of 
the construct.   65 
Preparation of gene gun cartridges.  
Cartridges were loaded following the manufacturer’s instructions. While coating, the 
end of the tubing was clamped with artery forceps to prevent pressure fluctuations 
disturbing the suspension and destroying the smooth deposition of gold onto the 
tubing. Delaying the start of rotation of the tubing for up to 30 seconds after the 
initial 180˚ turn, rather than the 3-4 seconds suggested in the manual improved the 
coating markedly.  
To ascertain the quality of the coating procedure, 3 cartridges from each coating run 
were discharged from the genegun into parafilm wrapped around a microscope slide, 
to check for even dispersal of the gold across the target area (Figure 3.2).  
Cell-free in vitro transcription/translation of genes cloned into vaccine 
constructs. 
A TnT rabbit reticulocyte coupled transcription/translation kit (Promega) with non-
radioactive detection of expressed protein was used to confirm functionality of the 
constructs in vitro, following the manufacturer’s instructions. Briefly, 0.2 µg of 
purified vaccine construct was incubated with 10 µl of cell free extract (1.5 reaction) 
containing all the requirements for gene transcription and translation, with the 
expressed protein labelled by incorporation of biotinylated methionine during 
translation. Expressed protein was subjected to PAGE followed by electrotransfer 
(30V, overnight) to nitrocellulose by conventional methods as described in Chapter 
4). The resulting Western blot was washed in TBST (137mM NaCL, 10mM Tris, pH 
7.4, 0.05% Tween) (3 times, 5 min/wash), blocked (TBST containing 1% w/v skim 
milk powder, room temperature for 1 h) and probed with streptavidin labelled with 
alkaline phosphatase (1:5,000 in TBST, 1 h, room temperature). After 3 further 
washes, labelled proteins were revealed by colour deposition where the specifically 
bound streptavidin/alkaline phosphatase interacted with the phosphatase substrate 
Western Blue (Promega).   66 
Transfection of cultured cells. 
Cos7 or MDBK cells were grown from stocks stored in liquid nitrogen. The stocks 
were rapidly thawed and initially cultured in 25 cm
2 cell culture flasks (Nunc) in 
growth medium (Dulbecco’s modified Eagle’s medium [DMEM] supplemented with 
glutamine, antibiotics and 10% foetal bovine serum for 3 days. To expand the culture, 
the cell monolayer was washed with 1 ml of sterile PBS (NaCl 137 mM, KCl 27 mM 
Na2HPO4  10 mM, KH2PO4  2 mM, adjust to pH 7.4), dissociated by incubation with 
Multicel cell dissociation buffer (ThermoTrace),  and split 1:3 in growth medium in 
25 cm
2 tissue culture flasks. The cells were passaged every 3 days. For 
immunofluorescence assays, cells from a 25 cm
2 maintenance flask were seeded into 
12-well or 48-well tissue culture plates (Nunc) and grown to near confluence. 
Transfection of the cells was achieved by incubation with 1 ml (12 well plates) or 500 
µl (48 well plates) of DMEM containing either 1 µg of the purified DNA vaccine 
construct pVAX/cap, or 1 µg of purified pVAX/tm, complexed to 2, 4, 8 or 16 µl of 
lipofectamine (Invitrogen) following the manufacturer’s instructions. 1 µg of pVAX 
vector (without any insert) complexed to 8 or 16 µl of lipofectamine was used as a 
control.  
Immunofluorescent staining procedure. 
Seventy two h after transfection the cells were fixed and permeabilised in situ with 
cold methanol, then reacted with either monoclonal anti-JDV CA BC10 (1:100 in 
PBS) or a polyclonal bovine anti-JDV serum with a high anti-TM titre (1:100 in 
PBS). The cells were then washed and specifically bound antibodies were detected 
with anti-species IgG conjugated to FITC (1:1000). The resulting fluorescence was 
detected with an Olympus BH-2 microscope, with UV excitation at 365-395 nm. 
Transactivation of pTAR/lacz construct with pVAX/TAT. 
The functionality of the pVAX/tat vaccine construct was tested by a pTAR/lacz 
assay. Near confluent cos7 cells were transfected with pVAX/tat and a reporter 
construct, pTAR/lacz as above. After incubation for 3 h, the transfection solution was 
removed from the wells, replaced with growth medium, and incubated again for 18 h. 
Transactivation of the pTAR/lacz construct by expressed Tat protein from the vaccine 
construct was detected by the development of an intense blue colour in transfected   67 
cells when incubated with the substrate solution (5 mM K4Fe(CN6).3H2O, 5 mM 
K3Fe(CN6), 2 mM MgCl2, 1 mg/ml 5-bromo-4-chloro-3-indolyl-ß-D-galactoside [X-
gal]). 
Optimisation of levels of lipofectamine for transfection. 
Cos7 cells were grown to near confluence in 24-well plates. Cells were transfected 
with the vaccine construct, pVAX/tat, the indicator plasmid, pTAR/lacZ, the positive 
control plasmid, pVAX/lacZ, and the negative control plasmid pVAX using different 
lipofectamine and plasmid concentrations, as detailed in Table 3.2. 
500 µl volumes of these solutions were combined as detailed in Table 3.2, each was 
pipetted onto a washed monolayer of cells, and incubated for 30 min (37˚C, 5% CO2-
in-air atmosphere). Cell monolayers were washed, substrate solution applied and 
incubated (4 h, room temperature). Positive cells in 5 fields of view from each well 
were counted.    68 
 
Table 3.2 Mixtures of lipofectamine and plasmid solutions used to transfect Cos7 cells cultured 
in 24 well plates. 
Plate  1  1 2 3 4 5 6 
A  5 + 1 5 + 2 5 + 3 5 + 4 6 + 1 6 + 2 
B  5 +1 5 + 2 5 + 3 5 + 4 6 + 1 6 + 2 
C  6 + 3 6 + 4 7 + 1 7 + 2 7 + 3 7 + 4 
D  6 + 3 6 + 4 7 + 1 7 + 2 7 + 3 7 + 4 
 
Plate  2  1 2 3 4 5 6 
A  8 + 1 8 + 2 8 + 3 8 + 4   
B  8 + 1 8 + 2 8 + 3 8 + 4   
C  9 + 1 9 + 2 9 + 3 9 + 4   
D  9 + 1 9 + 2 9 + 3 9 + 4   
 
1. 250 µl DMEM (no antibiotics or lipofectamine) 
2. 250 µl DMEM + 20 µl lipofectamine. 
3. 250 µl DMEM + 40 µl lipofectamine. 
4. 250 µl DMEM + 60 µl lipofectamine. 
5. 250 µl DMEM + 10 µg pVAX. 
6. 250 µl DMEM + 5.0 ug pVAX and 5.0 µg pVAX/tat. 
7. 250 µl DMEM + 5.0 ug pVAX and 5.0 µg pVAX/lacZ. 
8. 250 µl DMEM + 5.0 ug pVAX and 5.0 µg pTAR/lacZ. 
9. 250 µl DMEM + 5.0 ug pVAX/tat and 5.0 µg pTAR/lacZ.   69 
Comparison of fugene and lipofectamine for transfection.  
Cos7 cells were grown to near confluence in 24-well tissue culture plates. Wells 1-6 
of Row A were incubated with 100 µl of antibiotic-free, serum-free DMEM medium 
containing 0.6 µl of Fugene (Roche) and 1 µg of the positive control plasmid 
pVAX/lacZ. The 6 wells of Row B were incubated with 100 µl of medium as before, 
containing 3 µl of lipofectamine and 1 µg of pVAX/lacZ. The 2 remaining rows were 
incubated with medium containing fugene or lipofectamine, but without plasmid, to 
examine the effect of the transfection solution on the cells. The columns of the plate 
were incubated for 1 min, 10 min, 30 min, 1 h, 2 h and 3 h. The transfection medium 
was then removed and replaced with growth medium. The cells were re-incubated 
and levels of transactivation assessed as described above. Cell death was estimated 
and expressed as a percentage of the monolayer destroyed. 
DNA vaccination of mice. 
Groups of 5 ARC/Swiss mice were vaccinated and bled according to the protocol in 
Table 3.3. Each vaccine dose consisted of 1 µg of each plasmid coated onto 0.5 µg of 
gold with 0.1 mg/ml PVP. Initial doses were administered at 300 pounds per inch
2 
(p.s.i.), subsequent doses at 250 p.s.i., into the shaved skin of the abdomen. All mice 
were bled before the initial vaccination, and following each subsequent vaccination, 
from the saphenous vein. The vein was occluded and pricked with a 30 G needle, then 
2-3 drops of blood were sucked by capillary action into a haematocrit tube, and 
immediately expelled into a 500 µl Eppendorf microfuge tube to clot. Sera was 
collected after centrifugation of the clot. At the end of the experiment, the mice were 
killed and immediately bled out by cardiac puncture. Skin samples were 
cryoembedded in OCT 4583 (TissueTek) and stored at -80˚C. Spleens were removed 
and stored at -80˚C in RNAlater (Ambion).   70 
Table 3.3 Protocol for DNA vaccination of mice. 
Plasmid combination for 
each group of mice 
1
st 
vaccine 
First 
bleed 
2
nd 
vaccine
2
nd 
bleed 
3
rd 
vaccine
 
Final 
bleed 
pVAX/pcDNA3.1rev  d0 d12  d21  d25  d55  d60 
pVAXtat/pcDNA3.1rev  d0 d12  d21  d25  d55  d60 
pVAXtm/pcDNA3.1rev  d0 d15  d20  d27  d56  d63 
pVAXcap/pcDNA3.1rev  d0 d15  d20  d27  d56  d65 
pcDNA3.1su/pcDNA3.1rev  d0 d12  d19  d21  d49  d56 
d denotes day post initial vaccination 
The sera from mice vaccinated with pVAX/tat:pcDNA3.1/rev and 
pcDNA3.1/su:pcDNA3.1rev, were screened for antibody by Western immunoblotting 
the appropriate antigen. His/Tat expressed in a eukaryotic system was a gift from Dr 
Ami Setiyaningsih, and SU/PIN was a gift from Dr Moira Desport. Immunoblots 
were initially stained with Ponceau red to identify the antigen band, which was 
marked with pencil. The blots were then blocked as above, and the section of the 
membrane bearing the antigen band carefully excised and cut into strips (to allow 
reassembly of the blot following probing with murine sera). Each section of the blot 
was probed with individual sera (1/10 in TBST) from the mice in both vaccine 
groups. Bound antibodies were detected with horseradish peroxidase conjugated anti-
mouse IgG, with colour developed by incubation with H2O2 and 4-chloronapthol 
(1mg/ml in methanol, 1ml of this mixed with 5 ml of TBS containing 3 µl of 30% 
H2O2). 
The sera from the pVAX/tm:pcDNA3.1/rev vaccinated group was screened by 
ELISA, using a synthetic peptide identical to the principal immunodominant domain 
of the JDV TM protein in an adaptation of a previously published method (Barboni et 
al., 2001), utilising an anti-mouse IgG horseradish peroxidase conjugate to detect 
specifically bound antibody. 
Sera from the pVAX/ca:pcDNA3.1/rev vaccinated group were also screened by 
ELISA, utilising a recombinant JDV CA antigen, Jgag6, expressed as a fusion protein 
in the Pinpoint system (Desport et al., 2005). This was diluted in ELISA carbonate 
coating buffer (pH 9.0) at a concentration of 1.25 µg/ml and 50 µl pipetted into each   71 
well. After overnight incubation at 4˚C, and subsequent washing with PBS/T (3 x 5 
min/wash), the plates were blocked (PBST containing 1% w/v skim milk powder) for 
1 h at room temperature. The plates were washed again, and 2-fold dilutions of test 
sera from an initial concentration of 1:10 in PBST were made in the rows, followed 
by incubation for 1 h at room temperature. The plates were washed, and specifically 
bound antibodies detected with anti-mouse IgG (1:2000 in PBST). Unbound 
antibodies were again removed by washing and the plate developed by incubation 
with a chromogenic substrate (HrP Substrate kit, BioRad, Cat no.172-1064). The 
colour development reaction was stopped with 2% w/v oxalic acid and the 
absorbance of the reaction read at 405nm in an ELISA plate reader (BioRad).    72 
Results. 
Plasmid constructs.  
Approximately 20-30% of antibiotic resistant colonies obtained following 
transformation with vector constructs contained inserts in the correct orientation, 
detected by directional PCR on boiled colonies. Forward and reverse sequencing of 
the plasmids purified from selected positive clones confirmed that no errors had been 
incorporated into the vaccine genes during PCR amplification when compared to the 
JDVTAB sequence.  
Quality of gold coated plasmids loaded into cartridges.  
The loaded cartridges were assessed for quality of coating by firing 3 cartridges from 
each batch into parafilm. Figure 3.2 shows the results of discharging 2 evenly coated 
cartridges and an unevenly coated one. The poor dispersal and delivery of the gold 
from the unevenly coated cartridge is clear, and evenly coated cartridges were 
selected for use in animal vaccination experiments. 
 
 
 
 
 
Figure 3.2 The appearance of gold microcarriers after discharge into parafilm to assess the 
quality of gold deposition during coating of the cartridge. Patterns 1 and 3 are from cartridges 
evenly coated with gold, the central shot, 2, is from an unevenly coated cartridge, and is 
unacceptable for use in animal experiments. 
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Expression of proteins in vitro by plasmid constructs. 
Western blot analysis of proteins expressed in vitro (Figure 3.3) showed that the 
product of the ca gene was far better expressed that those coded for by the tat and tm 
genes, although all 3 proteins were successfully transcribed and expressed in this 
system. 
 
 
 
 
 
Figure 3.3 Developed Western blot of a gel following PAGE of the proteins expressed from 
vaccine constructs in the TnT rabbit reticulocyte cell-free expression system. The vaccine 
proteins JDV CA (lane 2), JDV Tat (lane 3) and JDV TM (lane 3) are arrowed. Molecular 
weight markers (MWM) are in kilodaltons (kDa).  
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Demonstration of expression of vaccine proteins by immunofluorescence. 
Capsid expression in transfected cells, detected by monoclonal antibody, was 
demonstrated by strong cytoplasmic fluorescence in roughly 2% of cells in the Cos7 
monolayer. A similar proportion of cells in the monolayers transfected with pVAX/tm 
fluoresced strongly, with both nuclear and cytoplasmic fluorescence (Figure 3.4).  
 
Figure 3.4 Photomicrograph showing the fluorescence resulting from intracytoplasmic 
immunostaining of expressed CA in cos7 cells transfected with pVAX/ca, following 
permeabilisation and labelling of expressed protein with anti-CA MAb and fluorescein 
conjugated anti-mouse IgG. 
Transactivation study. 
Transfection of cells was more effectively achieved when lipofectamine was used as 
a transfectant, compared with fugene (Figure. 3.5). However, more cell death was 
seen after prolonged incubation (over 60 min) with almost all cells detached from the 
well when this transectant was used (Figure 3.6). To minimise cell death, a 
transfection time of 10 min was used to determine the optimum ratio of lipofectamine 
to plasmid DNA for transfection. Cells were optimally transfected with 
pVAX/tat:pTAR/lacZ at a lipofectamine:DNA ratio of 4 µl:1 µg (Figure. 3.7).   75 
Figure 3.5 (a) Intense blue staining of cos7 cells co-transfected with pVAXtat and pTARlacZ 
resulting from trans-activation of the TAR by Tat expressed from the vaccine construct.  
(b) Negative control transfected with pTARlacZ and empty pVAX vector 
 
 
 
 
Figure 3.6 Comparison of the transfection rates of cos7 cells when 2 transfectants were used to 
introduce pVAX/tat and the marker plasmid pTAR/lacZ into the cells. Lipofectamine was 
more effective but incubation for longer periods (over 60 min) resulted in a high proportion of 
cell death. 
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Figure 3.7 Determination of the optimal ratio of lipofectamine:plasmid DNA for transfection of 
cos7 cells. DNA was complexed to lipofectamine in 500µl of medium at a ratio of 1µg total DNA 
to 0,2,4,6 µl of lipofectamine, and the resulting mix used to transfect near confluent cells in 24 
well plates.  
DNA vaccination of mice. 
After injection of mice, all the cartridges used were checked visually after firing, and 
all gold had been removed at both firing pressures. The area of impact of the gold on 
the skin was clearly visible immediately after firing, and the gold from the previous 
vaccination was still visible at the next vaccination 12 to 15 days later. The skin 
subjected to gold bombardment at the first vaccination with a firing pressure of 300 
p.s.i. showed signs of reddening and petechiae, and subsequent vaccinations were 
administered at 250 p.s.i, which prevented this effect. No mice showed any ill effects 
or change in demeanour after the administration of the DNA. 
All of the mice vaccinated with the pVAX/tat:pcDNA3.1/rev construct on days 0 and 
21 seroconverted to Tat produced in a eukaryotic cell culture system by 4 days after 
the second vaccination; the reaction was weak. This weak response was not 
detectable 5 days after the third vaccination.  
One of 5 mice vaccinated with pcDNA3.1/su:pcDNA3.1rev seroconverted at the first 
test bleed 12 days after the first vaccination. Two of the 5 mice were antibody-
positive by 3 days after the second vaccination, on day 19. All the Western 
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immunoblot reactions were weak and reactivity could not be detected in the third test 
bleed 7 days after the third vaccination on day 49. 
Sera from the mice vaccinated with pVAX/ca and pVAX/tm coadministered with 
pcDNA3.1/rev were screened by ELISA. No evidence of specific antibody was 
detected in any of the sera of the mice after vaccination with these 2 constructs.    78 
Discussion. 
The experiments described in this chapter indicated that all of the constructs were 
capable of producing protein in vitro, and that 2, pVAX/tat and pVAX/su, 
administered intradermally resulted in an antibody response in mice.  
Several methods were used to demonstrate in vitro expression of the proteins from 
the plasmid constructs. One of these was a coupled transcription/translation kit which 
allowed transcription of mRNA from the T7 promoter incorporated in the pVAX 
plasmid (Figure 3.1), with subsequent translation of proteins utilising the cell 
machinery in the reticulocyte lysate. An advantage of this procedure was that it 
allowed non-radioactive detection as the kit allowed incorporation of biotinylated 
methionine into the translated proteins, with subsequent detection on Western Blot 
with streptavidin-alkaline phosphatase. The system suggested there were higher 
levels of expression of CA than Tat and TM. This result is similar to that seen with 
CA protein in the bacterial expression systems reported later in this thesis (Chapter 
6). This high level of CA expression in the bacterial systems was thought to be due to 
either greater solubility of the expressed protein, the codon utilisation in the gene, its 
secondary mRNA structure, or its low bacterial toxicity. In the TnT system, RNA 
structure may have played a part in the low expression of Tat and TM, but codon 
preference should not have been a problem for these genes as viral proteins are 
normally produced in eukaryotic cells. The apparent low levels of Tat expression by 
this system may be due to low levels of incorporation of methionine, as methionine is 
under-represented in this protein. However this cannot account for the apparent 
difference in the expression of CA and TM and the results do indicate that the 
different levels of expression are real. Immunofluorescent staining of transfected cells 
with monoclonal anti-CA antibody again demonstrated expression of CA protein, 
with about 2% of transfected cells exhibiting strong cytoplasmic staining. Detection 
of expressed TM was with a hyperimmune polyclonal bovine anti-JDV serum, and 
although fluorescent cells were present in the transfected monolayer, cross reaction 
with intranuclear Rev protein expressed from the coadministered pcDNA 3.1/rev 
construct could have been responsible for some of the staining seen, especially the   79 
intranuclear staining, as BIV Rev is localised to the nucleus in vivo (Oberste et al., 
1993; Schoborg and Clements, 1994; Schoborg et al., 1994). The construct encoding 
Rev was co-administered with the vaccine constructs to investigate any requirement 
for Rev in expression of the vaccine genes. The transport of singly spliced or 
unspliced viral mRNA transcripts from the nucleus of infected cells is dependant on 
the interaction of Rev with the Rev responsive element (RRE) (located in the env 
region of the viral genome) to overcome the default pathway where mRNA 
transcripts are spliced before nuclear export to produce the transcripts coding for the 
regulatory proteins (Frankel and Young, 1998). However the inclusion of this 
construct was erroneous, as the vaccine genes were amplified from cDNA where 
splicing had already occurred, removing any Rev-dependancy from the expression of 
the administered vaccine genes (Chadwick et al., 1995b).  
While the transcription/translation kit used seemed to demonstrate only low levels of 
Tat expression, the strong transactivation of the pTAR/lacZ construct suggests there 
was significant expression of Tat from pVAX/tat. This assay was developed in our 
laboratory (Setiyaningsih, 2006), to enable functionality assessment of vaccine 
constructs for quality control during production of plasmids for animal trials, and 
modifications described in this Chapter were developed to reduce problems of cell 
death in the transfected cultures by using alternative transfectants, decreasing the time 
of interaction of the plasmid/transfectant complex with the cells, and very gentle 
treatment of the cells post-transfection. The assay is dependent on a transactivation 
region or TAR motif, which in HIV-1 is a hairpin structure at the 5’ end of the 
nascent viral RNA transcript. The multifunctional viral protein, Tat, binds to this 
region of the 5’ LTR and is capable of increasing the transcription of viral RNA by 
several orders of magnitude (Frankel and Young, 1998). Replacement of the promoter 
region in the pVAX/lacZ reporter plasmid with the TAR region from JDV gave a 
construct that would not express unless transactivated by Tat, and so successful 
transfection of cells was indicated by upregulation of the lacZ gene in co-transfected 
plasmid and development of the intense blue colour when the substrate, X-gal, was 
incubated with the cells. The high levels of cell death in transfected cells may also   80 
have been indicative of Tat expression, as extracellular Tat has toxic properties 
(Gallo, 1999).  
Having shown functionality of the constructs in vitro with several assays, activity in 
vivo was assessed by the inoculation of mice using intradermal bombardment with 
gold particles to deliver the vaccine constructs. This technique has several advantages 
over the intramuscular injection of DNA. Most importantly, many workers have 
attained strong cellular and humoral responses to several antigens after administration 
of small (<1-2.5 µg) amounts of DNA to mice with a biolistic device (Chen et al., 
1997; McCluskie et al., 1999). This contrasts with the much larger (up to 1 mg) 
amounts per injection required to raise an immune response in mice when the DNA is 
administered intramuscularly (Morel et al., 2004). The difficulty in raising a strong 
response in larger animals (Beard et al., 1999), is suspected to be in part dose-related, 
and it was hoped that biolistic transdermal vaccination would remove the need for 
large amounts of foreign DNA to be injected into the muscle, as found necessary in 
other attempts to DNA vaccinate cattle (Cox et al., 1993; Babiuk et al., 2003). The 
smaller amounts of DNA required would have ultimately made for a reduced cost of 
production of the vaccine in Indonesia, and as animals would ultimately be used for 
food at some time  post-vaccination, an intradermal rather than intramuscular 
injection site would provide for greater safety.  
To reduce costs, a mouse model rather than a bovine model was used to test the 
constructs for functionality in vivo. Surprisingly, mice did not appear to respond to 
CA vaccination whereas this protein was well expressed in both the TnT cell free 
system and in transfected cells. The CA antigen for screening of sera was produced as 
a soluble fusion protein in bacteria and has been shown to be recognised by sera from 
both naturally infected, and recombinant CA vaccinated cattle (Desport et al., 2005), 
indicating that the mice had failed to seroconvert rather than the antigen being 
undetectable due to conformational changes. The mice also failed to respond to the 
TM DNA vaccine construct, for reasons that were not clear. 
While mice did not seem to respond to the CA and TM vaccine construct, all mice 
vaccinated with pVAX/tat produced antibody to Tat. The bands obtained in Western   81 
immunoblots were not strong, indicating that high levels of antibody had not been 
produced. A similar weak antibody response was obtained against SU protein on a 
blot probed with sera from 2/5 of the pcDNA3.1/su vaccinated mice. The Western 
immunoblot antigen in this case was a bacterially expressed GST fusion protein and 
may not have possessed the array of epitopes present on a correctly folded 
glycosylated protein, expressed in a eukaryotic system. This same antigen was not 
recognised strongly by sera from naturally JDV-infected recovered cattle, and the 
lack of appropriate glycosylation of the bacterial protein may well have prevented 
strong recognition by the murine sera. Induction of an antibody response to the 
intracellularly expressed proteins was probably secondary to the induction of a cell 
mediated response, as endogenously produced protein in APC would be presented to 
T-cells in the context of the MHC class 1 pathway. However, re-presentation of 
antigen, produced in transfected keratinocytes, released, and processed by APC to be 
presented to the immune system in the context of MHC class II pathway, could give 
rise to a humoral response and antibody production. Tat protein in natural HIV-1 
infections is known to be released from infected cells into the milieu (Chang et al., 
1997), where it is capable of penetrating bystander cell membranes in a non-receptor 
mediated manner. It is possible that the seroconversion seen in the tat and su 
vaccinated mice was a result of release of Tat and SU by transfected keratinocytes 
and its uptake and processing by APC in these animals. The seroconversion to Tat in 
these mice was a significant finding, as anti-Tat antibody levels are inversely 
correlated with rate of progression to AIDS in humans, and antibodies to Tat can 
inhibit viral replication in HIV-1 infected cells in culture (Re et al., 2001). Other 
functions of the Tat molecule, such as transactivation of transcription factors and 
protection against apoptosis, are also successfully stopped by addition of anti-Tat 
antibody to infected cell cultures (Re et al., 2001). SU is not known to be released 
from transfected or naturally infected cells. Cell death may have released some 
expressed protein and the poor rates of seroconversion may reflect this route of 
antigen interaction with the immune system. 
The non–response to vaccination with TM and Capsid constructs, and the weak 
responses to SU and Tat constructs, may have been overcome by the use of an   82 
adjuvant. Many DNA vaccine experiments have highlighted the need for adjuvancy 
to enhance the reactogenicity of the administered construct (Sin et al., 1998; 
Somasundaram et al., 1999; Nobiron et al., 2001). First generation vaccines, 
incorporating live attenuated, or killed organisms contain a wide range of antigenic 
determinants, capable of providing sufficient of the signals required for good 
immunogenicity (Schijns and Tangeras, 2005). The quest for ever more molecularly 
defined antigens has often led to an decrease in immunogenicity as the non-specific 
determinants are removed from the vaccine formulation (O'Hagan, 1998; Singh and 
O'Hagan, 1999). In the case of DNA vaccination, the requirement for these 
costimulatory signals has led to attempts to replace the traditional adjuvants with a 
defined molecular adjuvant, either from incorporation of CpG motifs into the 
construct, co-administration of cytokine or interleukin genes, or chemical adjuvants 
such as alum (Scheerlinck, 2001; Sasaki et al., 2003). The efficacy of adjuvants is 
due to activation, by these co-stimulatory signals, of the APC which are then capable 
of activating naïve T-cells (Lima et al., 2004). CpG motifs, present in bacterial DNA 
at a far higher level of occurrence than in eukaryotic DNA, are potent activators of 
APC, but the amount of DNA administered by gene gun inoculation may be too low 
for CpG motifs to act as an effective adjuvant. Future work will require investigation 
of the adjuvant requirements of JDV DNA vaccines. 
It is also possible that expression but non-release of the CA and TM proteins led to a 
solely CMI response, that was not detected in cell proliferation assays attempted by 
another member of the research group (unpublished data). Nucleic vaccination 
involves endogenous expression of foreign genes, and induction of humoral 
responses is enhanced by tailoring the administered genes to include secretion signal 
peptides, allowing direction of the proteins produced down the secretion pathways of 
the cell (Lewis et al., 1997; Boyle et al., 1998; Bucht et al., 2001). Further 
modification of the constructs coding for the vaccine genes to include secretion 
signals would be required to test this hypothesis.  
Although encouraging initial results were obtained in terms of determining the 
conditions required to cause expression in the skin of cattle, and in proving both in 
vitro and in vivo that the constructs were functioning and capable of eliciting an   83 
immune response, several factors led to the work being stopped. Firstly, during the 
course of these studies it became apparent that registration of a DNA vaccine in 
Indonesia was going to be difficult; there was no precedent there, and very few 
precedents in any country. Secondly, it was felt that as adequate supplies of high-
quality antigen were not available to screen vaccinated animals for humoral and CMI 
responses, that any attempts to further optimise the vaccine constructs by co-
administration of cytokines or incorporation of individual epitopes such as the major 
homology region (MHR) of CA as a marker epitope would be frustrated by lack of an 
adequate assay to quantify levels of response. The levels of Tat expressed in cos7 
cells was low, requiring cells from 12 x 25 cm
2 flasks to purify sufficient protein for 
one small Western blot. Purification of viral antigen in Indonesia would therefore be 
difficult due to problems in maintaining equipment, and development of eukaryotic 
expression systems for all of the proteins of interest in Indonesia was considered a 
very difficult challenge. In the light of these obstacles, the work on DNA vaccines for 
JDV was discontinued.    84 
Chapter 4 
Development of a model for the kinetics of Jembrana 
disease virus replication and clearance during acute 
infection. 
Summary.  
This chapter describes the development of a simple model to describe the progression 
of the acute phase of JDV in a manner that allows meaningful comparison of data 
obtained from different animals, as all parameters showed large animal-to-animal 
variation.  
Introduction. 
Infection with JDV causes an acute febrile response lasting between 5-12 days and 
animals characteristically develop anorexia, leucopenia, oral erosions and 
enlargement of superficial lymph nodes (Soesanto et al., 1990). High levels of 
infectious virus were detected (10
8 ID50/ml plasma) during the febrile period, 
reducing to 10
5 ID50/ml on the first day after the febrile period and further declining 
to about 10
 ID50/ml at 42 and 72 days after infection (Soeharsono et al., 1995b). The 
leucopenia was principally due to a loss of lymphocytes and most of the 
haematological changes occurred during the febrile period and are well documented. 
Immunosuppression during infection is characterised by a delayed seroconversion to 
viral proteins, until approximately 6 weeks after infection. Surviving animals are 
resistant to reinfection, retain infectious virus for at least 2 years and do not appear to 
suffer relapses (Soeharsono et al., 1990). Attempts to cultivate JDV in continuous 
cell lines in vitro have so far been unsuccessful in Indonesia, although evidence of 
limited persistence in cultured peripheral blood mononuclear cells (PBMC) has been 
reported (Kertayadnya et al., 1993).  
Quantification of lentiviruses without using traditional cell culture techniques is now 
well established and surrogate assays such as measurement of HIV-1 p24 CA protein, 
(Lombardi et al., 1994; Kashiwase et al., 1997) viral reverse transcriptase (RT) 
activity (Yamamoto et al., 1996), and quantification of the amount of viral genomic   85 
RNA or integrated DNA in tissues or plasma by quantitative PCR are all currently 
used. Comparison of a capture ELISA for JDV CA protein that has been used to 
monitor JDV CA protein levels at the point of disease control and a recently 
developed quantitative RT-PCR (qRT-PCR) method for viral RNA in plasma has 
shown good correlation (Stewart et al., 2005). The qRT-PCR method is more 
sensitive, allowing a more clear analysis of the dynamics of JDV replication. 
Most lentiviruses have relatively labile genomes which are prone to variation and the 
development of quasispecies is common (Kyaw-Tanner and Robinson, 1996; Zheng 
et al., 1997; Baccam et al., 2003). The complete genome of JDVTAB (Chadwick et al., 
1995b), has been compared in a recent analysis to JDV gag, pol and env sequences 
from isolates obtained from different timepoints and geographical regions. JDV 
proviral DNA, unlike the other lentiviruses, shows a remarkably high level of 
nucleotide conservation, particularly between isolates from the same region taken at 
different times (Desport, 2007). However, another strain obtained from an affected 
animal in a different region, Pulukan, of Bali in 2001, termed JDVPUL, showed some 
divergence in the env sequences.  
In order to describe any effect of candidate vaccines on the kinetics of viral 
replication and clearance during JD, in addition to those seen on the febrile response 
and leucopaenia in experimentally infected controls, a model for typical JDV 
infections was required. An analysis of the kinetics of virus replication in 
experimentally infected Bali cattle was conducted and the results of these 
experimental infections and an analysis of the results are described in this chapter. 
Observed deviations from the model in 20% of experimentally infected cases are 
described and the implications for diagnosis and control of the disease are discussed. 
Materials and methods. 
Experimental cattle. 
Female Bali cattle between 6 and 12 months of age were purchased from Nusa 
Penida, an island off the coast of Bali that is considered free of JD, and transported to 
BPPH V in Denpasar, Bali. The animals were housed together in a fly-proof building, 
and fed a diet of elephant grass and concentrate ad libitum. Animals were housed for   86 
1 week prior to experiments and were tested using antibody ELISA (Hartaningsih et 
al., 1994) to ensure that they were JDV seronegative. 
JDV infectious doses. 
2 levels of challenge dose were used, either “low” an estimated 4x10
2 ID50, or “high”, 
an estimated 1-2 x10
3 ID50. The ID50 for JDV was determined previously by titration 
in animals (Soeharsono et al., 1990) and these workers found that the titre of 
infectious JDV in animals on the second day of the febrile reaction was about 10
8 
ID50/ml, and this was correlated to levels of circulating viral CA protein by an antigen 
capture ELISA and qRT-PCR (Stewart et al., 2005). In these experiments, the 
approximate ID50/ml in the plasma of a donor animal on the second day of fever 
which had been previously infected with a stored (-80
°C) spleen suspension 
containing the desired virus strain was therefore determined by antigen capture 
ELISA in Bali prior to preparation of the infection dose. The correct infection dose of 
virus was then obtained by appropriate dilution, in DMEM, of the donor animal 
plasma to give a final volume of 2 ml. This was administered by intravenous injection 
into the jugular vein of each animal as shown in Table 4.1. Confirmation of the viral 
titre in the donor animal plasma was carried out retrospectively by qRT-PCR, as 
detailed below. 
Table 4.1 Estimated and actual infection doses of each strain of JDV for Trials II-V. 
Trial Donor 
Plasma viraemia 
level in donor 
determined by 
ELISA (ID50) 
Infectious dose 
administered to 
cattle (ID50) 
Infectious dose 
determined by 
qRT-PCR 
II CB  65  1.5 x10
8  1 x 10
3 Not  determined 
III CB  143  8 x 10
8  4 x 10
2  1.01 x 10
3 
IV Not  known  1.6 x 10
7  1 x 10
3  Not determined 
V CB  115  1 x 10
8  1 x 10
3  6.4 x 10
2 
Sampling regimes in infected cattle.  
Clinical signs were monitored post-infection, and some animals were killed and 
necropsied at various times post recovery. Rectal temperatures were taken daily for 
21 days post infection. Blood samples were collected into EDTA for preparation of 
plasma and estimation of leucocyte concentration, and serum samples were prepared   87 
by centrifugation from clotted blood taken into tubes without EDTA. All plasma and 
serum samples were stored at -80
0C until analysed.  
Viral RNA extraction. 
Plasma samples were clarified by centrifugation (8,000 g, 5 min) prior to extraction 
of RNA. Total RNA from either 140 µl (Trial II, IV and V) or 280 µl (Trial III) of 
thawed plasma from each sample time-point was extracted using a QIAmp Viral 
RNA mini kit (QIAGEN) following the manufacturer’s instructions, with a final 
elution volume of 60 µl in buffer EB. Extracted RNA was stored at –80
°C until 
required.  
Quantitative reverse transcription polymerase chain reaction (qRT-PCR). 
All primer and probe sequences were derived from the previously published JDVTAB 
sequence; Genbank accession No. U21603 (Chadwick et al., 1995b). The primer set 
(Invitrogen) utilised is shown in Table 4.2. These primers were designed to amplify a 
121 bp fragment of the JDV gag gene. 
Table 4.2 Primers and probe for qRT-PCR. 
Primer. Sequence. 
JDV gag1f  5’-GGGAGACCCGTCAGATGTGGA-3’ 
JDV gag1r  5’-TGGGAAGCATGGACAATCAG-3’ 
Probe  FAM-5’-CCCACAACTTAGAAAGAACTTCCCCGCTG-3’-BHQ-1 
The fluorogenic probe (Geneworks) was labelled at the 5’ end with the reporter dye, 
6-carboxyfluorescein, and at the 3’ end with the Black Hole-2 quencher dye. 
qRT:PCR reactions were performed initially in an ABI 7700 Sequence Detection 
System (PerkinElmer), and subsequently in a Rotor-Gene 3000 (Corbett Research). 
Initially, an Access RT-PCR kit (Promega) was used to make a reaction master mix 
consisting of final concentrations of:0.5X AMV/Tfl reaction buffer, 0.8 mM of each 
dNTP, 2 mM MgCl2, 100 nM of each primer, 0.1 µM fluorogenic probe, 0.2 U/rxn 
RNAseIn (Promega), 0.4% (w/v) Triton X-100, 2 mM DTT, 0.1 U/µl AMV-RT and 
0.1 U/µl Tfl DNA polymerase in a final volume of 23 µl, in 100µl tubes (Axygen) in 
a 76 well rotor. 2 µl of extracted total RNA were added to each tube, and each sample   88 
was assayed in duplicate, with fluorescence excited at a wavelength of 470 nm and 
detected at a wavelength of 510 nm. The one-step RT-PCR protocol consisted of an 
RT step at 48°C for 45 min, a 3 min inactivation step at 95°C , followed by 40 cycles 
of 95°C for 30 seconds, 58°C for 30 seconds and 60°C for 30 seconds (Stewart et al., 
2005). Fluorescence data was collected in the annealing and extension steps of the 
PCR cycle.  
An improvement on this assay was introduced in the analysis of the RNA samples 
obtained from the animals in Trial V. For these assays, a premixed 2X mastermix, 
(Iscript, BioRad) was used, with the addition of both primers and fluorogenic probe 
to a final concentration of 100 nM as above, and ultrapure water added to give a final 
1X concentration. MMLV reverse transcriptase was used in this assay following the 
manufacturer’s instructions. 1 µl of RNA sample was added to 9 µl of master mix in 
100 µl tubes (Axygen) and the one-step RT-PCR protocol consisted, in this case, of 
an RT step of 50°C for 10 min, a 5 min inactivation step at 95°C with a 2 second 
pause at 92
°C to prevent thermal overshoot , followed by 40 cycles of 92
°C for 2 
seconds, 95°C for 15 seconds, 58°C for 30 seconds and 60°C for 30 seconds. 
A standard curve was generated in each run by amplification of duplicate serial 10-
fold dilutions of a plasmid, pCR2.1 (Invitrogen) containing nucleotides 19-2881 of 
the sequence of the JDVTAB isolate, encompassing the target amplicon. Copy 
numbers of the plasmid added to each standard reaction were calculated, with 1 copy 
of plasmid equivalent to 1 viral genome. Estimation of the relative efficiency of the 
RT step was performed by including a standard RNA sample in each run, and blanks 
(no probe, no template, no RT, template no RT) were included in each run. The 
results obtained from the Prism 7700 were analysed with Sequence Detector 1.9.1 
software, and for the later experiments, the Rotor-Gene proprietary software, Version 
6.0, was used. 
Calculations. 
The rate of increase in viral titre(γ) was calculated for each sampling interval as 
(lnTitreTn-lnTitreTn-1)/(Tn-T-1), where T was time in hours post-infection. The   89 
doubling time or clearance half-life for each sampling interval was calculated as 
ln(2)/γ, expressed in h. 
Total leucocyte concentrations were expressed as the percentage decrease normalised 
to the concentration on the day of infection. 
Fever score was used as a measure of the severity of the febrile period, and calculated 
as the area under the body temperature curve, but above the 39.5
°C cutoff line. 
Statistical analysis. 
The mean results for each measure in each phase were compared with Student’s 2-
sample t-test . 
Data condensation.  
The phases of the progression of acute JD were defined in terms of the rate of 
increase and decrease of the viral titre in the plasma of infected animals, and are 
shown below. The mean of data obtained for each parameter measured during the 
experiment was calculated for the period of each phase, and these were then 
compared for statistical differences using Student’s 2-sample t-test . 
Table 4.3 Definitions of the phases of virus load during JD in animals experimentally infected 
with JDVPUL. 
Phase. Name  Definition. 
1 Lag  No virus detected in consecutive samples PI 
2 Initial  appearance  Doubling time of viral titre in plasma <10 h. 
3 Initial  plateau  Doubling time of increases to >10 h 
4 Second  growth  phase  Doubling time <10 h. 
5 Plateau  Doubling time or half-life >10 h. 
6 Resolution  Begins when half-life first <10 h (>10hs later). 
7 Post  recovery  24 h immediately following “recovery”. 
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Results. 
Typical febrile responses to infection with JDV TAB and JDV PUL. 
A range of responses to infection were seen (Figure 4.1) and these are summarised in  
Table 4.3. In the majority of experimentally infected animals, the clinical disease 
followed a typical course: an incubation period of several days, followed by a febrile 
period with a range of clinical signs, resolving as body temperature returned to 
normal. The animals either recovered, or died shortly after the febrile period. Apart 
from this typical disease profile, 2 other patterns of disease were also seen (described 
below). The temperature profiles from 17 mock-vaccinated Bali cattle experimentally 
infected with JDV during 4 separate infection experiments were analysed to 
determine the range of values that are normally observed during the acute phase of 
JDV infection. The mean temperatures post-infection were calculated for the normal 
responders for each of the 4 trials, as the virus strains used and doses varied between 
trials. The mean incubation period before the onset of fever in both of the groups that 
were infected with JDV TAB (Trials II and III) was 7 days, even though the animals in 
Trial III received a lower infection dose, and the animals infected with JDVPUL 
developed fever an average of 1.2 days later.  
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Figure 4.1 Mean daily rectal temperatures of groups of cattle following infection with 2 strains 
of JDV (JDVTAB and JDVPUL).    91 
 
Table 4.4 Summary of clinical and virological observations in 12 cattle experimentally infected 
with 2 strains of JDV. 
Strain of 
JDV and 
dose 
Animal Peak 
viraemia 
(days 
post-
infection) 
Infection 
to onset of 
fever 
(days) 
Infection 
to peak 
fever 
(days) 
Infection 
to end of 
febrile 
period 
(days) 
Duration 
of febrile 
period 
(days) 
Fever 
score
* 
Outcome 
of 
infection 
CB 61  10 7 11  13 6  5.7  Survived 
CB 62  11 7 11  13 6  6.1  Survived 
JDVTAB 
1000 ID50 
CB 63  8  6 11  13 7  9.9  Survived 
CB 83  12 7 11  14 7  5.5  Survived 
CB 85  11 9 11  15 6  5.6  Survived 
CB 86  12 7 12  15 8  6.8  Survived 
JDVTAB 
400 ID50 
Mean  10.67 7.17 11.17  13.83 6.67  6.60   
CB 108  10 5 12  14 9  9.4  Survived 
CB 110  11 10 12 13  3  2.2  Survived 
CB 135  13 9 11  16 7  8.2  Survived 
CB 137  12 9 11  15 6  7.3  Survived 
CB 138  10 9 12  15 5  4.5  Survived 
Mean  11.20 8.40 11.00  14.60 6.00  6.32   
JDVPUL 
1000 ID50 
CB 109  11 9 11  12 3  2.2  Died 
* Fever score defined as area under body temperature curve above the 39
°C cutoff line.    92 
 
Table 4.5 Viraemia (genome copies/ml plasma) at various stages of the febrile response in 
animals that survived the infection. Onset of fever onset was determined as the first day after 
infection when rectal temperature exceeded 39.5 and end of febrile period was defined as the last 
day where rectal temperature exceeded 39.5°C. 
Strain of JDV and 
dose 
Animal  At onset of febrile 
period (log10) 
At peak viraemia 
(log10) 
At end of febrile 
period (log10) 
CB 61  11.81 12.22  9.77 
CB 62  11.09 11.97 11.17  JDVTAB 
1000 ID50 
CB 63  10.56 11.29  6.81 
CB 83  10.08 11.76  9.82 
CB 85  9.15 10.63 6.53  JDVTAB 
400 ID50 
CB 86  10.33 11.11  7.48 
 Mean  10.50  11.50  8.60 
CB 108  6.28 11.76 8.39 
CB 110  9.95 10.63   
CB 135  9.74 11.11 9.64 
CB 137  9.57 10.41 7.61 
CB 138  8.96 10.34 8.14 
JDVPUL 
1000 ID50 
Mean  8.90 10.85 8.44 
Mean viraemia at the onset of fever was lower for typical responders infected with 
JDVPUL than in those infected with JDVTAB. The peak viraemia, and that at resolution 
of fever, was also lower in these animals. The numbers for viraemia at onset and at 
peak were significantly lower (p=0.02 and p=0.05 respectively) when log10 values 
were compared. 
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Figure 4.2 Differences in the clinical parameters (febrile response and leucopenia) and virus load 
in animals infected with 2 strains of JDV that survived the infection. Phases of the acute disease 
are labelled 1-6 and defined as described below.   94 
The occurrence and duration of the phases, and the means of the values of the 
observed and calculated measures for each phase could then be compared between 
strains with a simple 2-sample t-test . Figure 4.2 shows schematic illustrations of the 
identified phases of acute JD following infection with 2 different strains of virus.  
Phase 1, a lag phase where no virus was detectable in samples taken up to 144 h post-
infection, was seen in 2/3 of the animals that responded typically to infection with 
400 ID50 of the JDVTAB strain (Figure 4.2a and Tables 4.6 and 4.7). In contrast, all 
animals inoculated with an estimated 1000 ID50 of JDVPUL had a detectable plasma 
virus load at the first sampling time-point (Figure 4.2b). During Phase 2, a rapid 
increase in the numbers of RNA genome copies/ml in plasma occurred in both 
groups. In 2 out of 3 animals infected with JDVTAB this phase was extended out to the 
start of Phase 5, with no slowing of the rate of increase in viral numbers, Phase 3, as 
seen in all animals infected with JDVPUL. The initial appearance of viral RNA in the 
plasma was accompanied by a slight decrease in leucocyte counts, more marked in 
JDVPUL, and a transient slight but significant (p=0.019) increase in rectal temperature, 
at day 3-4 post infection, in animals infected with JDVTAB. The numbers of viral 
genomes/ml plasma increased faster in those animals infected with JDVTAB than with 
JDVPUL, where a decrease in virus load was seen during Phase 3 in 2 out of 4 animals. 
These animals then tended to have a longer Phase 4 than JDVTAB infected animals, 
reaching a lower maximum titre. In JDVPUL infected animals, the lower peak virus 
load was largely due to a slower increase in numbers or actual decline seen in Phase 
3, as although the rate of increase in the virus load during Phase 4 was slower, the 
duration of this phase was longer.  
The body temperature slowly increased during Phase 4, and all animals became 
febrile, defined as a rectal temperature of 39.5
°C or over, as the plasma viraemia 
increased. Animals infected with JDVPUL became pyrexic at a lower plasma viral titre 
than those infected with JDVTAB. The clinically febrile period encompassed Phase 5: a 
plateau phase, with maximum and constant viral titres in plasma suggesting the rate 
of viral replication was in equilibrium with the rate of clearance. This phase was also 
characterised by continued fever and low leucocyte counts. This plateau phase was 
longer in JDVPUL infected animals, but was followed by a shorter Phase 6, as defined   95 
by a return to a rectal temperature of less than 39.5
°C. The lower maximum viraemia 
reached meant that the animals returned to normal more rapidly despite clearance 
half-lives being longer in these animals. As viral titre started to spontaneously 
decrease in Phase 6, leucocyte counts rapidly increased to the levels seen prior to 
challenge, or higher, and body temperatures returned to normal. The only animal that 
died after infection with JDV in these experiments, CB 109, showed a decrease in 
body temperature but a large increase in viral titre with no recovery of the leucocyte 
counts (Table 4.7). Phase 7 was the 24 h period immediately following recovery from 
clinically elevated rectal temperture. 
Table 4.6 Comparison of summary of clinical and virological response in animals surviving 
infection with JDV TAB or JDV PUL (Viraemia expressed as log10 viral genomes/ml). 
Phase 
Parameter  Strain of 
JDV  1 2 3 4 5 6 7 
JDV PUL    38.4 38.8 39.5 40.7 39.8 38.8  Rectal temperature 
(
°C)  JDV TAB  38.9 39.1 38.8 39.3 40.5 39.9 38.9 
JDV PUL    98.6 90.2 67.8 45.3 60.9 98.2  Leucocyte count 
(% of value at day 0)  JDV TAB  95.1 76.5  104.5  73.6 49.4 67.2   
JDV PUL    3.3  4.5  7.6 10.0 9.4  7.9  Plasma viraemia 
(log10 genomes/ml)   JDV TAB  0  4.8  5.5  9.0 10.9 9.5  7.9 
JDV PUL    0.14 0.02 0.13 0.03 -0.12  -0.11 
Growth rate (γ) 
JDV TAB  NA 0.15 0.05 0.12 0.02 -0.11  -0.15 
JDV PUL    4.89 -22.04 5.52 33.38 -7.82 -7.91  Doubling time/ 
clearance half-life (h)  JDV TAB  NA  4.50 13.70 5.88 69.40 -6.38 -6.42 
JDV PUL    62.4 72  96 102 24  24 
Duration (h) 
JDV TAB  96  104  48 72 80 64 24 
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Table 4.7 Summary of clinical and virological responses in animal CB 109 infected with the 
Pulukan/01 strain that died 12 days after infection (Viraemia expressed as log10 viral 
genomes/ml). 
Phase. 
Parameter 
1 2 3 4 5 6 7 
Temperature (
°C)    38.6 38.8 39.5 40.0     
WBC  (% day 0)   100.00  71.63  63.49  61.71     
Plasma viraemia (log 10)    5.39 6.89 9.90  11.06     
Growth rate (γ)    0.148 0.086 0.148 0.132     
Doubling time/half-life (h)    4.67 8.05 4.69 5.26     
Duration (h)    72 120 24  72     
 
Table 4.8 Results of comparison, using a 2 sample t-test , of the mean of measures of parameters 
for each phase of the clinical and virological response in surviving groups after infection with 
JDVTAB and JDVPUL. 
Parameter  Differences in values 
Growth rate  No significant differences in any phase 
Doubling time/half-life  No significant differences in any phase 
Plasma viraemia  No significant differences in any phase 
Body temperature  Phase 2: JDVTAB infected animals significantly higher (p=0.019).  
Duration of phase  Phase 2: JDVTAB infected animals significantly shorter (p=0.016). 
Phase 6: JDVTAB infected animals significantly longer (p=0.004).  
Atypical febrile responses to infection with JDVTAB and JDVPUL. 
6 animals did not respond as expected to infection. 4 of these, CB 64, CB84, CB134 
and CB 136 did not develop a typical febrile response during the period of analysis, 
with no febrile response in 2 animals (CB 84 and CB 136) and only a transient mild 
febrile response with a maximum temperature of 39.7
°C seen after 4 (CB134) and 16 
days (CB64) (Figure 4.3 and Table 4.9). Previously these may have been discounted 
as failed infections but the presence of viral RNA in plasma indicated that replication 
of virus had occurred in these animals (Table 4.10). 2 patterns of viral replication 
were seen in these animals: CB 64, CB 84 and CB 134 exhibited an undulating viral 
titre increasing to a maximum titre of about 10
8 genomes/ml; CB 136 showed a more 
typical viraemic pattern (Figure 4.3) and 2 animals, CB 109 and CB 111, had   97 
elevated body temperatures for an extended period before the onset of a typical 
febrile response, with virus present but not increasing in titre during this period 
(Figure 4.3). 
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Figure 4.3 The clinical and virological responses in animals that responded atypically to infection 
and 1 animal (CB 109) that died. 
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Table 4.9 Observed parameters in animals that did not respond to infection as expected. 
Strain of 
JDV and 
dose 
Animal Peak 
viraemia 
(days 
post-
infection) 
Infection 
to onset 
of fever 
(days) 
Infection 
to peak 
fever 
(days) 
Infection 
to end of 
febrile 
period 
(days) 
Duration 
of febrile 
period 
(days) 
Feve
r 
score
* 
Outcome 
of 
infection  
JDVTAB 
1000 ID50 
CB 64  14 15 16 17 2  0.2  Survived 
JDVTAB 
400 ID50 
CB 84  13  NA NA NA NA 0  Survived 
CB 111  3 and 14  3 and 12  7 and 13  10  7 and 6  7.2  Died 
CB134  14  4 4 5 1 0.1  Survived  JDVPUL 
1000 ID50 
CB 136  12  N/A N/A N/A N/A 0  Survived 
NA denotes not applicable as no febrile response was detected. 
Table 4.10 Viraemia (genomes/ml plasma) at relevant fever setpoints in animals that responded 
atypically. 
Animal.  Viraemia at onset of fever  Peak JDV RNA (copies/ml plasma) 
CB 64  3.0 x10
10  1.5 x10
11 
CB 84  N/A  8.6 x 10
7 
CB 111 (biphasic)  1.6 x10
6 (2.3 x10
10) 1.6  x10
6 (3.0 x10
10) 
CB134  3.75x10
1  1.95 x10
8 
CB 136  N/A 6.47x10
7 
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Discussion. 
It is evident that experimental infection with JDV results in a broad spectrum of 
related responses, ranging from apparent failure of infection to the death of the 
animal. This broad range means that it is difficult to define the response, and this is 
necessary to determine the efficacy of a vaccine. Clinical disease in 70% of the 
experimentally challenged animals followed a typical progression, with symptoms 
developing as the plasma virus load increased, and resolving with clearance of the 
virus, which even during the course of the experiment in some cases reached 
undetectable levels. Virus is still present, however, for a long period at low levels 
after apparent clinical recovery, as blood taken from recovered animal was found to 
be infectious with a titre of approximately 10 ID50 9 months after infection 
(Soeharsono et al., 1995b).  
The progress of a typical acute episode, as measured by rectal temperature, could be 
correlated to the plasma virus load. However, at set points in the disease process, 
determined using rectal temperature as a correlate of infection, such as the beginning 
and end of the febrile period, considerable variation was found in the levels of the 
plasma virus load in animals infected with JDVPUL or JDVTAB. This high level of 
animal to animal variation, and in particular the difference in incubation period before 
onset of the febrile period, would normally make it difficult to compare the effects of 
infection with 2 viral isolates using conventional statistics. To address this problem, 
in this thesis a simple model was developed that better describes the progress of acute 
JD. This model uses differences in the calculated doubling time and rates of clearance 
of virus in plasma, to divide the acute period of disease into several phases, defined in 
Table 4.3. These were identified consistently throughout each infection with the 
JDVPUL strain of JDV, and it was decided to use this as the exemplar of a typical JDV 
infection. To examine differences in viral strains and subsequently the effects of 
vaccination, using data obtained from qRT-PCR assays for levels of JDV RNA in the 
plasma, data condensation of the other measures taken during the experiment was 
required to allow simple comparison of the effects of infection with the 2 strains of 
virus.    100 
The proposed model is similar to that used by several groups in attempting to predict 
from the severity of the initial acute disease, the eventual progression to an AIDS-like 
state in animals and humans, and also to examine the effects of intervention with 
drugs or vaccination on viral load (Perelson et al., 1996; Bonhoeffer et al., 1997; 
Nowak et al., 1997; Stafford et al., 2000). One of the limitations of this type of 
analysis is that the levels of viral RNA in plasma only represents overspill of virus 
from the main sites of replication. Large numbers of JDV infected cells have been 
reported in the spleen and lymph nodes during the acute phase of the disease 
(Chadwick et al., 1998), and it is likely that the levels in plasma are probably only a 
proxy for the actual overall viral load at any point in the disease. However, 
quantification of plasma viral RNA is the only measurement available to easily and 
directly examine the effects of strain difference or vaccination on the progress of the 
disease. 
The differences in the plasma virus load in the early stages of JD seen after infection 
with the 2 strains of JDV, could be due to both host and virus related factors. These 
could include factors such as the retention of virus in the tissues, differences in the 
rates of viral replication and viral infectivity between strains, or differences in the 
ability of the early innate immune response, before the development of an adaptive 
response, to control virus.  
The differences in the length of  time between viral challenge and onset of clinical 
disease is closely correlated to the number of infectious virus particles used in the 
challenge dose (Soeharsono et al., 1990). Initial experiments on transmission of JDV 
established that the plasma of animals in the second day of the febrile period  
contained 10
8 ID50 infectious doses / ml. These results were obtained by titration in 
animals. Quantification by RT-qPCR of the levels of virus in the plasma of animals at 
the same stage of fever as those used in the initial experiments consistently gave 
considerably higher virus numbers. This was expected as the numbers of virus 
particles capable of causing infection is estimated to be 1% or lower of  the total 
particles present. The use of RT-qPCR routinely to calculate the challenge dose 
routinely was not possible in Indonesia, so a capture ELISA for JDV CA was 
developed, and as this showed good correlation with the results obtained by RT-  101 
qPCR was utilised to determine the challenge dose, with results confirmed later by 
RT-qPCR (Stewart et al., 2005). This approach allowed the numbers of infectious 
virus particles administered to be determined to within a log of the value desired.         
The reasons for the difference in the disease process induced by JDVTAB and JDVPUL 
are not known but small differences in sequences between these 2 strains of JDV may 
be sufficient to cause differences in the phenotype. Preliminary sequence analysis has 
shown that JDVPUL is genetically similar to JDVTAB but differs in the vif (S.Peterson, 
personal communication), env and LTR sequences. In MVV, single mutations in the 
gene encoding CA and in vif together have been shown to confer a highly pathogenic 
phenotype on an apathogenic infectious clone (Gudmundsson et al., 2005). JDVPUL 
also has a 7 base insertion in the U3 region of the LTR compared to JDVTAB 
(Setiyaningsih, 2006; Desport, 2007). Differences in this region of the LTR increased 
replication capacity of EIAV in vitro (Madden and Shih, 1996). JD has similarities in 
aetiology to EIAV, in that the same organs are implicated as sites of tissue 
replication, and that both diseases are ultimately successfully immunologically 
controlled by host reponses, although the transient episodes of viraemia declining in 
severity over time characteristic of EIAV are not reported in cattle after recovery 
from the acute stage of JD.  
Animals infected with JDVTAB do not have detectable virus for several days post 
infection, in contrast to JDVPUL where virus was detectable at an earlier stage. The 
actual moment of detectable levels of virus appearing in the plasma was not always 
accurately determined, as insufficient samples were taken in the first few days post-
infection, and it is likely that all the animals would have had a definable initial lag 
phase if sufficient samples had been taken. The time of initiation of Phase 2 would 
also have been influenced by too long an interval between the early sampling times, 
and this was addressed in later experiments. The start and end of Phase 3, and 
subsequent phases, were more accurately identified as more samples were taken at 
this stage of the infection. 
The site of initial replication of JDV is not known, although virus is present in the 
spleen on the first day of fever (Chadwick et al., 1998). The splenomegaly   102 
characteristic of the disease (Dharma et al., 1991) indicates that initial infection is 
originally blood-borne, and as antigens, such as viruses, arriving by this route are 
trapped by professional antigen presenting cells in the spleen it is probable that this is 
site of initial replication (Janeway, 2001). Initial rates of replication may differ due to 
the LTR insertions mentioned above, or perhaps the ability of the viral strains to 
disseminate may differ. The sudden appearance of virus in the blood probably 
represents rapid release from another body compartment, probably the spleen. The 
total white cell count over these initial days post-infection declined slightly in both 
groups, possibly as infected cells are removed from the circulation by the spleen, and 
this first round of replication must give rise to the virus seen in the initial appearance. 
The tropism of JDV has not been confirmed, but in common with all other 
lentiviruses is likely to be either lymphocytes or macrophages (Chadwick et al., 
1998). 
The plasma virus load in JDVTAB infected animals rose rapidly from first detection 
whereas in animals infected with JDVPUL there was a significantly longer initial 
plateau phase (Phase3). This may indicate retention of virus in tissue compartments, 
or possibly an earlier and more effective innate immune response to JDVPUL, leading 
to pyrexia at a lower viral titre in the plasma, due to release of inflammatory 
mediators from macrophages, neutrophils and activated lymphocytes. Phase 4 was 
associated with a rapid increase in plasma viral titre, and a corresponding leucopaenia 
which was previously shown to be due to lymphopaenia and neutropaenia (Soesanto 
et al., 1990). The febrile onset occurred during this phase, and is associated with a 
marked proliferative response in the T cell areas of the spleen (Dharma et al., 1994). 
This lymphoproliferative response would provide an increased number of target cells 
for the virus if the tropism is for T-cells, allowing unrestrained viral replication to the 
high levels seen at the peak of viraemia. The observation that the plasma virus load in 
JDVTAB infections was consistently higher (up to 100-fold) than that with JDVPUL, 
despite there being no difference in the time post-infection, suggests that immune 
activation occurs at a lower plasma viral load in animals infected with JDVPUL. The 
earlier response seems to limit viral replication, resulting in lower plasma virus load 
and a lesser febrile response. The leucopenia during Phases 2 and early Phase 3 as   103 
cells are recruited to the spleen in the immediate period post-infection was greater 
when animals were infected with JDVPUL than with JDVTAB (Figure 4.2). The 
rebound increase of peripheral leucocytes later in this phase also indicated greater cell 
proliferation in response to infection in these animals, than in JDVTAB infected 
animals. The peak viraemic period during JDVPUL infection was only ~0.5 log lower 
than JDVTAB, indicating that growth and release continues during Phase 5 for longer 
with this strain. Phase 5, where the plasma virus load plateaus, presumably as rates of 
increase match clearance rates, may represent saturation of the system as all available 
target cells are depleted and the innate immune system starts to alter the balance in 
favour of viral clearance, or may be the result of an efficient CMI response being 
rapidly induced. As control of viral replication is established, and the target cell 
population is depleted, the levels of virus fall quickly, in Phase 6, and the leucopaenia 
resolves, with rapid increase to higher than original levels of leucocytes. In this phase 
there must be some immune control mechanism to limit resurgence of virus as the 
immune system returns to normal, and a very low viral setpoint is established, the 
duration of which is not known.The significantly longer Phase 6 caused by slower 
clearance rates of JDVTAB  meant that numbers of virus at clinical recovery were 
similar.  
Despite the apparent presence of a marginally more effective early response to 
JDVPUL over the entire series of infection experiments using these 2 strains, higher 
mortalities occurred in animals challenged with JDVPUL, surprisingly given the lower 
mean maximum temperatures and viraemia characteristic of disease caused by this 
strain. The requirement of lentiviruses for terminally differentiated cells as sites of 
replication means that induction of an early response that is ineffective can potentiate 
the severity of disease by increasing the numbers of potential target cells, and CB 
109, infected with JDVPUL, which died after a short low fever, illustrated this. This 
animal had entirely failed to control viral replication, with no decrease of circulating 
virus seen although it had apparently recovered as fever abated. Total depletion of 
target cells responsible for cytokine release and pyrexia could account for this. 
Experimentally infected animals normally have a case fatality rate of about 17% 
(Soesanto et al., 1990). In a control group of 4 or 5 animals this represents a mortality   104 
of less than 1 animal per group which explains the death of only 1 normally 
responding cow after infection with the JDVPUL strain. 
Over the entire series of experiments atypical responses were seen in control animals 
infected with both strains of virus, and these responses fell into 2 categories. Some 
animals with no febrile response (Figure 4.3) showed an apparently typical pattern of 
viral replication, with an increase to a plateau followed by spontaneous clearance but 
with maximum levels of virus somewhat lower than in animals showing clinical signs 
e.g CB136. Similar responses have been seen in African green monkeys challenged 
with SIVAGM, where virus replicates to a high level without immune activation and 
the associated pathology (Broussard et al., 2001) and in captive sooty mangabeys 
naturally infected with SIVSM (Rey-Cuille et al., 1998). Other cows showed an 
undulating viraemia during the acute phase, with no accompanying febrile response. 
Studies in at-risk humans report that between 10% and 60% of patients infected with 
HIV-1 do not experience a primary acute disease, although in studies including 
control groups the incidence of acute disease is higher, from 81% to 87% (Kahn and 
Walker, 1998). Mock vaccinated cats in FIV vaccine trials also show a small 
proportion that are resistant to infection (Verschoor et al., 1996). 
During the recovery phase of JD the earliest detectable immune responses are against 
the JDV CA protein (Hartaningsih et al., 1994). The typical responders in these trials 
had detectable antibodies between 41-58 days post infection and a peak response at 
122-125 days post infection (Personal communication, J. Lewis; data not shown). 
Sampling of 2 responding animals in Trial V was discontinued before the full 
response was developed as these animals were used in a further vaccine trial. The 
atypical responders from these groups did not develop antibody responses to JDV CA 
that were detectable using the JDV antibody ELISA (Table 4.11), although weak 
responses were observed by Western blot (Personal communication, J. Lewis; data 
not shown). No febrile response was seen during viraemia and very low levels of 
antibody to JDV proteins were detected. The failure of these animals to seroconvert 
strongly to the presence of highly antigenic CA protein is interesting. Suppression of 
the immune system by proteins expressed from endogenous retroviruses has been 
reported (Larsson and Andersson, 1998). Dual infection with other   105 
immunosuppressive viruses may be a factor, some studies have shown cattle infected 
with both BIV and bovine leukaemia virus (BLV) are immunosupressed (Hidalgo and 
Bonilla, 1996), although this is not reported by other investigators (Flaming et al., 
1997; Isaacson et al., 1998). 
All animals were given a large challenge dose, to ensure as far as possible that 
infection would occur. A perhaps more realistic approach, of repeated small 
challenges to establish infection (McDermott et al., 2004), could not be implemented 
due to time and cost restraints. Producing a standard infection dose (Table 1), was 
difficult as there is no culture system or infectious clone for JDV, and storage of 
purified virus in liquid nitrogen is not possible for extended periods in Bali. The 
protocol used to produce the virus for experimental infection involved passage in a 
donor animal, with live virus infectious doses being prepared on the second day of 
fever (Kertayadnya et al., 1993). There is a possibility of enhancing pathogenicity of 
the infection strain by selecting for virus that has evaded immune control by this 
method. The virus commonly used in infection experiments in macaques, SHIV89.6P, 
has developed extreme pathogenicity through serial passage as it has lost its dual 
receptor requirement, needing only CXCR4 to infect CD4 T-cells (Feinberg and 
Moore, 2002). Cats challenged with FIV obtained during the acute phase of disease in 
a donor animal developed fatal disease more rapidly than when virus was prepared 
from the same donor cat during the chronic phase of disease (Diehl et al., 1995). 
However, JDV transmission is postulated to be via an insect vector, suggesting that 
transmission would be most likely to occur during the acute phase of the disease 
when viral titres are high. Therefore, taking the infectious dose at the height of fever 
is likely to at least reflect the viral population at the moment of natural transmission, 
even if the dose is unrealistically high to ensure infection within the timescale of the 
experiment.  
In conclusion, the divison of the disease into these phases, and the condensation of 
the data from each phase allowed statistical comparisons to be made between 
measures taken in different phases from the 2 infection groups. Subtle differences 
between the diseases seen post-infection with 2 strains could be identified. Further 
work with larger numbers of animals, and more frequent sampling throughout the   106 
immediate period post infection and up to the point where virus becomes 
undetectable in all animals will shed more light on possible variations in the 
pathogenicity of different strains of JDV. 
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Chapter 5  
The effect of an inactivated viral vaccine on plasma viral 
load during experimentally induced Jembrana disease. 
Summary.  
In this chapter the effects of vaccination with a tissue derived, inactivated viral 
preparation on viral growth and clearance during the acute phase of experimentally 
induced JD in Bali cattle are described. 
Introduction.  
The most successful vaccines against the animal lentiviruses are those using whole 
attenuated, or inactivated virus preparations. At least some measure of protection has 
been induced with inactivated viral preparations in cats against feline 
immunodeficiency disease (Yamamoto et al., 1993; Hosie et al., 2000), in horses 
against equine infectious anaemia (Issel et al., 1992), and against intravaginal 
challenge with SHIV89.6 in macaques mucosally immunised with inactivated SHIV89.6 
(Ambrose et al., 2003). However, potentiation of lentiviral disease following 
vaccination is occasionally seen in goats vaccinated against CAEV  
(Russo et al., 1993).  
An inactivated viral vaccine against JDV has been developed in Bali, Indonesia. It 
consists of detergent inactivated virus in homogenised spleen tissue taken from an 
experimentally infected donor animal at the peak of viraemia (Hartaningsih et al., 
2001). However, widespread prophylactic vaccination regimes are not employed in 
Indonesia, as the expense of producing the vaccine is high, and there are fears of 
spreading not only JDV, but other pathogens, if inactivation should fail. The efficacy 
of this vaccine has been determined previously by analysis of clinical symptoms and 
pathological signs and has been shown to reduce the febrile period and severity of 
disease after challenge with live virus (Hartaningsih et al., 2001). Advances in the 
technology of qRT:PCR have allowed accurate quantitation of the levels of 
circulating lentiviral RNA in plasma after infection, with low limits of detection and a 
wide dynamic range compared with p24 ELISAs (Hofmann-Lehmann et al., 2000;   108 
Klein et al., 2003). The recent development of a qRT:PCR assay in our laboratory for 
the detection of JDV RNA in plasma (Stewart et al., 2005), has facilitated a much 
closer examination of the effects of different vaccination regimes on the rate of viral 
replication and clearance.  
Materials and methods. 
Experimental cattle. 
Experimental cattle were purchased and maintained as described previously in 
Chapter 4. 
Vaccine.  
The vaccine was prepared as previously described (Hartaningsih et al., 2001). Briefly, 
the capsule was removed from the spleen of an animal experimentally infected with 
the Pulukan strain of JDV, and was homogenised at a ratio of 10% w/v in Medium 
199 (ICN) at 4
0C. Virus was inactivated by addition of Triton-X 100 to a final 
concentration of 1% v/v and subsequent stirring for 30 mins at room temperature. The 
antigen preparation was mixed and homogenised with a mineral oil adjuvant (MOA) 
at a ratio of 2:1 MOA:antigen. 2 vaccinations, each of 1 ml, were administered 
intramuscularly into the neck of the cattle, 56 and 28 days before challenge. Control 
animals were given 3 x 1 ml doses of GST (1 mg/ml) homogenised in an equal 
volume of IFA. Post vaccination, the cattle were examined daily for any sign of 
clinical disease. Rectal temperatures were taken, and the absence of a febrile response 
was used to confirm the complete inactivation of JDV in the vaccine. 
JDV challenge dose.  
All animals in this experiment were challenged with an estimated 4x10
2 50% ID50 of 
the JDVTAB strain of JDV, determined by ELISA as previously described in Chapter 
4. Confirmation of the viral titre in the plasma of the donor animal was performed 
retrospectively by a quantitative RT-PCR as described below.  
Samples.  
The sampling regime for the animals was as described in Chapter 4.   109 
Viral RNA extraction. 
The method was as described in Chapter 4, using 280 µl samples of plasma instead of 
140 µl. 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR). 
qRT-PCR was performed as described in Chapter 4, with the master mix made using 
the Access RT-PCR kit from Promega, and 2 µl samples of RNA. 
Production of biotinylated proteins for use as Western blot antigens. 
To produce antigens that would be recognised only by antibody to the vaccine protein 
in sera from experimental cattle, and not by those raised to the GST fusion partner, 
the same genes as were cloned into the pGEX-6P expression vector (Chapter 6) were 
also ligated into the PinPoint Xa-1T-tailed vector (Promega) for the expression of 
biotinylated proteins in E. coli. The vector is supplied with all 3 possible reading 
frames to suit cloning of any amplicon with an overhanging A, as added by taq 
polymerase during amplification, and genes of interest were cloned in-frame with the 
N-terminal biotinylatable tag. The resulting recombinant plasmids were transformed 
by heat-shock into JM109 competent E. coli. A 200 µl volume of recovered 
transformed cells were plated on LB agar plates supplemented with 100 µg/ml 
ampicillin and incubated (37˚C, overnight). The colonies were screened for 
transformants with inserts in the correct orientation by directional PCR (Chapter 3) 
using gene specific forward primers and SP6 reverse vector primers. Thermocycling 
conditions were standard, with a Tm of 50˚C. Positive clones were verified by 
sequencing as described in Chapter 3. Protein expression was induced by the addition 
of IPTG to a final concentration of 0.1 mM to log-phase cultures of bacterial clones 
in LB broth, supplemented with 100 µg/ml ampicillin and biotin at a concentration of 
2 µM. The expression of the proteins was monitored by PAGE and a Western blot 
technique using an alkaline phosphatase labelled streptavidin probe and WesternBlue 
chromogenic substrate (Promega).   110 
Seroconversion of vaccinated animals. 
Prior to challenge, the serum of all the animals were tested by Western blot for the 
presence of antibodies to JDV viral proteins, as described in Chapter 4, using viral 
antigens expressed as described above. 
Calculations. 
Doubling times, fever score and statistical analysis were performed as described in 
Chapter 4.   111 
Results. 
All animals vaccinated with the inactivated JDV vaccine had seroconverted, prior to 
challenge, to the viral CA and MA proteins, when assayed by Western blot. Only 1 
had detectable antibody to SU, and none had detectable antibodies to viral TM or Tat. 
No control animals had pre-existing antibodies to JDV (Table 5.1). 
Table 5.1 Seroconversion to JDV proteins prior to challenge, as determined by Western 
immunoblot. 
JDV vaccinated animals  Mock vaccinated animals  JDV 
protein 
antigen  CB 75  CB 76  CB 77  CB 78  CB 83  CB 84  CB 85  CB 86 
CA  + + + + _ _ _ _ 
MA  + + +  + _ _ _ _ 
SU  _ _ + _ _ _ _ _ 
TM  _ _ _ _ _ _ _ _ 
Tat  _ _ _ _ _ _ _ _ 
± denotes weak response 
Challenge dose. 
The challenge dose estimated by ELISA was 400 ID50 but by qRT-PCR was 
determined to be 1.1 x10
3 ID50.  
Duration and severity of febrile response. 
3 of the 4 animals in the control group developed a febrile response (a rectal 
temperature of ≥39.5
0C) within 7-8 days of infection; the other animal in the control 
group did not develop a febrile response. In the vaccinated group, 2 of the 4 cattle 
developed a febrile response after a similar period, but animal CB76 developed fever 
18 days post-infection, and a further animal did not develop a febrile response. The 
absence of a febrile response in some infected animals was previously observed in 
Chapter 4, and these animals were considered as atypical responders.  
Of the animals that developed a febrile response, the mean duration of fever was 
significantly shorter (p=0.05) in the vaccinated group (5.3 days) than the control 
group (7 days). The results for each animal are shown graphically in Figures 5.1 and 
5.2, and summarised in Table 5.2.    112 
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Figure 5.1 (A) Clinical response of individual mock vaccinated cattle experimentally infected with 
JDV, showing typical (CB 83, 85, 86) and atypical responses (CB 84). 
(B) Clinical response of individual vaccinated cattle experimentally infected with JDV, showing 
typical (CB 75, 76,77) and atypical responses (CB78). 
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Table 5.2 Clinical parameters in mock vaccinated and vaccinated cattle experimentally infected 
with JDV. Animals that did not develop clinical changes (atypical responders) have been 
excluded from statistical calculations 
Group Animal  Peak 
viraemia 
(days post 
infection) 
Time from 
infection 
to onset of 
fever 
(days) 
Time from 
infection 
to peak 
fever 
(days) 
Time from 
infection 
to end of 
febrile 
period 
(days) 
Duration 
of febrile 
period 
(days) 
Fever 
score 
(Area 
under 
curve) 
Duration 
of 
leucopenia 
(days) 
CB 83  12 7 11  14 7 5.5 1 
CB 85  11 9 11  15 6 5.6 0 
CB 86  12 7 12  15 8 6.8 3 
Control 
Mean  11.67 7.67 11.33  14.67 7.00  5.97  2 
Atypical CB  84  13 12 12 12  1 0.4  - 
CB 75  9 8  10  14  6  5.4  1 
CB 76  20 18 19 23  5 5.5 0 
CB 77  10 9  9 14 5 3.2 4 
Vaccinated 
Mean  13.00 11.67 12.67 17.00  5.33  4.70  1.66 
Atypical CB  78  22  - - - - -  ND 
Table 5.3 Plasma virus load determined by qRT-PCR at set points in the disease process (figures 
in italics inferred using calculated doubling times).  
Group Animal.  Viraemia  at 
onset of 
fever. 
Peak 
viraemia 
Viraemia at 
end of 
febrile 
period 
CB 83  1.21x10
10  5.79x10
11  6.62x10
9 
CB 85  7.12x10
8 4.26x10
10  3.41x10
6 
CB 86  2.14x10
10  1.27x10
11  3.04x10
7  Control 
Mean 1.14x10
10 2.5x10
11 2.22x10
9 
Atypical CB  84 
  8.57x10
7  
CB 75  2.34x10
7  1.79 x10
9  1.29x10
5 
CB 76  3.38x10
8  7.91 x10
9  4.44x10
4 
CB 77  1.11x10
8  1.63 x10
10  2.11x10
6  Vaccinated 
Mean 1.57x10
8 8.67x10
9 7.61x10
5 
Atypical CB  78  9.36x10
9  1.47x10
10  5.16x10
7 
Table 5.4 Statistical analysis of significant differences between observed parameters. 
Measure. Differences. 
Duration of fever.  Control significantly longer (p=0.033) 
Viraemia at onset.  Controls higher (approaching significance; p=0.06)   114 
Duration and severity of leucopenia. 
White cell counts for the typical responders in the vaccinated group declined sharply 
immediately after challenge, followed by a transient recovery to levels similar to 
before infection. This recovery was not sustained, and a moderate leucopenia 
followed. The typical responders in the control group did not show a comparable 
initial decrease and rebound in white cell numbers, and the duration of the leucopenia 
tended to be longer, although using the definition previously applied  
(<4000 WBC/µl) there was no difference between the groups. The results for each 
animal are shown graphically in Figures 5.1.  
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Figure 5.2 Direct comparison of viral plasma titres (genomes/ml aligned to day 0 of fever 
setpoint) from individual vaccinated and control animals. (Red filled points indicate that sample 
was taken on a day when animal was febrile, dotted lines indicate viral load in vaccinated 
animals, solid lines indicate data from control animals).  
 
All infected animals in both the vaccinated and mock vaccinated groups had 
detectable levels of circulating viral RNA in the plasma over the period of the 
experiment, even in those animals with no febrile response. The control animal that 
did not develop a febrile response had an undulating plasma virus load, peaking at 
10
8 virus genomes/ml. The vaccinated animal that did not develop a febrile response   115 
also showed a plasma virus load typical of that detected in febrile animals, with a 
peak of 10
10 genomes/ml. The peak viraemia in all of the vaccinated animals was less 
than that of  those control animals that developed a febrile response. In the vaccinated 
animals, peak plasma virus loads coincided with either the day of onset of fever or the 
next day, then fell rapidly, whereas higher levels of plasma virus persisted in the 
febrile controls for several days, in 2 animals (CB83, CB86) not peaking until 6 days 
after onset of fever (Figure 5.2).  
Modelling of disease. 
Utilising the method described in Chapter 4, the disease period for each animal was 
divided into phases, utilising the rates of increase and decrease of viral RNA in the 
plasma to define the phases. The phases of the disease process, based on the rates of 
increase and decrease of viral RNA in the plasma, for each group are shown in Figure 
5.3. The rectal temperature and leucocyte counts are means for each day of the 
experiment. The mean viraemia line represented condensed data from each phase.    116 
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Figure 5.3 Schematic representation of condensed viraemia data, with mean daily 
temperature and WBC counts for control and vaccinated groups.   117 
 
Table 5.5 Condensed data from each phase for control and vaccinated groups.  
Phase 
Parameter Group 
1 2 3 4 5 6 7 
Control  38.9 39.0 38.7 39.0 40.5 39.6 38.9  Rectal 
temperature 
(
°C)  Vaccinated  38.5 38.9 38.7 39.5 40.2 39.7 38.8 
Control  95.1 85.6  133.0  73.6 49.4 67.2    Leucocyte count 
(% Day 0)  Vaccinated  89.4 78.8 84.5 69.7 61.0 71.4   
Control  0  4.38 5.68 7.84  10.91  8.90 7.89  Log10 plasma 
virus load 
(genomes/ml)  Vaccinated  0  3.49 4.48 7.57 9.65 7.81 5.69 
Control    0.137 0.010 0.100 0.019 -0.105  -0.146  Growth/ 
clearance rate 
(γ)  Vaccinated  0 0.120  0.091  0.087  -0.053  -0.174  -0.096 
Control  0  5.38 -4.42 7.16 69.40  -6.69 -6.42  Doubling time/ 
clearance half-
life (h)   Vaccinated  0.00 3.89  25.96  5.55  123.39  -4.36  -8.33 
Control  96  120  60 72 80 66 24  Duration of 
phases (h)   Vaccinated  104 80 136 72  36  48  24 
Growth rate is a measure of the rate of increase or decrease in viral titre, essentially the gradient 
of the titre curve in each phase, doubling time is derived from this, and is the calculated time for 
viral numbers/ml to double at that growth rate.  
Table 5.6 Significant results, obtained by statistical analysis, using an unpaired t-test to compare 
the condensed data. 
Parameter Statistical  significance 
Rectal temperature   Phase 1: Controls significantly higher (p=0.014) 
Leucocyte count   Phase 2: Controls higher count, approaching significance (p=0.06) 
Log10 plasma virus load  Phase 5: Controls significantly higher (p=0.02) 
Phase 6: Controls significantly higher (p=0.05) 
Growth / clearance rate  
Phase 2: Controls higher, approaching significance (p=0.06) 
Phase 5: Controls significantly higher (p=0.05) 
Phase 6: Controls lower, approaching significance (p=0.07) 
Doubling time / clearance half-life  Phase 6: Control half-life longer, approaching significance (p=0.06). 
Phase duration  Phase 5: Control significantly longer (p=0.02) 
Control animals had significantly (p=0.014) higher rectal temperatures and a less 
marked reduction in total leucocyte counts immediately post-infection than the 
vaccinated animals. A higher viral growth rate in the control animals seen in Phase 2 
(p=0.06) and Phase 5 (p=0.05), combined with slower clearance rates during Phase 6 
gave significantly higher viral loads for a longer duration during Phases 5 and 6 in 
this group (Table 5.6).  118 
Discussion. 
Because of the acute nature of JD, with about 20% case fatality rates at this stage with 
no recurrence, vaccination is aimed at amelioration of the acute phase of the disease 
(Hartaningsih et al., 2001), to decrease the duration and severity of the viraemia thus 
reducing the chances of transmission. 
This current study differs in some regards from previous studies using the same 
vaccine preparation, where 4/10 vaccinated animals had no febrile response or 
leucopenia after challenge (Hartaningsih et al., 2001). In these previous reports, non-
vaccinated animals were used as controls, whereas in the current experiments the 
control animals were vaccinated with an unrelated protein (GST) in a mineral oil 
adjuvant. An ideal control would have been vaccination with uninfected spleen 
homogenate. However, the development of a febrile response 7-8 days after infection, 
the depletion of leucocytes, and development and duration of viraemia in these mock 
vaccinated animals was similar to that seen previously in non-vaccinated animals 
experimentally infected with a similar infectious dose of virus (Soeharsono et al., 
1995b), confirming that the mock-vaccination had no effect on disease progression. 
In previous experiments (Hartaningsih et al., 2001), indirect indicators of the severity 
of the viral infection, such as changes in mortality rates, severity of leucopenia, 
duration of the febrile period, and the length of the incubation period were used to 
assess vaccine efficacy and to describe any amelioration of the disease process. The 
most significant difference between the methodology employed in the current 
experiments and that used previously was the development of a qRT-PCR assay to 
quantify viral load (Stewart et al., 2005). This procedure was incorporated to try to 
determine if the apparent protection of animals seen in the earlier experiments was 
due to suppression of virus replication, and perhaps the induction of a sterilising 
immunity, or if other mechanisms were involved. Additionally, the production of 
recombinant proteins, and use in Western blot analysis, allowed assessment of the 
antibody responses induced by the inactivated vaccine preparation. 
The use of the inactivated viral vaccine has been demonstrated to induce an antibody 
responses to several viral proteins (Hartaningsih et al., 2001) and the nature of this   119 
response was demonstrated by the use of various recombinant viral protein antigens 
(Table 5.1). A response to SU was not detected in a majority of vaccinated animals 
but whether this was due to a lack of a response or an inability to detect the response 
with the recombinant protein antigens is unknown. Antigenicity of the SU could have 
been affected by the detergent used to inactivate the virus, or the use in the Western 
blots of a truncated recombinant antigen possibly lacking epitopes recognised by sera 
raised to native protein. The absence of a detectable response to Tat was not 
unexpected, as Tat is reported to be highly expressed early in infection only 
(Setiyaningsih, personal communication) and may not be present at high levels in the 
vaccine preparation prepared from spleen tissue taken on the second day of the febrile 
period. Experience in this laboratory is that naturally recovered animals have a weak 
or undetectable antibody response to Tat, indicating weak antigenicity of this JDV 
protein, at least for the humoral immune system (Setiyaningsih, personal 
communication). 
3 different patterns of infection were seen in cattle infected with JDV in the current 
experiment. A normal pattern of disease, where infection was followed by an acute 
disease process with a marked febrile response and concomitant viraemia, was seen in 
6/8 animals; this was typical of the JD infections reported by Soesanto et al (1990). A 
second pattern of limited viral replication without a febrile response was seen in 1 of 
the 8 animals, and a third pattern of infection was seen in another of the 8 animals 
where there were high levels of circulating virus with no febrile response. Similar 
varying patterns of viral replication have been seen in SIV-infected macaques in 
vaccine trials, with varying patterns apparently unrelated to any effect of the vaccines 
used (Waisman et al., 1996; Silvera et al., 2002). For clarity, animals with a normal 
pattern of infection will be discussed first. 
The most obvious indicator of protection is a decrease in the duration of the febrile 
response. The mock-vaccinated control animals had a significantly longer febrile 
period than the 3 responder vaccinated animals, and a shorter incubation period 
before the onset of fever. Quantification of the plasma virus load in responder 
animals showed that, as expected, the duration of the febrile period correlated with 
the plasma virus load, with elevated temperatures occurring only when the plasma   120 
virus load was high (Figure 5.1). However, there was a trend for the vaccinated 
animals to become febrile at a lower viral titre than the control mock-vaccinated 
animals (Figure 5.2), although a failure to collect plasma RNA samples on the day of 
onset of fever for 2 vaccinated animals prevented confirmation of this. The 
development of fever at lower viral titres and the rebound in peripheral blood 
leucocyte counts in the vaccinated group indicated a primed CMI response, as 
inflammatory mediators leading to fever in viral infections include chemokines 
induced by T lymphocyte-produced interferon gamma (IFNγ). In lentiviral infections 
it is known that immune activation favours viral replication (Fauci et al., 1991; Poli 
and Fauci, 1993). Thus there is a balance between rate of viral production and rate of 
immune mediated viral clearance in a lentiviral infection The vaccinated animals also 
had markedly slower rates of increase of the plasma virus load, and lower body 
temperatures over the first 7 days post-infection than the controls (p=0.06, Table 5.6), 
which might have been associated with the presence of specific antibody to JDV as a 
consequence of the vaccination. Opsonisation of virus by circulating antibody could 
promote phagocytosis of virus by macrophages via Fc receptor-mediated uptake, or 
infected cells coated with antibody may be removed by natural killer cells. This 
would have the effect of removing the replication-enhancing effects of IFNγ earlier in 
the progression of the infection, decreasing sequestration of T-cells to the secondary 
lymphoid tissue and so lessening the destruction of the germinal centres seen in 
unmodified JD. This would have the further effect of allowing earlier immune 
reconstitution, and subsequent development of an antibody response post challenge. 
Vaccinated animals showed improved preservation of immune function post 
challenge, maintaining or increasing antibody levels to viral proteins. Control animals 
showed no induction of antibodies for an extended period post challenge (personal 
communication, J.Lewis). Antibody does not seem to be involved in the resolution of 
natural infections, as circulating antibodies to JDV components are not detectable 
until at least 8 weeks post-infection (Hartaningsih et al., 1994) coinciding with 
recovery of the lymphoid architecture (Dharma et al., 1994). 
Peak plasma virus loads were significantly higher in control animals during Phases 5 
and 6 and the duration of the high levels of viraemia in Phase 5 was significantly   121 
longer in these animals (Table 5.6), indicating vaccination had an effect on the 
kinetics of virus replication. Although the vaccinated animals had apparently 
recovered after a shorter fever than the controls, circulating virus was still present on 
the day of recovery, although the titres were far lower than in the control animals at 
this setpoint. The febrile response in one control animal, CB 83, resolved while viral 
titre was still very high. Failure to maintain a strong response may be due to the 
immunosuppressive nature of the disease, in that depletion of effector cells by the 
viral load prevents maintenance of response and hence a longer high level viraemia. 
Pro-inflammatory cytokines have been shown to be associated with viral replication 
in vivo (Poli et al., 1999; Decrion et al., 2005), and immune activation enhances viral 
replication in chimpanzees infected with HIV-1 (Fultz et al., 1992). In this trial, 
following failure to establish sterilising immunity and thus prevent establishment of 
an infection, the induction of a vigorous and successful immune response will be 
accompanied by fever. In this case there will be a balance between the effectiveness 
of viral clearance, at what level of virus the response is induced, and the intensity of 
that response and associated inflammation. The trend for a response to be induced by 
lower levels of virus in the vaccinated animals highlights the balance between 
effective immune activation and potentiation of viral replication.  
A classical indicator of infection with JDV is the precipitous drop in circulating 
leucocytes as the febrile response develops. Although the precise cellular tropism of 
the virus is unknown, infected cells appear earliest in the spleen (Chadwick et al., 
1998). Presumably, antigens that are introduced to the host directly via the blood are 
taken up by antigen presenting cells in the spleen and the recruitment of naïve T cells 
and other lymphocytes would contribute to the loss of these cells from the circulation 
and the ensuing enlargement of this organ. Vaccinated animals showed a sharp 
decrease in total leucocyte counts 3 days post-infection, corresponding to a slight 
transient rise in body temperature, which was more marked in the animals with the 
more severe leucopenia. Previous studies have shown that the leucopenia in 
experimentally infected non-vaccinated animals was due mainly to a severe 
lymphopenia, with mild neutropenia (Soesanto et al., 1990). Possibly the initial fall in 
leucocyte counts reflects earlier clearance of infected cells in the peripheral blood by   122 
antibody dependent cellular cytotoxicity (ADCC) or a potentiation of initial infection 
of monocytes by Fc-mediated uptake of antibody coated virus. Increased trafficking 
of activated lymphocytes to the lymph nodes could also account for the initial 
decrease in peripheral blood lymphocytes. Transient increases in JDV titre have been 
noted in other experiments around 3 days post-infection (unpublished observation). 
Unfortunately, it was not possible to perform cell proliferation assays to directly 
measure specific cell responses in this experiment. It would be useful to examine cell 
population subsets early in infection before virus is detectable to determine 
differences in the profile between vaccinates and controls, to gain an insight into the 
very early pathogenesis of JD.  
One of the most interesting observations during these experiments was that JDV 
infection in naïve animals did not necessarily cause a febrile response. 2 animals, 
CB84 and CB78 (1 from each group), did not develop fever. Failure of challenge was 
suspected with the control animal, and protection was hoped for in the vaccinated 
animal. qRT-PCR revealed that both animals had circulating virus. The control 
animal, CB84, had a lower level of virus replication than the other animals and also 
exhibited a sharp increase in leucocyte counts at the point where the other animals 
showed the most rapid decrease, just before the leucocyte examinations were 
discontinued in this animal. The vaccinated animal, CB 78 had a comparable 
viraemia to the other members of the group, with only a slight contemporary body 
temperature rise. As the target cells of JDV are suspected to be both macrophages and 
lymphocytes (Dharma et al., 1991; Dharma et al., 1994), activated anti-JDV T-cells 
in vaccinated animals may present a different pool of potential host cells in these 
animals, leading to productive infection, but not necessarily acute clinical disease. 
Without further work to identify the target cell type for JD, and to explore the role of 
antibody, complement, and the cytokine milieu in the immediate post-infection 
period, as well as the role of the genetics of the cattle in determing susceptibilty to 
JDV, it is impossible to know the reasons why some animals tolerate high viral loads 
while others succumb to acute disease or even die.   123 
In conclusion, despite the problems inherent in attempting immunological control of 
lentivirus infections, it is apparent that vaccination of Bali cattle with inactivated 
virus not only reduced the duration of the acute clinical signs of infection but also 
reduced the magnitude and duration of viraemia when they were subsequently 
infected with JDV. This should result in reduced mortality, and a reduction in the 
opportunity for transmission of the virus which should facilitate the control of JD. 
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Chapter 6 
Evaluation of recombinant Jembrana disease virus Tat and 
capsid proteins as vaccines for control of Jembrana disease.  
Summary. 
In this chapter, the use of a pGEX-6-P system (Pharmacia) to express JDV proteins in 
E. coli is described. The proteins were expressed as insoluble inclusion bodies and 
methods for purification and solubilisation of the proteins are described. 3 vaccine 
trials are described where Tat and CA protein vaccines were tested in Bali cattle, 
individually and in combination. After vaccination 3 times at approximately fourteen 
day intervals, the efficacy of the vaccine was tested by subsequent challenge of the 
vaccinated cattle 14-21 days later with JDV, and assessment of the effects of 
vaccination on resultant clinical signs and plasma virus load. A strong antibody 
response to the administered CA and Tat proteins occurred. There was evidence of 
ameliorisation of the disease process in animals vaccinated with a combination of CA 
and Tat, which resulted in lower plasma virus loads in the early stages and at the peak 
of the acute disease process, and lower levels of fever and leucopenia. Vaccine 
proteins administered with incomplete Freund’s adjuvant were more efficacious than 
vaccines administered with QuilA. 
Introduction. 
Attempts to control JD in Indonesia include the use of a detergent-inactivated tissue-
derived whole virus vaccine which has been shown (Chapter 5) to reduce the febrile 
period and viral load in experimentally vaccinated and challenged animals 
(Hartaningsih et al., 2001). Because such a vaccine can only be produced on a limited 
and non-commercial scale, is expensive and might contain adventitious agents, the 
use of subunit virus proteins produced by recombinant DNA technology has been 
investigated.  
Vaccination with recombinant protein expressed in Escherichia coli has induced 
protection against diseases such as foot and mouth disease (Goeddel et al., 1979) and 
influenza (Neirynck et al., 1999) but attempts to induce a protective immune response   125 
to lentiviruses by vaccination with recombinant structural proteins have met with 
varying degrees of success, from partial protection against homologous FIV challenge 
in cats vaccinated with SU expressed in bacteria (Leutenegger et al., 1998) to 
enhancement of disease in animals vaccinated with baculovirus expressed 
glycoproteins (Wang et al., 1994; Siebelink et al., 1995; Raabe et al., 1998). 
Several recombinant proteins were trialled as potential vaccines for the control of JD 
and the results are reported in this chapter. Only results from cattle vaccinated with 
recombinant GST fusions to the CA, Tat and MA proteins in various combinations 
are presented; other proteins including SU and TM were trialled but without 
detectable efficacy and these results have not been included.  
The CA protein has been trialled by various groups as a means of induction of a 
protective immune response to lentiviruses (Caley et al., 1997; Steger et al., 1999; 
Fraser et al., 2002; Soutullo et al., 2005). It is also known that Bali cattle vaccinated 
against JDV with the tissue-derived whole virus vaccine, and naturally recovered 
animals, also develop strong antibody responses to CA (Desport et al., 2005) which 
has at least 3 separate antigenic domains, one of which is the highly conserved major 
homology region (Grund et al., 1994), and would be expected to cross-react 
antigenically with a broad spectrum of virus strains.  
MA was included as analysis of antibody responses to JDV proteins in cattle that had 
been vaccinated with the inactivated viral vaccine (Chapter 4) showed a strong 
response to MA that correlated with a lack of fever in one animal (J. Lewis, personal 
communication). The genes for these 2 proteins are sequential and in-frame with each 
other (Chadwick et al., 1995b) and it was decided to trial this protein but expressed 
together with CA as a single fusion, reducing purification costs.  
Tat has been proposed as a suitable candidate for use as a vaccine in many lentiviral 
infections. The protein is multifunctional, and as well as its primary function as a 
transactivator essential for viral replication, Tat is also released into the milieu 
around infected cells (Frankel and Pabo, 1988; Verhoef et al., 1996) and can enter 
uninfected cells by a non-endocytotic pathway, directly through the cell membrane 
(Tyagi et al., 2001). The subsequent upregulation of viral receptors (Huang et al.,   126 
1998) and down regulation of MHC increases the susceptibility of the cell to 
infection and decreases the likelihood of its recognition by the immune system 
(Pugliese and Gioannini, 1993). A vaccine inducing a neutralising antibody response 
to Tat, presents the possibility of interfering with these effects of exogenous Tat, 
potentially decreasing the severity of JD. 
Materials and methods. 
Expression of GST fusion proteins. 
Proteins were expressed from JDV genes ligated into the pGEX-6-P system 
(Pharmacia); proteins expressed in this bacterial system are N-terminally fused to 
glutathione-S-transferase (GST) to aid in purification and identification. The 
constructs were prepared as previously described (Burkala et al., 1998) and contained 
the full-length JDV cap gene and exon1 of the JDV tat gene. The gene coding for 
MA and CA was amplified by standard PCR methods from plasmid clone#139 with 
the primers in Table 6.1. A Tm of 54˚C for the first 4 cycles was used followed by 25 
cycles with a Tm of 60˚C. The resulting PCR amplicon was digested with BamH1 and 
short fragments of DNA and contaminating enzyme removed with a PCR cleanup kit 
(QIAGEN). The purified fragments were ligated into BamH1-digested pGEX 6P1 
using standard methods (Sambrook, 1989). Positive clones were identified by 
directional PCR as described in Chapter 3, and a glycerol stock of a culture of the 
clone was prepared. Proteins were expressed from log-phase cultures of transformed 
Top10 E. coli in 2YT broth supplemented with 100 µg/ml ampicillin and incubated at 
37˚C with vigorous shaking. Protein expression was induced by the addition of IPTG 
to a final concentration of 0.1 mM when the cultures reached an OD600 of 0.6, except 
for the expression of GST/Tat where induction was initiated at late log phase, when 
an OD600 of 0.9 had been attained. After induction, cultures were grown to stationary 
phase, and bacterial pellets harvested from 400 ml amounts of culture by 
centrifugation (8000 g, 20 min, 4˚C). Pellets were resuspended in lysis buffer (50 mM 
Tris-HCl pH 7.5, 50 mM NaCl, 5% v/v glycerol) and frozen at -80˚C until required.    127 
 
Table 6.1 Primers used to amplify entire matrix/capsid region of the JDV genome 
Primer Sequence 
398JMABamfor  5’-GACCGGATCCGGACGTTTCCAGTCGTTGG-3’ 
JCAPBamrev,  5’-GCAGGGATCCCAAGAATTGCATCTTCTGTTTAC-3’ 
Purification of GST fusion proteins. 
Tat used in Trial I, a preliminary trial not reported here, was purified from pelleted 
bacteria lysed by freeze/thawing (5 cycles of -186˚C to +42˚C). The lysate was 
centrifuged (18,000 g, 3 min) and the pellet was washed 5 times by resuspension in 
wash buffer, (50 mM Na2HPO4, 300 mM NaCl, 2 mM EDTA, 10% glycerol, 2% 
Triton X), mixing with a rotating mixer at 4˚C for 30 min, followed by centrifugation 
(18,000 g, 3 min). The final washed pellet was resuspended in solubilisation buffer A, 
(6 M urea, 50 mM Na2HPO4, 1 mM EDTA, 1 mM mercaptoethanol, 20% glycerol) 
and rotated (4˚C, overnight). After a final centrifugation, the supernate was analysed 
for levels of Tat protein by PAGE and Western immunoblotting as described in 
Chapter 3. Further development of the method subsequently employed a proprietary 
extraction buffer, B-PER (Pierce) in place of the wash buffer. The final stage of 
preparation was exhaustive dialysis against PBS, using “Snakeskin” dialysis tubing 
with a 10kDa molecular weight cutoff (Pierce).  
In Trials II and III (Table 6.2), the proteins were purified as for Trial I, but instead of 
using dialysis to concentrate them, the refolded solutions were ultrafiltered in an 
pressure filtration cell (Amicon), utilising a 10 kDa cutoff membrane (Ultracell; 
Amicon) pressurised with nitrogen (70 psi) to give a final volume of 1/20 of the 
original solution. 
In Trials IV and V, protein inclusion bodies were initially purified by repeated 
washing by centrifugation as above but instead of solubilising, refolding and 
concentrating as in Trials I, II and III, the inclusion bodies were solubilised in as 
small a volume as possible of solubilisation buffer C (2 M urea, 2 M Tris pH12,  
0.2 mM dithiothreitol).    128 
Preparation of GST for mock vaccination of control cattle. 
Bacteria transformed with the pGEX plasmid with no insert were grown in 2YT 
supplemented with ampicillin (100 µg/ml) and induced with IPTG (final 
concentration 0.1 mM) at a culture OD600 of 0.6. After 4 h of further growth, the 
bacteria were harvested by centrifugation (18,000 g, 3 min), washed in PBS by 
centrifugation and resuspended in 50 µl of lysis buffer/ml of original culture, and 
lysed by freezing and thawing as detailed above. After clarification of the lysate by 
centrifugation, the supernatant was passed 3 times through a column of glutathione / 
Sepharose resin (0.2 ml volume, equilibrated with PBS). Bound GST was displaced 
with 10 column volumes of 30 mM glutathione in PBS and was soluble.  
Quantification of proteins. 
Densitometry was used to quantify the levels of protein in the vaccine preparations. 
Appropriate dilutions of each preparation were denatured in loading buffer (100 mM 
Tris-HCl pH 6.8, 10% v/v glycerol, 2% w/v SDS containing 0.4 ml mercaptoethanol 
and 0.2 ml of bromophenol blue) and electrophoresed in 10% resolving 
polyacrylamide gels with 4% stacking gels under reducing conditions in a Mini 
Protean system (Bio-Rad). A range of concentrations between 50 ng and 1 µg/lane of 
reference proteins BSA (66 kDa) and lysozyme (16 kDa) were also run in parallel 
lanes on each gel, and where required, molecular weight markers (BioRad 
PrecisionPlus, 100 kDa, prestained) were included in 1 lane of the gel. The gels were 
stained with Coomassie brilliant blue (0.05% bromophenol blue in 45% v/v 
methanol, 45% water 10 % glacial acetic acid, rocking, overnight, RT) and immersed 
in destain (45% v/v methanol, 45% water, 10 % glacial acetic acid) until the gel 
background was clear. After washing and rehydrating in distilled water, the gels were 
imaged on a ProExpress Imaging System (PerkinElmer), and the resulting high 
resolution images subjected to image analysis with ProPic software (PerkinElmer). 
Pixel density mapping allowed the amounts of protein present in each non-saturated 
band on the imaged gel to be calculated. The amounts of the vaccine proteins present 
were then calculated from a standard curve of the various concentrations of the 
reference proteins included in each gel. The concentration was determined as the   129 
mean of the concentration obtained using the standard curve for each reference 
protein.  
Vaccine trials. 
3 vaccine trials were conducted using 4 or 5 animals per vaccine group as detailed in 
Table 6.2, with mock vaccinated control animals in each trial. After vaccination, the 
animals were infected with either JDVTAB or JDVPUL at the doses and times shown in 
Table 6.2. The method of infection and the sampling regime after infection was as 
previously described in Chapter 5. All animals were tested for antibody to the vaccine 
protein prior to challenge by Western blot as previously described in Chapter 3. The 
plasma viral load was determined as previously described in Chapter 4. 
Analysis of the results of the effect of vaccination on clinical parameters and viral 
load were made as described previously (Chapter 4) by dividing the acute disease 
resulting from infection into 7 phases and utilising an unpaired t-test to compare the 
mean values in each phase.  
An aliquot of RNA extracted from the plasma of animal CB137 from Trial V, 12 days 
PI, was included in each qRT-PCR assay of the virus load, as a positive control and to 
determine the repeatability of the assay. 
Table 6.2 Details of the vaccination regimes, vaccine antigens used and challenge doses used in 3 
vaccine trials to determine the efficacy as vaccines of various recombinant Tat, CA and MA 
proteins. 
Vaccination 
times (days 
after initial 
vaccination)  Trial  
Cattle 
per 
group 
Antigen Adjuvant  Protein 
per dose 
1 2 3 
Time of 
challenge 
(days after 
final 
vaccination) 
Challenge 
strain (and 
estimated 
dose) 
4 Tat 
4 CA 
III 
4 GST 
IFA 2  mg 0  14  35  32 JDVTAB  
(400 ID50) 
4  Tat + CA  IFA
4  Tat + CA  QuilA
IV 
4 No  vaccination 
2 mg 
each 
protein  
0 14  28  21  JDVPUL  
(1,000 ID50) 
5  Tat + CA 
5  Tat + MA/CA 
IFA 
V 
5 No  vaccination   
2 mg 
each 
protein 
0 14  28  23  JDVPUL  
(1,000 ID50)   130 
Results. 
Protein expression and purification. 
 All the GST-tagged proteins used as vaccines were expressed as insoluble proteins 
that accumulated within inclusion bodies. These were partially purified by differential 
centrifugation and exhaustive washing to remove soluble contaminating proteins. 
Subsequent solubilisation of the inclusion bodies in a small volume of 6 M urea 
resulted in a concentrated protein solution that was quantified by densitometry. 
Typical examples of these SDS-PAGE gels are shown in Figure 6.1. After high 
resolution imaging, the pixel density of each imaged band was measured and used to 
create a 3-D image of that band, which was analysed by the ProPic
TM software to give 
a volume. Plotting of the calculated band volumes against the known concentrations 
of the reference proteins BSA and lysozyme gave a calibration curve, which was then 
used to quantify the recombinant protein concentration. The caluclated purity of each 
final recombinant protein product used in the vaccine trials is shown in Table 6.3. 
A                                                 B 
Figure 6.1 A) Typical gel for densitometric quantification of CA protein used for preparation 
of the vaccine used in Trial V. Gel contains, from left; MWM (BioRad), lane 1;100 ng of BSA 
and lysozyme, lane 2; 250 ng BSA and lysozyme, lane 3; 500 ng of BSA and lysozyme, lane 4; 
1,000 ng BSA and lysozyme, lane 5; empty, lane 6 CA preparation 1, lane 7; 1/10 dilution of 
CA preparation 1, lane 8 CA preparation 2. lane 9; 1/10 dilution of CA preparation 2. 
B) Typical gel for final quantification of protein content of several vaccine preparations. Lane 
1 to 4, increasing amounts of BSA and lysozyme as in a), lane 5; CA+SU, lane 6; Tat+CA, lane 
7;Tat+MA/CA (5 µl of 1/10 dilution of protein preparations) lane 8; CA+SU, lane 9; Tat+CA, 
lane 10;Tat+MA/CA (equivalent of 0.5 µl final vaccine preparations loaded/well).   131 
 
 
Table 6.2 Final purity of proteins used in vaccine preparations for vaccine Trials III, IV and V. 
The percentage purity was calculated by densitometric quantification of the electrophoresed 
proteins from a standard curve derived from reference protein standards using ProPic
TM 
(PerkinElmer) software.  
Protein  Trial III  Trial IV  Trial V 
GST-Tat  ~81.5% ~76%  ~88% 
GST-CA  ~73.4% ~89%  ~94% 
GST-MA/CA  N/A N/A  ~89% 
GST  ~100% ~100% ~100% 
Seroconversion to recombinant JDV proteins in vaccinated animals. 
All cattle developed antibody detectable by Western blotting to the recombinant virus 
proteins prior to the third vaccine dose, before challenge with infectious virus, but in 
many cases prior to the second vaccine dose (as shown in Table 6.14 for cattle in 
Trial 5). Examples of the seroconversion to the vaccine proteins during Trial IV 
detected by Western immunoblotting are shown in Figure 6.4.   132 
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Figure 6.4 Examples of Western immunoblots demonstrating seroconversion to protein antigens used as 
vaccines in groups of cattle as shown in Table 6.1. Standard molecular weight markers are shown on left 
in each immunoblot, and the relevant antigen is indicated by an arrow.  
(A) Response to Tat-IFA vaccine in Trial IV; 4 cattle and 4 lanes per animal with sera collected 7, 21, 35 
and 42 days (the day of challenge) after the initial vaccination, indicating the presence of antibody in all 
4 cattle commencing 21 days after the initial vaccination.  
(B) Response to Tat-QuilA in Trial IV; 4 animals and 4 lanes per animal with sera collected 7, 21, 35 and 
42 days (the day of challenge) after the initial vaccination, indicating the presence of antibody in only 1 
animal 21 days after the initial vaccination but in all 4 animals commencing 35 days after the initial 
vaccination.  
(C) Response to CA in group of 5 cattle vaccinated with combination of Tat and CA antigens during 
Trial V; 5 cattle and 5 lanes per animal with sera collected 0, 14, 28, 42 and 49 days (the day of 
challenge) after the initial vaccination, indicating the presence of antibody at 14 days in 2 cattle and at 28 
days in all cattle  
(D) Response to Tat in group of 5 cattle vaccinated with combination of Tat and CA antigens during 
Trial V; 4 animals and 5 lanes per animal with sera collected 0, 14, 28, 42 and 49 days (the day of 
challenge) after the initial vaccination, indicating the presence of antibody commencing at 28 days in all 
cattle.  
(E) Response to MA in group of 5 cattle vaccinated with combination of Tat, MA and CA antigens 
during Trial V; 4 cattle and 5 lanes per animal with sera collected 0, 14, 28, 42 and 49 days (the day of 
challenge) after the initial vaccination, indicating the presence of antibody commencing at 14 days in 2 
cattle and all cattle 28 days after the initial vaccination.    133 
Repeatability of quantitative RT-PCR assay for viral plasma RNA. 
An aliquot of RNA extracted from the plasma of animal CB 137, 12 days PI was 
included in each run during assays of the viral load from Trial V, as a positive control 
and to determine the repeatability of the assay. The standard deviation of the mean for 
the log10 transformed load determined in each of 12 assays was 0.119. 
Vaccine trial with Tat and CA (Trial III). 
Seroconversion to recombinant JDV proteins in vaccinated animals. 
All cattle developed detectable antibody to the administered recombinant proteins 
prior to challenge with infectious virus (Table 6.4). 
Table 6.4 Seroconversion of animals to administered proteins prior to challenge  
Cow   WB 
Antigen  Day 0  Day 67 
(Challenge) 
CB 67  - + 
CB 68  - + 
CB 69  - + 
CB 70 
Tat 
(pin) 
- + 
CB 79  - + 
CB 80  - + 
CB 81  - + 
CB 82 
CA 
(pin) 
- + 
CB 83  - + 
CB 84  - + 
CB 85  - + 
CB 86 
GST 
- + 
The observed clinical parameters after infection with 400 ID50 of JDVTAB during Trial 
III, after cattle were vaccinated 3 times, with Tat adjuvanted with IFA, are shown in 
Table 6.5. The only significant differences between the observed parameters in the 
vaccinated and control groups (Table 6.6) were in the duration of the incubation 
period that was significantly (p=0.013) shorter in the control group.    134 
Table 6.5 Observed clinical parameters during Trial III in cattle vaccinated with Tat (IFA) CA 
(IFA) and in control animals mock vaccinated with GST (IFA) (as described in Table 6.1) 
following challenge with 400 ID50 of JDVTAB.  
Vaccine 
(adjuvant)  Animal 
Time from 
infection to 
peak 
plasma 
viral load 
(days) 
Duration 
of febrile 
period 
(days) 
Time from 
infection to 
onset of 
febrile 
period 
(days) 
Time from 
infection to 
peak of 
febrile 
period 
(days) 
Time from 
infection to 
end of 
febrile 
period 
(days) 
Maximum 
rectal 
temp. (
°C) 
during 
acute 
disease 
Fever  
score  Outcome 
CB 67  11  0   N/A   N/A  N/A  39.0  0  Died 
(d.11) 
CB 68  12 6 9  11 11 41.0  6.1  Survived 
CB 69  11 7 8  11 15 41.1  7.4  Survived 
Tat 
(IFA) 
CB 70  8  0  N/A    N/A N/A 39.1 0  Died 
(d.9) 
CB 79  8  2 10 10 12 40.1  1  Survived 
CB 80  12 5 9  12 14 41.4  6.4  Survived 
CB 81  11 6 9  11 15 41.3  6.7  Survived 
CA 
(IFA) 
CB 82  12 5 9  11 14 41.2  5.4  Survived 
CB 83  12 7 7  10 14 40.7  5.5  Survived 
CB 84  13  N/A  N/A N/A N/A 38.9   0  Survived 
CB 85  11 6 7  11 15 41.0  5.6  Survived 
GST 
(IFA) 
CB 86  12 8 7  12 15 41.1  6.8  Survived 
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Figure 6.5a Graphic depiction of clinical parameters (rectal temperatures [
°C], total 
leucocyte count as percentage of day 0 values, and log10 plasma viral load [genomes/ml]) in 
individual cattle in Trial III after 3 vaccinations with (A) GST (IFA) and (B) Tat (IFA), 
and challenge with 1,000 ID50 of JDVPUL.   136 
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Figure 6.5b Graphic depiction of clinical parameters (rectal temperatures, total leucocyte 
count as percentage of day 0 values, and log10 plasma viral load) in individual cattle in Trial 
III after 3 vaccinations with CA/IFA, and challenge with 1,000 ID50 of JDVPUL. 
Table 6.6 Significant differences between the measured responses (shown in Table 6.5) to JDV 
challenge in Tat (IFA) and CA (IFA) vaccinated and GST vaccinated control animals in Trial 
III.  
Observed measure  Significant differences between groups 
Significantly shorter (p=0.013) in control than in Tat (IFA) vaccinated group 
Time to onset of febrile 
period 
Significantly shorter (p=0.0003) in control than in CA (IFA) vaccinated group 
Duration of  febrile period  Significantly longer (p=0.039) in controls than in CA (IFA) group 
The acute disease was divided into 7 phases (Table 6.7) and an unpaired t-test was 
used to compare the mean values for each measure in each phase (Table 6.8).    137 
 
Table 6.7 Summary of condensed data for each measure during each of the 7 phases following 
viral challenge in Trial III. 
Phase 
Clinical parameter  Vaccine 
group  1 2  3  4  5  6  7 
Control  38.93 39.08  38.77  39.30  40.55  39.95  38.93 
Tat (IFA)   38.62  38.55  39.20  40.41  39.73  39.05  Temperature (
°C) 
CA (IFA)  38.42 38.61  38.63  39.02  40.19  39.37   
Control  -4.91 -23.48  4.55  -26.43 -50.6  -32.82   
Tat (IFA)   -18.25  -32.71  -33.44  -36.6  -7.71   
Leucocyte count 
(% of day 0) 
CA (IFA)  -2.34 -6.34  -19.67  -21.63 -43.39 -22.8   
Control  0.00 4.78  5.52  9.03  10.91 9.54  7.89 
Tat (IFA)   6.67  8.52  9.12  10.15  9.24  8.09 
Log10 plasma viral load 
(genome copies/ml) 
CA (IFA)   5.29  6.37  8.04  10.30  8.99   
Control  0.00 4.50  13.70  5.88  69.40 -6.38  -6.42 
Tat (IFA)   3.11  18.64  5.38  103.68  -7.83  -7.99 
Viral doubling time / 
clearance half-life (h) 
CA (IFA)   8.01  12.93  7.08  160.76  -9.50   
Control  96 104  48  72  80  64  24 
Tat (IFA)   72  96 24  144  36 24  Phase duration (h) 
CA (IFA)  72 64  72  40  120 24   
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Figure 6.6 Graphic depiction of clinical parameters in cattle in Trial III after 
immunisation with either GST (IFA) (a control mock vaccination), CA (IFA) or Tat (IFA), 
and subsequent challenge with 1,000 ID50 of JDVPUL. The results shown are a mean of 
measures from the 4 animals in each group at each phase of the acute disease process (as 
defined in Chapter 4).    139 
 
Table 6.8 Significant differences between the measures in each phase (shown in Table 6.7) to 
JDV infection in surviving Tat vaccinated, CA vaccinated and control animals in Trial III.  
Measure Compared  groups  Significant differences in measures by phase 
Rectal 
temperature  CA (IFA) v. controls 
Phase 1: Significantly higher (p=0.01) in controls 
Phase 2: Significantly higher (p=0.06) in controls 
Phase 6: Significantly higher (p=0.02) in controls 
Depression of 
leucocyte count  Tat (IFA) v. controls  Phase 6: significantly greater (p=0.003) in controls 
Tat (IFA) v. controls  Phase 2: significantly longer (p=0.0007) in controls   Viral titre 
doubling time / 
clearance half 
life   CA (IFA) v. controls  Phase 2: significantly shorter (p=0.02) in controls 
Phase 6: significantly shorter (p=0.02) in controls 
Tat (IFA) v. controls  Phase 5: significantly shorter (p=0.051) in controls  
Phase 6: longer (approaching significance p=0.066) in controls. 
Duration of 
phases 
CA (IFA) v. controls 
Phase 2: significantly longer (p=0.044) for controls 
Phase 5: significantly shorter (p=0.03) for controls 
Phase 6: significantly longer (p=0.015) for controls 
   140 
Comparison of IFA and QuilA as adjuvants for vaccination with Tat 
(Trial IV). 
Seroconversion to recombinant JDV proteins in vaccinated animals. 
All cattle in the 2 vaccine groups developed detectable antibody to the administered 
recombinant proteins prior to challenge with infectious virus (Table 6.9). All animals 
vaccinated with the vaccine in IFA had detectable responses to Tat by day 21, and 
maintained strong responses up to the point of challenge. In contrast only 1 of 4 
animals vaccinated with the vaccine in QuilA had a response by day 21, and the 
responses in this group at later timepoints prior to challenge were not as consistently 
strong as those in the group where IFA was used as an adjuvant. 
Table 6.9 Differences in the seroconversion of cows to Tat when Tat+CA vaccine was 
administered using IFA or QuilA as adjuvant. (+/- indicates a barely detectable WB response, + 
is positive and ++ denotes strongly positive). 
Cow   WB 
Antigen  Day -7  Day 21  Day 35  Day 42  
CB 92  - +/-  ++  ++ 
CB 93  - ++  ++  ++ 
CB 94  - ++  ++  ++ 
CB 95 
Tat+CA 
(IFA) 
- +  ++  ++ 
CB 100  - -  +/-  +/- 
CB 101  - - +  ++ 
CB 102  - -  ++  + 
CB 103 
Tat+CA 
(QuilA) 
- +/- +  + 
The clinical parameters observed after challenge with JDV for Trial IV where cattle 
were vaccinated 3 times with Tat administered using either IFA or QuilA as an 
adjuvant are shown in Table 6.10 and Figure 6.7 a, b, and c. It was apparent that the 
severity of the disease in those animals vaccinated with Tat adjuvanted with QuilA 
was increased compared with both control animals and those vaccinated with the 
same protein preparation administered with IFA. 3/4 animals in the Tat/QuilA group 
died during the febrile period, 2/4 in the control group and 0/4 in the group 
vaccinated with Tat/IFA. The control animals had detectable virus in the plasma 
sooner after challenge than the vaccinated groups, and had a shorter doubling time 
than both vaccinated groups during the initial appearance of virus in the plasma.   141 
The significant difference between the observed parameters in the vaccinated and 
control groups are shown in Table 6.11. When the observed results for each group 
were compared with those of the control group with a t-test, both of the vaccinated 
groups show a more rapid progression to the peak of the fever, despite there being no 
difference in the time taken for viral titres to reach a maximum. Those animals 
vaccinated with QuilA as an adjuvant showed marked potentiation of the disease, as 
3/4 animals died, and the mean maximum temperature for the group was significantly 
higher than the mean for the control group.  142 
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Figure 6.7a Graphical depiction of measured clinical parameters (rectal 
temperatures [
°C], total leucocyte count as percentage of day 0 values, and log10 
plasma viral load [genomes/ml]) in individual cattle in Trial IV after vaccination 
with (A) Tat+CA (IFA) and (B) Tat+CA (QuilA) and challenge with 1,000 ID50 of 
JDVPUL.   143 
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Figure 6.7b Graphical depiction of measured clinical parameters (rectal 
temperatures [
°C], total leucocyte count as percentage of day 0 values, and log10 
plasma viral load [genomes/ml]) in individual control cattle in Trial IV after 
challenge with 1,000 ID50 of JDVPUL.   144 
Table 6.10 Observed clinical parameters after challenge with 1,000 ID50 of JDVPUL during Trial 
IV from cattle vaccinated with Tat+CA (IFA), Tat+CA (QuilA) and in non-vaccinated control 
animals (as described in Table 6.1). 
Vaccine 
(adjuvant)  Animal 
Time 
from 
challenge 
to peak 
plasma 
viral load 
(days) 
Duration 
of febrile 
period 
(days) 
Time from 
infection to 
onset of 
febrile 
period 
(days) 
Time 
from 
infection 
to peak of 
febrile 
period 
(days) 
Time 
from 
infection 
to end of 
febrile 
period 
(days) 
Maximum 
rectal 
temp. (
°C) 
during 
febrile 
period 
Fever 
score  Outcome 
CB92  11 8  6  10  14  41.2  7.7  Survived 
CB93  11 4  9  10  13  41.2  5.8  Survived 
CB94  10 4  8  10  12  41.1  4.5  Survived 
Tat + CA 
(IFA) 
CB95  11 4  8  10  14  41.1  5.5  Survived 
CB100  11 4  8  10  dead  41.5  3.9  Died 
(d.11) 
CB101  11 7  8  11  15  41.6  7.7  Survived 
CB102  11 4  9  10  dead  41.5  5.8  Died 
(d.12) 
Tat + CA 
(QuilA) 
CB103  10 6  8  10  14  41.5  6.3  Died 
(d.15) 
CB108  10 9  5  12  14  41.4  9.4  Survived 
CB109  10 3  9  11  12  40.4  2.2  Died 
(d.12) 
CB110  11 3  10 12  13  40.4  2.2  Survived 
 N/A 
CB111  14 6  12 13  17  41.0  7.2  Died 
(d.?) 
Table 6.11 Significant differences between the measured responses (shown in Table 6.9) to JDV 
challenge in vaccinated and control animals in Trial IV. 
Clinical parameters  Compared groups  Significant results 
Tat (IFA) v controls  Significantly longer (p=0.001) in control 
than vaccinated group.  Days from challenge to 
peak febrile response 
Tat (QuilA) v controls  Significantly longer (p=0.005) in control 
than vaccinated group. 
Maximum rectal 
temperature  Tat (QuilA) v controls  Significantly lower (p=0.012) in control 
than vaccinated group. 
The acute disease was divided into 7 phases (Table 6.11, Figure 6.8) and an unpaired 
t-test was used to compare the mean values in each phase (Table 6.12).    145 
Table 6.12 Summary of condensed data for each measure during each of the 7 phases following 
virus challenge in Trial IV. 
Phase 
Clinical parameter  Vaccine group 
1 2 3 4  5  6 7 
Control    38.63 39.26 39.96  40.47  39.75 38.65 
Tat + CA (IFA)  39.10 39.03 39.73 39.88  40.96  39.93 38.80  Temperature (
°C) 
Tat + CA (QuilA)  38.83 39.29      40.74  39.60 38.90 
Control    8.21 17.25  38.54 46.37 44.44  16.31 
Tat + CA (IFA)  0.00  4.66 22.72  33.10 35.30 27.24 1.19  Leucocyte count 
(% day 0) 
Tat + CA (QuilA)    2.35 17.25  38.54 49.07 44.44 4.44 
Control    5.40 7.28 9.76 10.57  10.21  8.11 
Tat + CA (IFA)  0.00  6.42  7.57 10.56 10.97 10.33 8.70 
Log10 plasma viral 
load (genome 
copies/ml)  Tat + CA (QuilA)  0.00 10.17      10.94 10.80 9.30 
Control    3.84 36.23 6.84 402.80 3.41  5.45 
Tat + CA (IFA)  0.00 4.00  13.31  6.48 53.63 6.37 3.05 
Viral doubling 
time/ clearance 
half-life (h)  Tat + CA (QuilA)   6.39    73.48  7.50  
Control   72  112  84  96  24  24 
Tat + CA (IFA)  72 90 40 84  60  36 24  Phase duration (h) 
Tat + CA (QuilA)  72 168      66  24  24 
Control  2/4, 1 animal died in Phase 5, 1 2 days after “recovery”. 
Tat + CA (IFA)  4/4 survived.  Survival 
Tat + CA (QuilA)  1/4, all 3 animals died in Phase 5.   146 
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Figure 6.8 Graphical depiction of calculated parameters from cattle in Trial IV after 
vaccination with either Tat+CA (IFA) or Tat+CA (QuilA), or non-vaccinated controls and 
subsequent challenge with 1,000 ID50 of JDVPUL. The results shown are a mean of 4 animals in 
each group (control group surviving animals only) at each phase of the acute disease process 
(as defined in Chapter 4).   147 
Table 6.13 Significant differences during each phase of the disease process between the 
calculated parameters (shown in Table 6.12 and graphically in Figure 6.8) following JDV 
challenge of vaccinated and control animals in Trial IV. 
Measure  Compared 
groups  Significant results. 
Tat + CA 
(IFA) v. 
controls 
Phase 2: significantly lower (p=0.04) in control than vaccinated group 
Phase 5: significantly lower (p=0.05) in control than vaccinated group 
Temperature 
Tat + CA 
(QuilA) v. 
controls 
Phase 2: significantly lower (p=0.0011) in control than vaccinated group 
Depression of 
leucocyte 
count 
Tat + CA 
(QuilA) v. 
controls 
Phase 2: significantly less depressed (p=0.00015) in control than vaccinated 
group 
Log10 plasma  
viral load 
Tat + CA 
(QuilA) v. 
controls 
Phase 2: significantly less (p=1.14x10
-6) in control than vaccinated group 
Viral 
doubling 
time/ 
clearance 
half life  
Tat + CA 
(QuilA) v. 
controls 
Phase 2: significantly shorter (p=0.012) in control than vaccinated group 
Phase 
duration  
Tat + CA 
(QuilA) v. 
controls 
Phase 2: significantly shorter (p=0.0044) in control than vaccinated group . 
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Comparison of Tat+CA, Tat+MA/CA as vaccines (Trial V). 
Seroconversion to recombinant JDV proteins in vaccinated animals. 
All cattle in the 3 vaccine groups developed detectable antibody to the administered 
recombinant proteins prior to challenge with infectious virus (Table 6.14). All 
animals administered the Tat vaccine had detectable responses to Tat by day 28, and 
maintained responses up to the point of challenge. The response to CA and MA 
(where administered) was detectable earlier, with 3/5 animals in the Tat + CA group 
showing a response by day 14, and 4/5 animals in the Tat + MA/CA group positive 
by the same timepoint. 
Table 6.14 The seroconversion of cows to Tat, CA and MA when Tat+CA, or Tat+MA/CA 
vaccine was administered using IFA (+/- indicates a barely detectable WB response, + is positive 
and ++ denotes strongly positive). 
Cow   WB 
Antigen  Day 0  Day 14  Day 28  Day 42  Day 49 
Tat  --+ + + + + CB119  CA  -+ /- + ++ ++
Tat  - - + ++ ++
CB120  CA  - - + ++ +
Tat  - - + ++ ++
CB121  CA  - - ++ ++ ++
Tat  - - ++ + +
CB122  CA  -+ /- + ++ ++
Tat  --+ +  +
CB123  CA  -+ /- ++ ++  ND 
Tat  --+ + +
MA  - + ++ ++ ++ CB 129 
CA  - + ++ ++ ++
Tat  - - + ++ ++
MA  - - + ++ ++ CB 130 
CA  -+ /- ++ ++ ++
Tat  - - + ++ ++
MA  -+ /- ++ ++ ++ CB 131 
CA  - + + ++ +
Tat  -+ /- + ++ ++
MA  --+ +  + CB 132 
CA  - - ++ ++ ++
Tat  -+ /- + ++ ++
MA  - - ++ ++ ++ CB 133 
CA  -+++   ND
The measured clinical parameters in individual cattle vaccinated with a mixture of 
either Tat + CA or Tat + MA/CA compared to control animals are shown in Tables   149 
6.13 and are shown schematically for each of the animals in the Tat+CA group 
(Figure 6.10), Tat+MA/CA group (Figure 6.11) and control group (Figure 6.12).  
Table 6.15 Observed clinical parameters during Trial V from cattle vaccinated with Tat+CA  
(IFA), Tat+MA/CA (IFA) and from non-vaccinated control animals (as described in Table 6.2) 
following challenge with 1,000 ID50 of JDVPUL. 
Vaccine Animal Time 
from 
challenge 
to peak 
plasma 
viral 
load 
(days) 
Duration 
of febrile 
period 
(days) 
Time 
from 
infection 
to onset 
of 
febrile 
period 
(days) 
Time 
from 
infection 
to peak 
of 
febrile 
period 
(days) 
Time 
from 
infection 
to end of 
febrile 
period 
(days) 
Maximum 
rectal 
temp. (
°C) 
during 
acute 
disease 
Fever 
score 
Outcome 
CB119  12 6 8 11 14 40.8  5.9 Survived
CB120  11 5 9 10 14 41.3  5.4 Survived
CB121  12  0 (1) N/A (12) 12 13 39.0  0 Survived
CB122  11 6 7 10 13 40.9  3.7 Survived
Tat+CA 
(IFA) 
CB123  11 2 11 11 13 40.5  1.3 Survived
CB129  11 6 6 11 12 41.1  5.2 Died  (d.12)
CB130  11 5 10 10 15 41.3  5.2 Survived
CB131  12 8 7 11 15 41.4  6.2 Survived
CB132  11 7 7 11 14 41.2  6.1 Survived
Tat+MA/CA 
(IFA) 
CB133  10 3 10 10 13 40.8  3.2 Survived
CB134  14 1 5 5 6 39.6  0.1 Survived
CB135  13 7 9 11 16 41.7  8.2 Survived
CB136  12  0 (4) N/A (10) 12 14 39.4  0 Survived
CB137  12 6 9 10 15 40.9  7.3 Survived
N/A 
CB138  10 5 9 11 15 40.6  4.5 Survived  150 
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Figure 6.9a Graphical depiction of measured clinical parameters (rectal temperatures [
°C], 
total leucocyte count as percentage of day 0 values, and log10 plasma viral load 
[genomes/ml]) in individual cattle in Trial V after vaccination with Tat+CA and challenge 
with 1,000 ID50 of JDVPUL.    151 
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Figure 6.9b Graphical depiction of measured clinical parameters (rectal temperatures [
°C], 
total leucocyte count as percentage of day 0 values, and log10 plasma viral load [genomes/ml]) 
in individual cattle in Trial V after vaccination with Tat+MA/CA and challenge with 1,000 
ID50 of JDVPUL.  
   152 
 
CB 134
0 2 4 6 8 10 12 14 16 18 20 22 24
30
50
70
90
110
130
150
0
2
4
6
8
10
12
38
40
42
Rectal Temp
%WBC Depression
Log10 Titre
%
 
o
f
 
D
a
y
 
0
 
W
B
C
 
c
o
u
n
t
.
CB 135
0 2 4 6 8 10 12 14 16 18 20 22 24
30
50
70
90
110
130
150
0
2
4
6
8
10
12
38
40
42
R
e
c
t
a
l
 
t
e
m
p
.
 
/
 
 
L
o
g
1
0
 
v
i
r
a
l
 
t
i
t
r
e
CB 136
0 2 4 6 8 10 12 14 16 18 20 22 24
30
50
70
90
110
130
150
0
2
4
6
8
10
12
38
40
42
%
 
o
f
 
D
a
y
 
0
 
W
B
C
 
c
o
u
n
t
.
CB 137
0 2 4 6 8 10 12 14 16 18 20 22 24
30
50
70
90
110
130
150
0
2
4
6
8
10
12
38
40
42
Days post challenge.
R
e
c
t
a
l
 
t
e
m
p
.
 
/
 
L
o
g
1
0
 
v
i
r
a
l
 
t
i
t
r
e
CB 138
0 2 4 6 8 10 12 14 16 18 20 22 24
30
50
70
90
110
130
150
0
2
4
6
8
10
12
38
40
42
Days post challenge.
%
 
o
f
 
D
a
y
 
0
 
W
B
C
 
c
o
u
n
t
.
R
e
c
t
a
l
 
t
e
m
p
.
 
/
 
L
o
g
1
0
 
v
i
r
a
l
 
t
i
t
r
e
 
Figure 6.9c Graphical depiction of measured clinical parameters (rectal temperatures [
°C], total 
leucocyte counts as percentage of day 0 values, and log10 plasma viral load [genomes/ml]) in 
individual non-vaccinated cattle in Trial V, following challenge with 1,000 ID50 of JDVPUL.  
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The acute disease process within each group was divided into 7 phases (Table 6.14, 
Figure 6.13) and an unpaired t-test was used to compare the mean values of each 
measure during each phase (Table 6.15). Statistically significant differences occurred 
predominantly in Phases 1-5 during the early phases of the disease process. 
Table 6.16 Summary of condensed data for each measure during each of the 7 phases following 
viral challenge during Trial V.  
Phase 
Measure  Vaccine 
group  1  2  3 4 5 6 7 
Control  NA  38.31  38.54 39.10 40.57 39.60 38.80 
Tat + CA  NA  38.43  38.44 38.68 39.58 39.70 38.86  Temperature (
°C) 
Tat + MACA  NA  38.39  38.45 38.94 40.17 39.67 39.00 
Control  NA  0.00 -13.64 -33.09 -55.63 -39.68  -0.92 
Tat + CA  NA 0.00 -4.88 -13.05  -35.08  -28.78  -19.07  Leucocyte count  
(% day 0) 
Tat + MACA  NA  0.00 -14.13 -15.92 -48.16 -32.40  2.86 
Control  NA 2.49  2.62  9.35  10.14  8.92  8.89 
Tat + CA  NA  1.46 2.18  8.41 10.28 8.53 10.07  Log10 viraemia 
(genome copies /ml) 
Tat + MACA  NA  2.30  2.55 7.90 9.82 9.58 7.91 
Control  NA 5.18 33.83  5.28  26.06 -5.66  -8.73 
Tat + CA  NA 8.34 23.79  5.29  60.87 -27.62 -8.08  Viral doubling time 
/clearance half-life (h) 
Tat + MACA  NA 6.95 110.63 5.08  31.97 -6.06  -8.78 
Control  NA 48  48  120  88  24  24 
Tat + CA  NA 48  48  96  129.6  48  24  Phase duration (h) 
Tat + MACA  NA  48 48  96 114 36  24 
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Figure 6.10 Graphical depiction of clinical parameters in cattle in Trial V after no 
vaccination (typical controls), or Tat+CA (IFA) or Tat+MA/CA (IFA) and subsequent 
challenge with 1,000 ID50 of JDVPUL. The results shown are a mean of measures from the 5 
animals in each group at each phase of the acute disease process (as defined in Chapter 4).  
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Table 6.17 Significant differences during each phase of the disease process between the 
calculated parameters (shown in Table 6.14 and graphically in Figure 6.15) following JDV 
challenge of vaccinated and control animals in Trial V. 
Measure  Compared 
groups  Significant results 
Tat+CA  
v. control 
Phase 4: significantly higher (p=0.029) in control than vaccinated group 
Phase 5: significantly higher (p=0.030) in control than vaccinated group 
Temperature 
Tat+MA/CA 
 v. control  Phase 5: significantly higher (p=0.046) in control than vaccinated group 
Tat+CA  
v. control 
Phase 3: significantly more depressed (p=0.020) in control than 
vaccinated group 
Phase 4: significantly more depressed (p=0.018) in control than 
vaccinated group 
Phase 5: significantly more depressed (p=0.029) in control than 
vaccinated group 
Depression of 
leucocyte count 
Tat+MA/CA 
 v. control 
Phase 4: significantly more depressed (p=0.033) in control than 
vaccinated group 
Tat+CA  
v. control 
Phase 2: significantly higher (p=1.73x10
-5) in control than vaccinated 
group 
Phase 3: higher (approaching significance p=0.069) in control than 
vaccinated group 
Phase 4: significantly higher (p=0.029) in control than vaccinated group 
Log10 plasma 
viral load 
Tat+MA/CA 
 v. control 
Phase 4: significantly higher (p= 0.0004) in control than vaccinated group
Phase 5: significantly higher (p=0.06) in control than vaccinated group 
Viral doubling 
time / clearance 
half life  
Tat+CA  
v. control 
Phase 2: significantly shorter (p=0.00014) in control than vaccinated 
group 
Phase duration   Tat+MA/CA 
 v. control  Phase 4: significantly longer (p=0.046) in control than vaccinated group 
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Discussion. 
Production of recombinant proteins in a prokaryotic expression system was chosen as 
the method of vaccine production as this was considered technically feasible in 
Indonesia. GST fusion proteins were used as vaccine proteins as several of the 
constructs had already been produced in earlier work in our laboratory (Burkala et al., 
1998) and high yields of protein were obtained. GST fusion vectors were easy to 
construct and there were many options for choosing the frame of insertion, strength of 
promoter and induction method. The pGEX-6P system (Amersham) was chosen for 
its standard induction technique utilising IPTG mediated de-repression of the lac 
operon, as this system gave flexibility in timing of induction, amount of inducer 
required and growth temperatures of the cultures. The use of GST as a fusion partner 
meant that soluble, or solubilised/refolded expressed proteins could be easily and 
cheaply purified and enzymatic cleavage of the GST fusion moiety was possible if 
required. There was also the added incidental advantage that vaccination with GST 
alone has been used to confer resistance to infection with Schistosoma japonicum in 
cattle (Wu et al., 2004). However, a number of the experimental cattle had pre-
existing antibody to GST, prior to vaccination, presumably as a result of infection 
with Schistosoma spp. (results not presented). Although these responses were weak in 
comparison to the response to GST obtained after vaccination, their presence 
presented some difficulty in analysing the rapidity of response to the recombinant 
GST-fused vaccines.  
Tat expressed as a GST fusion protein in E. coli accumulated as inclusion bodies in 
the bacterial cells. Such insoluble inclusion bodies in E. coli were first noted in 
bacteria growing in the presence of an amino acid analogue, appearing as an 
amorphous granule in the cell, consisting of misfolded proteins without any defined 
surrounding layer (Prouty et al., 1975). The CA-GST fusion protein was also 
deposited as inclusion bodies, but in this case about 50 % of this protein was 
expressed in a soluble form, detectable by Western blot in the centrifuged bacterial 
lysate supernate. The over-expression of the recombinant protein in bacterial 
expression systems is thought to outstrip the supply of chaperones to aid in the   157 
folding process in vivo, leading to the deposition in inclusion bodies, especially where 
hydrophobic domains exist in the recombinant protein (Thomas and Baneyx, 1996) as 
in JDV Tat (Setiyaningsih, 2006). The formation of inclusion bodies when over-
expressing proteins in bacterial expression systems has both advantages and 
disadvantages in respect of purification and retention of structure and activity of the 
expressed protein. 
The production of Tat and CA within inclusion bodies would ideally have led to 
research into methods of solubilisation and refolding of the proteins that would 
conserve their native conformation. It can be important to achieve correct refolding if 
specific activities of the protein, such as enzymatic or binding function, need to be 
retained, or if conformational epitopes need to be conserved. In these current studies, 
however, a decision was made to utilise and test simple purification methods that 
would be applicable to production in Indonesia. Solubilisation of the inclusion bodies 
was easily achieved in high pH buffers containing urea. Recombinant Taenia ovis 
protein vaccines administered as solubilised protein in a urea/dithiothreitol buffer 
were associated with an enhanced immune responses to the vaccine moiety of the 
fusion protein (Rothel et al., 1997) and the possibility of similar enhancement with 
JDV protein fused to GST caused this method of solubilisation to be adopted. The 
antibodies to GST seen in animals prior to vaccination described above made analysis 
of the possible differences in the relative strength of the responses to the vaccine 
protein and the fusion moiety described by these workers difficult. 
A humoral response to the administered vaccine proteins was seen soon after 
administration of the second vaccine dose, normally 14 days apart. 3 vaccine doses at 
short intervals were given to ensure a strong response, with challenge only a short 
period after the final vaccine dose. The rapidity of the whole process was primarily to 
decrease costs of keeping the cattle indoors for an extended period in Indonesia. 2 
vaccine doses more widely spaced may have had the same effect as 3 doses with a 
short interval between doses and the development of full vaccine efficacy, especially 
in induction of a CMI response to lentivirus vaccines, may not be attained for several 
months after the final boost (Hammond et al., 1997; Craigo et al., 2005). Further 
studies will be required to optimise the vaccination regime.   158 
The vaccine proteins were quantified by densitometry rather than by a biochemical 
total protein assay as this enabled the purity of the protein and hence the actual 
amount of vaccine protein administered to be determined. The high quality of the 
imaging system used to do this allowed accurate quantification of the protein bands 
as long as the loading of the gel kept the amounts of protein to be stained within the 
linear range of Coomassie brilliant blue staining. Other dyes such as Sypro Ruby 
have a greater range of linearity but it was found that the protein of interest could be 
diluted into the linear range so enabling the use of the readily available Coomassie 
brilliant blue. 
All animals seroconverted to the proteins used in the vaccines, as determined by 
Western blot using recombinant protein antigens expressed with the PinPoint system. 
Protein antigens produced by this system were used to give a different tag than the 
vaccine proteins, thus ensuring that seroconversion had occurred to the vaccine 
protein and not solely the GST fusion partner. It would arguably have been better to 
use native antigen obtained by purification of virus from the plasma of infected 
animals (Kertayadnya et al., 1993) to assess seroconversion. Native antigen may have 
possessed conformational epitopes not present on the bacterially expressed protein 
but this was unobtainable during these experiments. Although desirable, it was not 
possible to monitor CMI responses under the laboratory conditions available in Bali. 
Three vaccine trials were reported in this chapter (Trials III, IV and V).  It is admitted 
that our expertise in producing the proteins and assessing the efficacy of the response, 
and overcoming problems associated with the collection of samples and conducting 
the various assays developed during the course of these 3 trials. Other trials had been 
conducted, primarily examining potential role of glycosylated JDV envelope 
glycoproteins, without any identifiable efficacy. However, JDV Tat and CA proteins 
had been included and some efficacy was identified, leading to the 3 trials reported in 
this chapter. 
A variable that was hard to control was the lack of a standard infectious inoculum of 
JDV. The practise in Indonesia has been to store infected spleen tissue at -80C and to 
use this to infect an animal, then collect plasma from the infected animal on the   159 
second day of the resulting febrile response and use this as an inoculum (Soeharsono 
et al., 1990). This is partly done to overcome the problems of continued temporary 
loss of electrical power resulting in poor freezer storage conditions. The titre of the 
virus was determined by antigen-capture ELISA (Stewart et al., 2005) and the virus 
diluted appropriately so that it contained an estimated 1,000 ID50 for each inoculated 
animal. While this produced a reasonably accurate estimation of the number of virus 
particles, it did not discriminate between infectious and non-infectious virus particles, 
and it did not consider possible differences associated with passage of the virus 
through animals. 
The first of the trials reported, Trial III, was an attempt to compare the effects of 
vaccination with Tat and CA but the significance of the results obtained was difficult 
to interpret. The death of 2 animals in the Tat vaccinated group in this trial occurred 
before the development of a febrile response or plasma virus load were seen and 
meant that numbers of the remaining cattle were too small for meaningful 
comparisons to be made. Although these deaths were obviously of concern, no reason 
could be determined for them, and this pattern of death was not seen in any other 
trials.  
In Trial IV, the effect of combining Tat and CA into a single vaccine was 
investigated, as was the effect of comparing the adjuvants QuilA and IFA for this 
combination. 2 major observations were made: first, that vaccine administered using 
QuilA potentiated the disease when these animals were challenged with JDV post-
vaccination; second, that Tat/IFA vaccination protected against challenge that was 
lethal for several animals in both the Tat/QuilA and control groups. The apparent 
stronger antibody response to Tat when it was adjuvanted with IFA may contribute to 
this protection, although it has been reported that Tat-neutralisation titres do not 
correlate with protection (Belliard et al., 2005). However these workers were 
investigating long term protection, not amelioration of the initial acute phase disease. 
The potentiation of infection associated with the use of QuilA as an adjuvant seen in 
Trial IV led to the deaths of 3/4 animals in this vaccinated group, compared with 0/4 
in the group utilising IFA as an adjuvant, and only 2/4 in the control group also 
employing IFA as adjuvant. QuilA has been reported to induce a Th1 cytokine profile   160 
in cats vaccinated with FIV (Stokes et al., 1999) and it is possible that a similar CMI 
response to JDV proteins administered with this adjuvant increased the number of 
target cells for the virus by altering co-receptor expression (Chen et al., 1999), thus 
potentiating the disease. In mice, however, QuilA induces a Th2 response (Victoratos 
et al., 1997). There was a weaker and delayed antibody response to Tat in the QuilA 
adjuvanted group compared with the IFA adjuvanted group, perhaps indicating a Th1 
cytokine profile in these animals. Cytokine profiling by qRT-PCR as performed in 
SIV infected macaques (Hofmann-Lehmann et al., 2002), would shed light on the 
type of response engendered and whether a CMI response is potentially deleterious in 
the case of JD. 
In Trial V, when combinations of Tat and CA were tested as vaccines, many more 
samples were taken and there was an increased precision of the methods used to 
monitor virus load that meant clear differences in the progress of the induced disease 
could be measured, resulting in greater confidence in the results obtained. In this trial, 
there was definite evidence of amelioration of the disease process in the vaccinated 
animals. They had lower plasma virus loads in the early stages and at the peak of the 
acute disease process, with lower levels of fever and leucopenia. The effect seen in 
Trial V, of apparent reduction in early viral replication, is in contrast to that seen 
when an inactivated tissue-derived whole virus vaccine was used (Chapter 5) when 
the predominant effect was an increase in the clearance rate of virus from the plasma. 
Whether the protective effect of the vaccine in Trial V was due to the immune 
response to CA or Tat or a combination of both is unknown. Antibodies to Tat have 
been shown to neutralise the effects of extracellular Tat on HIV-1 replication and to 
correlate with protection of cynomolgus monkeys (Cafaro et al., 1999; Maggiorella et 
al., 2004) but not rhesus macaques (Silvera et al., 2002) from SHIV89.6P challenge. 
The differences in protection attained in these 2 primate types was attributed to the 
naturally lower replication and pathogenicity of SHIV89.6P in cynomolgus monkeys 
compared with rhesus macaques but there were differences in the vaccination regimes 
and routes of challenge. As in the case of the Bali cattle challenged with JDV, 
sterilising immunity was not achieved but in the SHIV89.6P trials in cynomolgus 
monkeys, vaccination did prevent progression to AIDS and in the vaccinated cattle it   161 
caused amelioration of the acute phase disease and no mortality; any decrease in the 
severity of the disease process and reduction in case fatality rates would be 
worthwhile pursuing in the Indonesian cattle industry.  
It is assumed that the protection seen in Trials IV and V was due to the effects of 
antibodies on extracellular Tat, decreasing early viral replication. Biologically active 
Tat can, unusually for a non-particulate antigen, be taken up by APC and induce a 
CTL response via the MHC class 1 pathway (Cafaro et al., 2000). However, the 
biological activity of the GST tagged Tat used in these trials was not tested by in vivo 
trans-activation studies, and cleavage of the GST tag from the protein prior to 
administration may have resulted in a more effective response. Simplicity of 
production methods was desired, and the expense of the enzymes required to cleave 
the proteins would probably prohibit scale-up of the potential vaccine in Indonesia.  
It is possible that a longer period between the final vaccination of the cattle and 
challenge would allow development of a CTL response; delayed induction of an 
effective response has been found in trials of FIV vaccines (Hosie and Flynn, 1996). 
Combined with the probable effects of Tat antibody on the infectivity enhancing 
functions of the extracellular protein, a more clear cut level of protection might then 
be expected.  
The core structural antigens, including CA, of lentiviruses are relatively conserved 
and contain several recognition determinants for CTL, and vaccination of macaques 
with VLPs containing CA decreased the viral load 10-100 fold following challenge 
with SIVmne despite the lack of neutralising antibody, presumably due to induction of 
CMI responses (Polacino et al., 1999). Bali cattle infected with JDV, or vaccinated 
with CA raise strong specific antibody responses (Hartaningsih et al., 1994; Desport 
et al., 2005), but the extent of any induction of CMI responses is not known. 1 animal 
in an early trial vaccinated with CA had a very short febrile episode, although it is 
possible that this was merely the result of an atypical response to infection, as seen in 
several animals in the susbsequent trials. Because of this, CA was included in the 
vaccine preparations, although any effect of administration was impossible to judge   162 
without further research into the fine specificity of the immune response to the 
vaccines. 
The inclusion of MA did not seem to have any marked effect on the efficacy of the 
vaccine, and in fact 1 animal in the group vaccinated with this protein died with an 
apparent uncontrolled viraemia. Although the structural MA protein has been shown 
to have pro-inflammatory effects in HIV-1 infection, which can be blocked by 
peptide directed antibody suggesting an extracellular function (De Francesco et al., 
2002), high levels of antibodies to MA were correlated with delayed progression to 
AIDS (Lange et al., 1987).  
In conclusion, although sterilising immunity was not achieved, detailed examination 
of the viral plasma loads, showed an effect of Tat-containing vaccines on the early 
stages of the acute phase of JD.    163 
Chapter 7 
General discussion 
A vaccine for the control of JD has been used for several years in Indonesia 
(Hartaningsih et al., 2001). The vaccine has been used on a small scale and 
particularly in areas where the disease has occurred for the first time (Hartaningsih, 
personal communication). While this vaccine provides a degree of protection 
(Hartaningsih et al., 2001), it is prepared from the tissues of clinically affected cattle 
and there are significant problems of cost, the possible spread of adventitious agents, 
the difficulty of commercialising the vaccine and ethical considerations which have 
restricted its use and necessitated a search for an alternative method of vaccination. 
The aim of the studies reported in this thesis was to determine the feasibility of 
utilising DNA vaccines or recombinant protein vaccines as alternatives, with greater 
safety, perhaps greater efficacy and reduced cost than the tissue-derived vaccine. This 
thesis primarily focuses on the potential application of JDV Tat and CA proteins. 
Many vaccines against lentivirus infection have been developed and tested. The most 
successful are attenuated live virus vaccines, with attenuation achieved either by 
laboratory adaptation by repeated serial passage or by genetic manipulation to remove 
virulence determinants. For JDV this type of vaccine is not yet possible as no culture 
method exists for the virus, despite repeated attempts to develop one. The possibility 
does exist to develop a heterologous vaccine using the closely related non-pathogenic 
BIV, which does replicate in cell cultures, and preliminary studies of this are 
underway in our laboratory. The only commercially available lentiviral vaccine is an 
inactivated whole virus preparation against several subtypes of FIV (Hohdatsu et al., 
1997; Pu et al., 2005). Inactivated whole virus vaccines are also experimentally 
effective against other lentivirus infections (Carlson et al., 1990; Issel et al., 1992), 
with levels of antigen administered (Hartung et al., 1992) and the length of time after 
vaccination prior to challenge being important in engendering an effective immune 
response (Montelaro et al., 1998). Another factor that might be important in the 
development of an effective immune response is possible changes in efficacy due to 
mutation of virus over time following serial passage through animals. This cannot be   164 
ruled out, although unusually for a lentivirus, JDV shows very little sequence 
variation between samples obtained from Bali over a period of 20 years (Desport et 
al., 2007). Inactivated tissue-derived virus vaccines have been used in the past to 
control diseases such as foot and mouth (Balamurugan et al., 2004) but were in this 
case supplanted by vaccine consisting of virus produced in cell culture. These 
vaccination methods involving the use of whole virus are not without problems of 
potential contamination with other infectious agents and research efforts have been 
directed to the development of sub-unit vaccines as an alternative. So, although a 
whole virus tissue-derived vaccines has been developed for JD (Hartaningsih et al., 
2001), in the absence of a cell culture method for replication of JDV, research on a 
sub-unit vaccine was initiated.  
A number of problems needed to be considered and solved prior to the development 
of a successful vaccine, in addition to the development of the actual vaccine. A 
significant difficulty was how to effectively assess the efficacy of Jembrana disease 
vaccines: animals with Jembrana disease do not always look overtly ill and there is a 
low case mortality rate of around 17%. Efficacy has therefore been previously placed 
on assessing the severity of both the febrile response and associated leucopenia, the 
only clearly measurable clinical parameters. The problems associated with reliance on 
clinical signs to assess efficacy were exacerbated as it became apparent during the 
course of the studies reported in this thesis that at the dose rate used to infect cattle, 
between 400 and 1000 ID50 of virus, some animals failed to develop the typical 
febrile response that was thought to occur in all infected animals (Wilcox et al., 
1995). It was demonstrated, however, that some animals without  febrile response 
were infected and had high titres of cell-free virus in the plasma, and these animals 
would perhaps have been previously considered unsuccessful attempts to produce 
infection. The reasons for the failure of these animals infected with 400 to 1000 ID50 
of virus to develop a febrile response needs further investigation; it was not reported 
previously when much higher doses of virus were used to infect animals (Soeharsono 
et al., 1990). It was noted also that these non-febrile but infected animals failed to 
produce antibody to the highly immunogenic CA protein post-challenge ( J Lewis, 
personal communication) suggesting it may be associated with a lack of activation of   165 
immune cells. It is possible that a pre-existing strong Th2 response skewed the 
response to virus infection as has been reported in naturally asymptomatically SIVsm 
infected mangabeys (Ansari et al., 2003); this might occur in response to parasitic 
infections that prevent establishment of a Th1 cytokine milieu which normally 
favours viral replication and associated bystander immunopathology. Conversely, 
however, once infection has been established, an artificially induced Th2-biased 
response has been shown to enhance progression of disease in rhesus macaques 
infected with SIV, even in the presence of neutralising antibody induced by 
vaccination, as induction of CTL required to control viral replication is not as 
efficient (Boyer et al., 2002).  
The situation in the few animals that displayed no signs of disease despite the 
presence of a high titre of circulating virus in the blood, and failed to produce 
antibody to the highly immunogenic CA protein post-infection, is similar to simian 
lentivirus infections in their respective naturally occurring hosts. (Silvestri et al., 
2003; Ling et al., 2004). Although JDV induces a more severe reaction in Bali cattle 
than in other cattle species, it is interesting to speculate that the lack of febrile 
response in cattle could reflect a tendency of JDV to adapt to Bali cattle over the 
years since the disease was first detected in this species. A possible avenue for further 
research would be to investigate the apparent rapidity of the co-evolution of Bali 
cattle and JDV to a state where the virus becomes commensal to the host. The closely 
related BIV does not cause any serious disease in Bos taurus and the rate that JDV is 
developing this relationship with Bos javanicus is of interest. 
Infection of vaccinated cattle with 400 to 1,000 ID50 of virus by the intravenous route 
was likely to be a greater infectious dose than would be experienced by cattle under 
field conditions, and probably presented the immune system with an unrealistically 
high infectious dose. The high dose rate was used, however, to ensure infection. It is 
possible that lower challenge doses that mimic natural infections might have revealed 
a greater protective effect from vaccination. Different ways of administering the 
infectious dose, for instance by housing an infected donor animal with the vaccinated 
cattle, or using a conjunctival route of infection (Soeharsono et al., 1990) rather than   166 
an intravenous route, or using a trickle challenge of low repeated doses mimicking 
spread by biting flies, could be tested in future.  
During the course of the studies reported in this thesis, it was apparent that there were 
some differences in the pathogenicity of the 2 strains of virus that were used to induce 
JD in experimentally infected animals. The differences were more apparent when the 
disease model reported in Chapter 4 was utilised to compare the progression of the 
disease induced by the 2 viruses. Previous experimental infection studies of JD have 
primarily utilised the JDVTAB strain which was first detected in 1987 (Kertayadnya et 
al., 1993). The reason for the difference in pathogenicity of JDVTAB and JDVPUL are 
not known but JDVTAB has been passaged in cattle many times over nearly 20 years 
and may have been genetically modified during this period, although as noted above 
the mutation rate appears low in JDV. Differences in pathogenicity and the disease 
induction rate between strains of EIAV have been reported to occur as a result of 
changes in the nucleotide sequences in the LTR region (Maury et al., 1997; Cook et 
al., 2003). This region has recently been found to be variable in JDV (Desport et al., 
2007), and might account for some of the differences in pathogenicity and disease 
induction observed during the course of these trials. Previously, it has been assumed 
that the pathogenicity of all strains of JDV was similar and the variation in virulence 
that has been detected might provide a future pathway to investigating the genetic 
basis of the pathogenicity of JDV. The lack of significant genetic variation between 
JDV isolates (Desport et al., 2007) bodes well for the efficacy of a vaccine against 
different strains in the field, as large differences in the level of protection following 
vaccination have been seen in horses challenged with genetically distinct 
heterologous or homologous virus (Issel et al., 1992) and protection against 
heterologous FIV challenge in cats requires the use of a dual subtype vaccine 
(Hohdatsu et al., 1997; Pu et al., 2005).  
The studies reported in this thesis have clearly indicated that any future efficacy 
testing should include an assessment of the virus load in the plasma of animals in 
vaccine trials, rather than relying on clinical observations to assess any amelioration 
of the disease, as infected asymptomatic animals still have the potential to spread 
disease. It was noted, however, that there was considerable variation in the rate of   167 
progression of the disease in different animals, and the virus load, even in those 
receiving the same infectious inoculum. The development of a simple model in 
Chapter 4 to describe the initial acute phase of JDV infection provided a means of 
statistically comparing the effect of vaccination by subdividing the acute disease 
period into phases and comparing the progression of the disease in individual 
animals. Mathematical models have been developed to describe the effects of 
treatment on the progression of HIV infection to AIDS, and to predict the length of 
symptom-free infection following the initial acute phase of HIV infection, as well as 
the effects of vaccination on the progress of the AIDS epidemic (Wodarz and Nowak, 
2002; Davenport et al., 2004). Most models have focused on prediction of the long 
term outcome of HIV infection in humans or non-human primates but efforts have 
also been devoted to the initial acute phase of disease (Stafford et al., 2000) despite 
the difficulty in obtaining daily samples from recently infected individuals to enable 
this. Unlike JDV infection, the acute phase of HIV infection often passes unnoticed 
and is not seen as the most serious manifestation of HIV infection, although 
intervention to decrease the severity of this phase has ramifications for the rapidity of 
progression to AIDS in humans (Blattner et al., 2004) and non-human primates 
(Staprans et al., 1999).  
The type of immune response required to control the infection was not adequately 
assessed as it was not possible to undertake analysis of cell-mediated immune 
responses in the vaccinated cattle in Bali. Although the Tat/CA vaccine finally tested 
in Trial V (Chapter 6) was not directly compared with the effects of the inactivated 
viral vaccine (Chapter 3), it was apparent that treatment with the inactivated virus 
improved the rate of clearance of the virus compared with the Tat/CA vaccine. 
Conversely, the recombinant protein vaccine slowed the initial increase in plasma 
viraemia relative to the conventional vaccine, possibly due to an anti-Tat response 
decreasing the effects of extracellular Tat on bystander cells, as discussed in Chapter 
6. Responses to Tat have not been detected after vaccination with the inactivated viral 
preparation (J Lewis, personal communication) possibly as this protein is expressed 
early in infection before the spleen of experimentally infected cattle is taken for 
preparation of vaccine. Large rebounds in the leucocyte populations post-challenge   168 
suggest the possible presence of a large primed population of cells, possibly 
responsible for enhanced clearance of virus. Some efforts to vaccinate against animal 
lentivirus infections have potentiated disease (McGuire et al., 1986; Karlas et al., 
1999) and it is possible in the studies reported in this thesis that the high number of 
mortalities, especially in Trial V where QuilA was investigated as an adjuvant, may 
have resulted from the induction of a strong CMI response providing a larger pool of 
susceptible target cells for virus replication. The type of response engendered by 
vaccination was important in these trials, with a balance between an effective 
response and a potentially exacerbating response apparently dependent on the 
adjuvant chosen. The inactivated viral vaccine appeared to have a significant effect in 
increasing the rate of clearance of plasma virus after the peak of viraemia. The most 
effective recombinant protein combination of Tat + CA in Trial V decreased the rate 
of appearance of viral genomes in the plasma in the earlier stages of the disease, prior 
to the peak viraemia. A vaccine regime consisting of inactivated JDV or BIV, 
coupled with recombinant Tat protein to exploit both arms of the immune system 
may be a fruitful avenue to explore in efforts to control JD. 
Important guiding criteria for this project were that the technology required for 
vaccine production in Indonesia needed to be simple, and the cost of production had 
to be low. A number of potential DNA vaccine constructs were produced and 
expression of proteins from these constructs was achieved in vitro and the constructs 
are available if it was desired to continue investigations into these type of vaccines in 
the future. Producing virus vaccines is fraught with many difficulties but an important 
factor that is often overlooked is the importance of being able to license the vaccine. 
During the course of the studies reported in this thesis it became apparent that while 
DNA vaccines offered substantial advantages in terms of cost, ease of production and 
stability (Whalen, 1996a), serious doubts emerged as to whether such a vaccine 
would be licensed in Indonesia. Although several potential DNA vaccines for HIV 
and other diseases are in Phase 1 clinical trials (Brave et al., 2005) or undergoing 
safety evaluation (Graham et al., 2006; Sheets et al., 2006), no precedents existed for 
their license in any country for use in any mammalian or avian species, and licensing 
such a vaccine in Indonesia was thought to be potentially difficult. It was this   169 
conclusion that resulted in a decision to at least temporarily terminate these studies of 
potential DNA vaccination.  
A bacterial expression system, with potential high yields of protein at a low cost was 
considered the most appropriate for use in Indonesia. Early studies, not reported in 
this thesis, indicated recombinant JDV SU and Tm proteins prepared in this system 
did not provide any protective efficacy and efforts were later directed to the use of 
CA and Tat. The failure of JDV SU and Tm to induce a protective immune response 
was possibly associated with the lack of post-translational modifications of the 
proteins in the bacterial system. However, a widely used feline leukaemia virus 
vaccine consisting of non-glycosylated SU produced in a bacterial expression system 
(Marciani et al., 1991) is effective (Hofmann-Lehmann et al., 1995), suggesting 
glycosylation of envelope proteins incorporated into a lentiviral vaccine may not 
necessarily be essential. Perhaps the choice of adjuvant could also be critically 
important for efficacy of these non-glycosylated envelope antigens. 
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